What are the best quality of life measurement instruments for eczema? Perspectives on popularity and quality as a contribution to developing a core outcome set. by Heinl, Daniel
 
 
 
 
 
 
 
AUS  DEM LEHRSTUHL FÜR EPIDEMIOLOGIE UND PRÄVENTIVMEDIZIN 
Prof. Dr. Michael Leitzmann  
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
 
 
WHAT ARE THE BEST QUALITY OF LIFE MEASUREMENT INSTRUMENTS FOR 
ECZEMA? PERSPECTIVES ON POPULARITY AND QUALITY AS A CONTRIBUTION TO 
DEVELOPING A CORE OUTCOME SET. 
 
 
 
 
 
Inaugural – Dissertation 
zur Erlangung des Doktorgrades 
der Medizin 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
vorgelegt von  
Daniel Heinl 
 
 
 
 
 
 
 
 
 
2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUS  DEM LEHRSTUHL FÜR EPIDEMIOLOGIE UND PRÄVENTIVMEDIZIN 
Prof. Dr. Michael Leitzmann  
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
 
 
WHAT ARE THE BEST QUALITY OF LIFE MEASUREMENT INSTRUMENTS FOR 
ECZEMA? PERSPECTIVES ON POPULARITY AND QUALITY AS A CONTRIBUTION TO 
DEVELOPING A CORE OUTCOME SET. 
 
 
 
 
 
Inaugural – Dissertation 
zur Erlangung des Doktorgrades 
der Medizin 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
vorgelegt von  
Daniel Heinl 
 
 
 
 
 
 
 
 
2018  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan:      Prof. Dr. Dr. Torsten E. Reichert 
 
1. Berichterstatter:     Prof. Dr. Christian Apfelbacher 
 
2. Berichterstatter:     Prof. Dr. Michael Koller  
 
Tag der mündlichen Prüfung:   04.09.2018 
5 
 
Inhaltsverzeichnis 
 
Inhaltsverzeichnis ....................................................................................................................... 5 
Zusammenfassung ...................................................................................................................... 7 
Einleitung ............................................................................................................................... 7 
Material und Methoden .......................................................................................................... 7 
Ergebnisse .............................................................................................................................. 8 
Schlussfolgerung .................................................................................................................... 8 
1. Introduction .......................................................................................................................... 10 
2. Material and methods ........................................................................................................... 13 
2.1 Review 1 ......................................................................................................................... 13 
2.2 Review 2 ......................................................................................................................... 13 
2.3 Review 3 ......................................................................................................................... 14 
3. Results .................................................................................................................................. 16 
3.1 Review 1 ......................................................................................................................... 16 
3.2 Review 2 ......................................................................................................................... 16 
3.3 Review 3 ......................................................................................................................... 17 
4. Discussion ............................................................................................................................ 19 
5. Abstract ................................................................................................................................ 25 
5.1 Introduction .................................................................................................................... 25 
5.2 Material and methods ..................................................................................................... 25 
5.3 Results ............................................................................................................................ 26 
5.4 Conclusion ...................................................................................................................... 26 
6. Bibliography ......................................................................................................................... 27 
7. Danksagung .......................................................................................................................... 32 
8. Veröffentlichte Artikel ......................................................................................................... 36 
8.1 Review 1 ......................................................................................................................... 37 
8.2 Protokoll zu Review 2 .................................................................................................... 46 
8.3 Review 2 ......................................................................................................................... 53 
8.4 Protokoll zu Review 3 .................................................................................................... 66 
8.5 Review 3 ......................................................................................................................... 76 
9. Anhang ................................................................................................................................. 88 
9.1 Anhang 1 (zu Review 1)................................................................................................. 88 
9.2 Anhang 2 (zu Protokoll zu Review 2) .......................................................................... 103 
9.3 Anhang 3 (zu Review 2)............................................................................................... 109 
6 
 
Inhaltsverzeichnis (Fortsetzung) 
 
 
9.4 Anhang 4 (zu Protokoll zu Review 3) .......................................................................... 155 
9.5 Anhang 5 (zu Review 3)............................................................................................... 163 
  
  
7 
 
Zusammenfassung 
Einleitung 
Das atopische Ekzem (AE, Synonyme: Neurodermitis, atopische Dermatitis) ist eine 
chronisch bzw. chronisch-rezidivierend verlaufende, entzündliche Hauterkrankung, die 
Kinder und Erwachsene betrifft. Ihr Leitsymptom ist Juckreiz. Da die AE einen negativen 
Einfluss auf die Lebensqualität (LQ) der Betroffenen ausübt, werden in einigen 
randomisierten kontrollierten Studien (RCTs) u.a. auch LQ-Messinstrumente verwendet, um 
die Wirksamkeit der untersuchten Therapie(n) zu bewerten. Allerdings werden in den RCTs 
zahlreiche verschiedene LQ-Instrumente angewandt, wodurch die sich auf Metaanalysen und 
systematische Übersichtsarbeiten stützende evidenzbasierte Entscheidungsfindung erschwert 
wird. Aus diesem Grunde strebt die Initiative Harmonising Outcome Measures for Eczema 
(HOME) den Aufbau eines core outcome set (COS), d.h. einer in jeder RCT zu erhebender 
Mindestauswahl an Outcomes, an. Ziel meiner Dissertation war es, durch die Vorlage dreier 
systematischer Übersichtsarbeiten in Bezug auf die LQ eine Grundlage für dieses COS zu 
schaffen. 
Material und Methoden 
In der ersten systematischen Übersichtsarbeit untersuchte ich, welche LQ-Instrumente bislang 
in RCTs bei AE-Patienten verwendet wurden. Hierzu wurde die Datenbank Global Resource 
of Eczema Trials (GREAT) nach RCTs bei AE-Patienten durchsucht. Aus den die 
Einschlusskriterien erfüllenden Studien extrahierte ich anschließend Informationen zu 
patientenberichteten Outcomes, vor allem zur LQ. Die zweite Übersichtsarbeit bestand aus 
einer systematischen Begutachtung der Messeigenschaften aller existierender 
Messinstrumente, die für die LQ-Messung bei Erwachsenen mit AE entwickelt und/oder 
validiert wurden. Im Anschluss an eine systematische Literatursuche in Pubmed und Embase 
nach Studien zu den Messeigenschaften von LQ-Instrumenten für erwachsene AE-Patienten 
wurden die inhaltliche und die methodische Qualität der Messeigenschaften mit Hilfe der 
COSMIN-Checkliste (COnsensus-based Standards for the selection of health status 
Measurement Instruments) bewertet. Eine Synthese der besten Evidenz, die die Ergebnisse 
verschiedener Studien zusammenfasste, bildete die Grundlage zur Einordnung der LQ-
Instrumente in vier Empfehlungskategorien (A-D). Ziel der dritten Übersichtsarbeit war es, 
die Messeigenschaften aller existierender Messinstrumente, die für die LQ-Messung bei 
Kleinkindern, Kindern und Jugendlichen mit AE entwickelt und/oder validiert wurden, 
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systematisch zu untersuchen. Ähnlich wie schon bei der zweiten Übersichtsarbeit fanden wir 
auch hier mittels einer systematischen Literatursuche in PubMed und Embase Studien zu den 
Messeigenschaften von LQ-Instrumenten für Kleinkinder, Kinder und Jugendliche mit AE. 
Wieder erfolgte die Bewertung von inhaltlicher und methodischer Qualität mit Hilfe der 
COSMIN-Checkliste; eine anschließende Synthese der besten Evidenz ermöglichte weitere 
Empfehlungen. 
Ergebnisse 
287 Volltextartikel, in denen über 303 Studien berichtet wurde, sowie 72 Abstracts erfüllten 
die Einschlusskriterien der ersten Übersichtsarbeit. 63 der 303 Studien (20,8 %) erfassten die 
LQ der Patienten und setzten hierfür 18 benannte und vier namenlose LQ-Instrumente ein, 
wobei die am häufigsten benützten Instrumente der Dermatology Life Quality Index (DLQI) 
für Erwachsene, der Children’s Dermatology Life Quality Index (CDLQI) für Kinder, der 
Infants’ Dermatitis Quality of Life Index (IDQoL) für Kleinkinder und der Dermatitis Family 
Impact (DFI) für Angehörige waren. Die zweite Übersichtsarbeit schloss 15 Artikel und 17 
LQ-Instrumente ein. Kein Instrument erfüllte alle Voraussetzungen für eine 
Anwendungsempfehlung. Sechs Instrumente wurden in Kategorie B eingruppiert, d.h. 
abhängig von den Ergebnissen weiterer Validierungsstudien gibt es Potential für eine 
Empfehlung derselben. Drei Instrumente wiesen eine schlechte inhaltliche Qualität in 
mindestens einem erforderlichen Kriterium auf und wurden daher in Kategorie C eingeordnet. 
Die verbliebenen acht Instrumente waren nur unzureichend validiert und fielen folglich unter 
Kategorie D. In die dritte Übersichtsarbeit schlossen wir 17 Artikel ein, die über die 
Messeigenschaften von 24 LQ-Instrumenten berichteten. Kein Instrument erfüllte alle 
erforderlichen inhaltlichen Qualitätskriterien. Für die US-Version der Childhood Atopic 
Dermatitis Impact Scale (CADIS) ist eine zukünftige Empfehlung in Abhängigkeit von 
weiteren Studienergebnissen möglich. Alle anderen Instrumente waren unzureichend 
validiert. 
Schlussfolgerung 
Zusammenfassend gibt es zwei Hauptergebnisse meiner Dissertation. Erstens erfasst nur eine 
von fünf RCTs LQ. Zahlreiche verschiedene Instrumente werden dafür eingesetzt, wodurch 
Vergleichs- und Synthesemöglichkeiten der einzelnen Studienergebnisse deutlich 
eingeschränkt werden. Zweitens kann z. Z. kein LQ-Instrument für die Aufnahme in das 
geplante COS empfohlen werden, bis nicht weitere Validierungsdaten zur Verfügung stehen. 
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Bis auf weiteres sollte sich die Forschung auf den Quality of Life Index for Atopic Dermatitis 
(QoLIAD) und den DLQI für Erwachsene sowie den CADIS und selbstberichtete Instrumente 
für Kleinkinder, Kinder und Jugendliche fokussieren.  
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1. Introduction 
Eczema (synonym: atopic dermatitis (AD)) is a common inflammatory skin disease that 
affects both children and adults. It is characterized by a chronic or chronically relapsing 
course, with pruritus being the main symptom.1 The prevalence of eczema has increased in 
the two preceding decades, with up to 20% of children in industrialized countries now 
affected.2 Likewise, recent studies in European and US populations suggest that prevalence 
rates in adults are in excess of 10%.3,4 Eczema places a considerable economic burden on 
patients and society and exerts a negative impact on the quality of life (QoL) of the patients 
and their families.5,6 
To understand what is meant when talking about impaired QoL of eczema patients, some 
general considerations on the construct QoL are necessary. The World Health Organization 
(WHO) defines QoL as “individuals’ perceptions of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns”.7 From this definition, it is obvious that QoL is a patient-reported 
outcome (PRO), typically assessed by filling in a questionnaire or responding to an 
investigator’s questions. QoL is usually referred to as a multidimensional construct, 
encompassing the domains of somatic sensation, physical and cognitive functioning, 
psychological well-being, and social interaction.8 However, it has to be noted that these 
holistic definitions may not be very useful to harmonize the mostly diverging views of 
researchers with respect to operational QoL definitions and QoL domains.9 In an attempt to 
create a more tangible concept of QoL for medical research and practice, the term “health-
related quality of life” (HRQoL) has been used. HRQoL focuses on the effects of a health 
condition on an individual’s QoL, as perceived by that individual; it is therefore a medical and 
health-care-related interpretation of QoL, whereas QoL goes beyond this and includes also 
non-medical aspects such as occupation, family and social life, and other influencing factors 
of an individual’s life.9,10 
Adding to the confusion, there are not only various definitions of QoL, but also different 
conceptual models. One approach is the utility model, derived from economic decision 
theory, where patients are asked to balance a shorter life with less dysfunction against a 
longer life with more dysfunction: The utility model allows transforming responses into 
Quality Adjusted Life Years (QALY).11 Another major conceptual model is health status 
measurement which is closer to the aforementioned definitions of QoL, since it proposes a 
multidimensional construct consisting of several domains for QoL measurement. While QoL 
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is quantified in a single numeric index (QALY) in the utility model, each QoL domain is 
assessed independently in health status measurement, with results often aggregated into a 
profile score.11 
Researchers started to think about QoL in the early 1970s, resulting in the development of a 
few early adult QoL instruments that were mostly generic, i.e. applicable across different 
diseases and different fields of medicine, such as the Sickness Impact Profile (SIP).12 A 
broader interest in QoL research was not observed until the 1990s, when many scientists 
began to expand and enhance the available conceptual considerations and developed 
numerous new QoL instruments.13 In this decade, a growing research interest in QoL 
measurement in children led to the inauguration of a number of QoL instruments specific to 
pediatric populations;14 also, the first dermatology-specific QoL measurement instruments 
were developed at that time.15,16 Since then, many QoL instruments for use in dermatology 
and eczema patients have been proposed. Rehal et al. found in a review that 14 different QoL 
scales were applied in eczema trials from 1985-2010.17 
As the measurement of QoL in clinical trials is particularly relevant for chronic skin disease 
such as eczema,18 it may at first glance seem very positive that researchers and clinicians can 
now choose from a wide array of QoL measurement instruments. However, some of the QoL 
instruments used are inadequately validated in eczema. As a result, evidence-based decision 
making is hampered because treatment effects may be over- or underestimated. Moreover, the 
use of different QoL scales in randomized controlled trials (RCTs) renders their comparison 
and evidence synthesis in systematic reviews and meta-analyses difficult. Consequently, 
important uncertainties remain in the treatment of eczema, requiring the conduct of high 
quality randomized controlled trials (RCTs).19,20 An internationally acknowledged way to 
improve the quality of RCTs and to increase researchers’ possibilities to compare the results 
of RCTs is the development of a core outcome set (COS).21 
A COS is a consensus-derived minimum set of outcomes to be assessed in a specific 
situation.22 In other words, COS cover a minimum of outcomes that should be measured and 
reported in all clinical trials of a specific medical condition. As their sole intention is to 
facilitate the comparison of outcomes across trials in systematic reviews and meta-analyses, 
COS do not preclude researchers from including additional outcomes in their studies. Many 
clinicians, methodologists, and other volunteers from all over the world are thus actively 
working to develop COS for various diseases, guided by the recommendations published by 
the Core Outcome Measures in Effectiveness Trials (COMET) initiative.23 The COMET 
initiative aims to promote COS research by providing guidance on developmental and 
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methodological issues, and by connecting researchers who are interested in COS 
development. 
With the goal of developing a COS for eczema trials, the Harmonising Outcome Measures for 
Eczema (HOME) initiative was founded in 2008. A multi-perspective Delphi study conducted 
by the initiators of the HOME initiative defined clinical signs measured by means of a 
physician-assessed instrument, symptoms of eczema, and the long-term course of eczema as 
the core outcome domains to be applied in all future eczema trials.24,25 At the HOME II 
meeting in Amsterdam in 2011, the international community confirmed these core outcome 
measures and also added QoL to the core set of outcome domains.26 The next crucial step in 
the process of standardizing eczema outcome measurements is to identify appropriate 
instruments to measure each of the four core outcome domains of eczema. For two domains, 
this process has been completed and the Eczema Area Severity Index (EASI) has been 
identified as the currently most adequate measurement instrument to assess clinical signs and 
the Patient-Oriented Eczema Measure (POEM) as the most adequate instrument to assess 
symptoms in eczema.27,28 
In an attempt to standardize processes and to provide a standard for COS development in 
dermatology, the HOME initiative has published a roadmap.29 According to this roadmap, the 
first step for each core outcome domain is a comprehensive review of what outcome 
measurement instruments have actually been used (review 1). After completing this review, a 
systematic review of validation studies of the identified instruments ensues, in order to 
highlight gaps in validation and to inform clinicians and researchers about the appropriateness 
of the existing outcome measurement instruments (review 2 and 3). Therefore, the aim of this 
MD thesis was to complete the aforementioned steps for the core outcome domain QoL, 
separately for adults, and infants, children, and adolescents. 
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2. Material and methods 
This MD thesis consists of three systematic reviews. Subsequently, material and methods are 
presented separately for the systematic review on what QoL instruments have been used in 
eczema trials (review 1), for the systematic review on the measurement properties of adult 
QoL instruments for eczema (review 2), and for the systematic review on the measurement 
properties of QoL instruments for infants, children and adolescents with eczema (review 3). 
This mode of presentation will also be applied to the results section. 
2.1 Review 1 
This systematic review investigated what QoL instruments have thus far been used in eczema 
RCTs. We searched the Global Resource of Eczema Trials (GREAT) database,30 which 
includes records of all RCTs of eczema treatments,31 for reports of RCTs, published in 
English or German language, from 2000 to May 2014. Detailed information on PROs, 
particularly QoL, was extracted. To ensure consistency in the data extraction, guidelines on 
what information should be gathered and how this information should be evaluated was 
agreed on beforehand. A second data extraction was performed for a random sample of 10% 
of the papers as a measure of quality assurance. For this sample, results were compared 
between the first and the second data extraction and discrepancies were resolved within the 
whole team. If only an abstract was available, we assessed QoL only. 
Our main outcomes were: i) the proportion of articles that assessed a QoL outcome, ii) the 
proportion of articles that assessed a PRO, iii) whether the inclusion of a QoL measure was 
related to whether the primary endpoint was a PRO, iv) what QoL instruments were used, v) 
the number of QoL instruments per study and vi) the number of studies published and the 
proportion including QoL instruments over time. A PRO was defined according to Patrick et 
al. as any report coming directly from patients, without interpretation by physicians or others, 
about how they function or feel in relation to a health condition and its therapy.32 The term 
‘composite index’ was used to describe any score or index that is composed of both a PRO 
and a non-PRO part. 
2.2 Review 2 
This systematic review investigated the measurement properties of adult QoL instruments for 
eczema and was developed in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement.33 A study protocol was published 
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beforehand and has also been registered in the International Prospective Register of 
Systematic Reviews (PROSPERO): CRD42015017138.34  
We conducted a systematic literature search in PubMed and Embase identifying studies on 
measurement properties of adult eczema QoL instruments. The eligibility criteria laid out in 
the protocol were applied.34 Only self-reported disease- or dermatology-specific, and not 
generic QoL measurement instruments, were eligible. We regarded different language 
versions of the same questionnaire separately because we consider these to be distinct 
instruments.  
We compared the content of each instrument on content domain level. For all eligible studies, 
we assessed the adequacy of the measurement properties using the predefined criteria for 
rating the adequacy of measurement properties recommended by the COSMIN group in a 
slightly modified version.35 The methodological quality of the included studies was evaluated 
with the COnsensus-based Standards for the selection of health status Measurement 
INstruments (COSMIN) checklist.36–38 In the COSMIN checklist (cf www.cosmin.nl), four 
domains are distinguished (reliability, validity, responsiveness, and interpretability) with 
related measurement properties and aspects of measurement properties. For each of the 
measurement properties, the COSMIN checklist consists of 5 to 18 items covering 
methodological standards (organized in nine boxes for the nine measurement properties). In 
addition, each item can be scored on a four-point rating scale (that is, ‘poor’, ‘fair’, ‘good’, 
‘excellent’). Taking the lowest rating for each item in one box, an overall quality score 
(‘poor’, ‘fair’, ‘good’, ‘excellent’) is obtained for each measurement property separately. The 
measurement property ‘criterion validity’ was not considered for the purpose of this 
systematic review since no gold standard exists for QoL.  
Where an instrument was evaluated in multiple studies, the findings were synthesized (‘best 
evidence synthesis’) provided the characteristics of the included studies were sufficiently 
similar and the methodological quality of the included studies was sufficient.39 The results of 
this best evidence synthesis were the basis to assign four degrees of recommendation (A-D) to 
the included QoL instruments. Finally, we aimed to identify one most appropriate (currently 
available) instrument to assess QoL in adults with eczema. 
2.3 Review 3 
This systematic review investigated the measurement properties of QoL instruments for 
infants, children and adolescents with eczema and was developed in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
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statement.33 A study protocol was published beforehand and has also been registered in the 
International Prospective Register of Systematic Reviews (PROSPERO): 
CRD42015023483.40 
For this systematic review, we applied in large parts the same methodology as we did for the 
second review. An important difference concerned the eligibility criteria: To be eligible, a 
study’s population needed to consist of patients younger than 16 years of age. A study with a 
mixed patient sample was eligible either if it presented a subgroup analysis for infants, 
children and adolescents with eczema or if infants, children and adolescents with eczema 
constituted at least 50% of the study population. The measurement instrument had to be a 
self- or proxy-reported questionnaire. The eligibility criteria laid out in the protocol were 
applied.40 Finally, we aimed to identify one best (currently available) instrument to assess 
QoL in infants, one best (currently available) instrument to assess QoL in children, and one 
best (currently available) instrument to assess QoL in adolescents with eczema.
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3. Results 
3.1 Review 1 
287 full texts reporting on 303 trials and 72 abstracts were included. 63/303 studies (20.8%) 
assessed QoL and used 18 named and 4 unnamed QoL instruments. PROs were assessed by 
85.9% of articles. We found a statistically significant association between a PRO or a 
composite index as the primary endpoint and the inclusion of QoL (p=0.002). Likewise, study 
authors that used a distinct non-PRO as primary endpoint were more likely to include QoL 
measurement than study authors that did not specify their primary endpoint in more detail. 
The Dermatology Life Quality Index (DLQI) (20/36 studies), the Children’s Dermatology 
Life Quality Index (CDLQI) (18/20 studies) and Infant’s Dermatology Quality of Life Index 
(IDQoL) (14/15 studies) were the most common measures in adults, children and infants, 
respectively. QoL of adult caregivers of children with eczema was most often assessed with 
the Dermatitis Family Impact (DFI, 14/20 studies). Of the 63 trials that assessed QoL, we 
found that the majority of studies (n=41, 65.1%) used only one QoL measurement instrument. 
Two QoL instruments were applied in 16 studies (25.4%) and the remaining 6 studies (9.5%) 
included three QoL measurement instruments. Analysis over time showed that although there 
were fluctuations from year to year, the proportion of trials that include QoL measures has 
remained largely static since 2000. 
For the studies which were reported in abstract form only, only 4 out of 72 (6%) assessed 
QoL. The CDLQI was used in 2 abstracts and the DFI in 1 abstract. Three further QoL 
instruments were reported, but were not named. 
3.2 Review 2 
15 articles reporting on 17 instruments were included. No instrument fulfilled the criteria for 
category A because there was none for which all measurement properties had been evaluated. 
Measurement error and cross-cultural validity of the QoL instruments in question were not 
evaluated in any of the included studies. Five language versions of the Quality of Life Index 
for Atopic Dermatitis (QoLIAD) were placed in category B, meaning that they have the 
potential to be recommended depending on the results of further validation studies. The 
QoLIAD was found to have adequate content and construct validity and proved to be 
internally consistent; its reliability, structural validity and cross-cultural validity are unclear, 
while responsiveness and measurement error have not been investigated at all. Because of 
adequate reliability and responsiveness, the Spanish DLQI also fulfilled the criteria for 
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category B, although less information is available for this questionnaire compared to the 
QoLIAD. The UK version of the DLQI was shown to have poor internal consistency, content 
and structural validity in eczema patients and was thus put in category C. Construct validity of 
both the Impact of Chronic Skin Disease on Daily Life (ISDL) and the Dutch QoLIAD was 
found inadequate, hence they were also placed in category C. Instruments in that category had 
poor adequacy in at least one required adequacy criterion and are therefore considered 
problematic for further use in eczema patients. The remaining eight instruments, namely 
Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH), 
Danish DLQI, German DLQI, Freiburg Life Quality Assessment core module (FLQA-c), 
Freiburg Life Quality Assessment for Dermatoses (FLQA-d), Italian QoLIAD, English 
Skindex-29 and German Skindex-29, were minimally validated and were thus placed in 
category D; since their performance in most measurement properties is largely unclear, further 
usage cannot be recommended until more validation data is available. 
3.3 Review 3 
17 articles, three of which were found by hand search, were included. These 17 articles 
reported on 24 instruments. No instrument can be recommended for use in all eczema trials 
because none fulfilled all required adequacy criteria. Among the tested instruments for 
pediatric eczema, the U.S. version of the Childhood Atopic Dermatitis Impact Scale (CADIS), 
a proxy-reported instrument, was the only one to be placed in category B, meaning it has the 
potential to be recommended depending on the results of further validation studies. While 
three of its measurement properties, i.e. internal consistency, reliability and hypothesis 
testing, were found to be adequate, the assessments of content validity and responsiveness 
were of poor methodological quality. Measurement error, structural validity and cross-cultural 
validity of the U.S. version of the CADIS have not yet been investigated. All other 
instruments including all self-reported ones, namely Italian CADIS (long version), Italian 
CADIS (short version), Dutch Childhood Impact of Atopic Dermatitis (CIAD), English CIAD 
(U.K.), English CIAD (U.S.), French CIAD, German CIAD, Italian CIAD, Spanish CIAD, 
Brazilian Portuguese DISABKIDS Atopic Dermatitis Module (DISABKIDS-ADM) in self- 
and proxy-reported version, Arabic IDQoL, Dutch IDQoL, English IDQoL (U.K.), Italian 
IDQoL, Swedish IDQoL, Danish CDLQI, English CDLQI (U.K.), Malay CDLQI, Serbian 
CDLQI, Spanish CDLQI (Mexico), Swedish CDLQI and an unknown language version of the 
DISABKIDS-ADM lacked significant validation data and were consequently grouped in 
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category D, meaning they should not be used until more validation data is available because 
their performance in most measurement properties is unclear. 
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4. Discussion 
Our first systematic review showed that study authors conducting eczema RCTs take 
apparently only little interest in measuring QoL, with only about one out of five trials 
including QoL instruments. To our disappointment, there is also no reason for optimism that 
the situation might improve in the near future, as our findings suggest that QoL measurement 
in eczema RCTs has not increased over time, which is in contrast to what we had initially 
assumed according to a previous review.17 A more recent study found that 33% of eczema 
RCTs conducted between 2010 and 2015 included QoL outcome measures, a figure markedly 
higher than ours (20.8%).41 However, in that review the authors counted also instruments like 
for instance the Beck Depression Inventory or State-Trait Anxiety Inventory among QoL 
instruments. This may at least partly explain the difference since we did not consider these for 
our review because they do not specifically measure QoL but other constructs (i.e. depression 
and anxiety in the example above). Nonetheless, the findings of Hill et al. on the most 
frequently applied QoL instruments in eczema are in accordance with the results of our 
systematic review. 
Our first systematic review showed that in adult sufferers of eczema, a multitude of 16 
different QoL instruments was used in 36 trials assessing QoL. However, the DLQI, and to a 
lesser extent the Skindex-29, were applied in the large majority of these studies, with all other 
questionnaires only used in one study each. According to our second review, the Skindex-29 
is almost not validated in eczema, which is why its appropriateness for eczema RCTs is 
unclear. In contrast, it has become obvious from our findings that the appropriateness of the 
DLQI for eczema patients is at least doubtful. While the Spanish DLQI was proven reliable 
and responsive and was thus placed in category B, the UK version of the DLQI was found to 
have poor internal consistency, content and structural validity in eczema and is therefore 
suggested not to be used anymore in eczema trials. Although internal consistency, content and 
structural validity of the Spanish DLQI in eczema patients are yet unknown, the results 
obtained in the instrument’s UK version challenge the applicability of the DLQI to eczema 
patients in general, and raise the question whether the Spanish version will perform better 
with respect to these measurement properties. Furthermore, 4 out of 36 trials assessing adult 
QoL applied modified or self-provided instruments which have not been validated at all. The 
most appropriate instrument to measure QoL in eczema currently available, the QoLIAD, was 
used in only one eczema RCT, though. Altogether, we could demonstrate that the 
overwhelming majority of eczema RCTs assessing adult QoL have thus far relied on 
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inappropriate or insufficiently validated measurement instruments to evaluate the QoL of the 
included patients, clearly demonstrating the necessity of an eczema-specific quality of life 
measurement instrument with sufficient validity evidence. 
In stark contrast to the findings for adults, only four QoL questionnaires were used in trials in 
infants, children and adolescents with eczema. When focusing on the validated ones only, two 
instruments are left over: the proxy-reported IDQoL, an eczema-specific measure for infants, 
and the self-reported CDLQI, a dermatology-specific QoL questionnaire. The included studies 
did not apply any QoL instruments specifically designed for adolescents. Findings from our 
third review suggest that both the IDQoL and the CDLQI are poorly validated in eczema, 
whereas the only instrument having the potential to be recommended for pediatric eczema in 
the future, the U.S. version of the CADIS, was not used in any of the studies assessed in our 
first review. Similar to the situation in adult patients, these results underline how urgently a 
quality of life instrument with sufficient evidence for its validity is needed for pediatric 
eczema.   
The fact that none of the investigated QoL instruments for infants, children, adolescents and 
adults could be recommended for inclusion in the COS being developed by the HOME 
initiative will delay its finalization for at least two years. However, our systematic review 
helped to reveal substantial validation gaps of most QoL instruments and forms the basis for 
prioritizing future research needs. One of the validation studies to be carried out should focus 
on clarifying the performance of the QoLIAD with respect to measurement error, reliability, 
structural validity, cross-cultural validity, and responsiveness; also, another examination of its 
construct validity seems advisable in light of a negative rating that the Dutch QoLIAD 
obtained for this measurement property. Except reliability and responsiveness, all other 
measurement properties of the Spanish DLQI need to be evaluated in another validation 
study, with particular attention to internal consistency, content and structural validity, where 
the English DLQI (UK) failed. With respect to pediatric patients, further validation studies of 
the CADIS, including all available language versions, are necessary; these should investigate 
measurement error, content validity, structural validity, cross-cultural validity, responsiveness 
and interpretability. Furthermore, we recommend performing additional validation studies for 
the IDQoL, which is the most frequently used QoL instrument in infants. Eventually, better 
validation of self-reported questionnaires for children and adolescents, particularly the 
CDLQI and the DISABKIDS-ADM, is desirable. 
Nevertheless, clinicians and researchers should include a QoL measurement instrument in all 
their upcoming eczema trials because QoL is one of the core outcome domains of the 
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proposed COS. As no distinct instrument for measuring QoL in eczema trials can be 
recommended at the moment, the HOME initiative suggests using any QoL instrument that is 
at least valid, reliable and feasible in eczema patients.42 Unfortunately, one result of our 
second and third review is that currently no such instrument is available. There is no optimal 
solution to this dilemma. Clinicians and researchers need to weigh up validity, reliability and 
feasibility. With respect to adult patients, we suggest that researchers should include one of 
the two instruments from category B, i.e. the QoLIAD in several language versions or the 
(Spanish) DLQI, in their trials. For infants and younger children, we recommend using the 
proxy-reported CADIS, whereas no clear advice can be given for older children and 
adolescents. In older adolescents, the suggested QoL instruments for adults may be used. 
 
Probably the most important question for the HOME initiative to be successful is how to 
increase the acceptance of the proposed COS in the scientific community. Although 
continually rising attendance figures of the HOME meetings indicate that many stakeholders, 
including dermatologists, patients, methodologists, and representatives from industry, are 
interested in developing a COS for eczema trials, there has also been criticism. Besides other 
reservations, a major point of concern is the (ostensibly) one-sided preference of 
methodologically questionable systematic reviews as basis for decision-making instead of 
focusing on original research and taking into account clinicians’ views.43,44 The assertion of 
an underrepresentation of clinicians at the HOME meetings and in the HOME processes can 
easily be refuted by the fact that at the third and fourth HOME meeting clinicians made up the 
majority of voters;45,46 moreover, the HOME initiative is open to anyone interested in a COS 
for eczema trials, invalidating the alleged dominance of methodologists.47 However, it is true 
that the processes used by HOME are puzzling for many clinicians. The methods are 
complicated and differ greatly from the ones used in RCTs and traditional systematic reviews. 
Moreover, the results of the reviews may indeed not be helpful for dermatologists in research 
and clinical practice to decide on the most appropriate instrument, as is demonstrated by 
review 2: the meaning of the result that two instruments were placed in category B grows not 
immediately apparent and probably leaves most clinicians none the wiser. Consequently, 
HOME’s most important challenge is to spell out its methods in more detail and to translate 
the findings of its processes into meaningful guidelines easily comprehensible for the 
practicing dermatologist. Nonetheless, there is a germ of truth in the criticized methodological 
weakness of the systematic reviews that the HOME initiative is relying on. 
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While there is general agreement in medicine that systematic reviews are vital for evidence 
based decision making,48–50 deficiencies in their methodology are considered to render their 
results less conclusive.51,52 Despite considerable differences to “traditional” systematic 
reviews which evaluate for instance information obtained in RCTs, methodological 
weaknesses are also found in systematic reviews of measurement properties such as ours. One 
of these weaknesses concerns the COSMIN checklist that we used to assess the 
methodological quality of the included studies. The inter-rater reliability of the COSMIN 
checklist was found to be poor,53 which is particularly relevant for our systematic reviews 
where two reviewers independently completed the COSMIN checklist for each study. 
Notably, the findings on poor inter-rater reliability refer to the initial version of the COSMIN 
checklist with a dichotomous response format; however, we used the refined version with a 4-
point rating system.54 Although the inter-rater reliability of the latter version has not been 
investigated, it can be assumed that this checklist would perform even worse than the 
dichotomous one because rating the methodological quality from “excellent” to “poor” is 
much more open to subjective judgment than only opting for “yes” or “no”, particularly since 
many of the response options to the items of the 4-point COSMIN checklist are formulated 
vaguely (e.g., distinction between “Multiple hypotheses formulated a priori” and “Minimal 
number of hypotheses formulate a priori”). Taking into account our experience from review 2, 
we tried to minimize inter-rater reliability in review 3 by involving the same reviewer in 
every pair that completed COSMIN boxes. However, this approach cannot overcome other 
problems associated with the COSMIN checklist such as the need for subjective judgment, the 
difficulty for the two reviewers to agree on a common rating, the fact that only for the initial 
dichotomous version a manual is available,55 and general criticism of the COSMIN 
checklist’s ostensibly unjustified rejection of well-established measures, e.g. effect sizes for 
responsiveness, as inappropriate.56  
The COSMIN checklist’s stringent requirements, which lead to the mentioned negative 
judgment of certain measures, are reflected in the fact that 25% of the evaluated measurement 
properties obtained a “poor” rating in the second review, as compared to 76% in the third 
review. As these measurement properties are not taken into account for the best evidence 
synthesis, there arises the question whether the high standards of the COSMIN checklist are 
justified or if less strict requirements would also be sufficient in order not to lose such a large 
amount of possibly valuable data. For instance, some of the checklist items judge reporting 
standards instead of methodological quality, and insufficient reporting can even lead to a 
“poor” rating for a measurement property despite adequate methodological quality (e.g., item 
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8 in box F, where missing information on the measurement properties of the comparator 
instruments results in a “poor” rating for hypothesis testing). Although good reporting in 
studies is of course desirable and sometimes even the prerequisite for adequate 
methodological quality, the COSMIN checklist should not evaluate the quality of reporting 
where it is not a requirement for methodological quality. As a result, some of the checklist’s 
standards are indeed too high and may unduly bar findings for some measurement properties 
from further analysis. This may also lead to a delayed finalization of COS development since 
the completion of additional validation studies often takes several years. A potential way out 
of that dilemma could be the findings of a recent Delphi study on how to select outcome 
measurement instruments for a COS. The participating experts reached consensus on 
minimum requirements for including an outcome measurement instrument in a COS; these are 
at least high quality evidence for good content validity and good internal consistency, and the 
instrument has to be feasible.57 Applying these minimum requirements in COS development 
could open the way for suggesting at least a provisional COS in situations where the 
COSMIN checklist would still require further validation before an outcome measurement 
instrument can be recommended.   
Nevertheless, it has to be noted that the COSMIN checklist was developed in a Delphi study 
involving 57 international experts in the field of psychology, epidemiology, statistics, and 
clinical medicine, whose consensus-based decisions determined items and response options of 
the checklist.38 Therefore, although a critical appraisal of the stringency of the COSMIN 
checklist’s standards is lacking in the literature, it can be assumed that most of the 
requirements formulated in the COSMIN checklist are reasonably high.       
Altogether, the COSMIN checklist – despite a number of shortcomings - is a useful 
instrument for evaluating the methodological quality of studies on measurement properties. 
However, a critical revision of its content in order to increase inter-rater reliability and to 
lower standards where they are unreasonably high seems to be required; the use of agreed 
minimum requirements may be useful for the time being. 
When discussing methodological deficiencies, attention must also be drawn to the adequacy 
criteria proposed by Terwee et al.35 The criteria used for our reviews are based on those 
presented by Terwee et al. in a template protocol available upon request from the COSMIN 
initiative.58 Importantly, these criteria have not been published in a scientific journal; 
however, they deviate from the ones Terwee et al. had previously suggested.35 As authors can 
only cite the latter ones, the transparency of reviews in this respect is suboptimal. New 
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adequacy criteria agreed upon by experts in the field in a Delphi study have been recently 
published and could be used in upcoming systematic reviews in order to avoid that problem.57 
Eventually, the criteria for best evidence synthesis applied by the HOME initiative59 appear to 
be suboptimal. According to these criteria, any measurement property of a QoL instrument 
which conflicting ratings are obtained for will be assigned the rating “+/-“, irrespective of the 
number of positive and negative ratings for that measurement property. Consequently, these 
criteria do not allow for improvement of QoL instruments that obtained negative ratings for 
some measurement properties. Even if further validation studies would result in a positive 
rating for the measurement properties in question, the overall rating according to the criteria 
for best evidence synthesis would only change from negative to conflicting, but could never 
become positive. In the light of the results of review 2, where we identified the need for 
further validation studies for two questionnaires that had obtained negative ratings for some 
measurement properties in some language versions, these criteria seem irrational and should 
thus be enhanced accordingly in the future. Improved criteria for best evidence synthesis that 
could be adopted by the HOME initiative have recently been proposed.57  
 
In conclusion, the three reviews that we conducted could clearly demonstrate the need for a 
COS in eczema that includes QoL instruments. Although some parts of the methodology 
applied were not optimal and could still be improved, our findings are based on evidence 
judged according to established and internationally acknowledged criteria. For both pediatric 
and adult eczema patients, no distinct QoL instrument can be recommended for inclusion in 
the proposed COS. Further validation work should focus on the QoLIAD and the DLQI for 
adults, the CADIS for infants, and the CDLQI and DISABKIDS-ADM for children and 
adolescents.  
The results of our systematic reviews informed the fourth and the fifth international consensus 
meeting to harmonize core outcome measures for atopic eczema.60 Due to the substantial 
validation gaps of the investigated QoL instruments, the attendants of the meetings felt not 
able to recommend one distinct QoL instrument for inclusion in the COS proposed by the 
HOME initiative, neither for adult nor for pediatric eczema. Further validation studies may 
hopefully increase the evidence base and thus enable the group to agree on a specific QoL 
instrument to be included in the COS. A well thought-out COS is essential to improve eczema 
treatment – both clinicians and patients will benefit in the end. 
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5. Abstract 
5.1 Introduction 
Eczema (synonym: atopic eczema (AE), atopic dermatitis (AD)) is an inflammatory skin 
disease with a chronic or chronically relapsing course and is common among adults and 
children. Its main symptom is pruritus. Because it negatively impacts the patients’ quality of 
life (QoL), some eczema randomized controlled trials (RCTs) include QoL measurement 
instruments to assess treatment efficacy. However, the use of numerous different QoL 
instruments, many of which are insufficiently validated, hampers evidence-based decision 
making through meta-analyses and systematic reviews. Therefore, the Harmonising Outcome 
Measures for Eczema (HOME) initiative seeks to establish a core outcome set (COS), i.e. a 
minimum set of outcomes to be assessed in every eczema RCT. In my MD thesis, I aimed to 
lay the ground for the QoL part of that COS by providing three systematic reviews on QoL 
instruments in eczema. 
5.2 Material and methods 
The first systematic review investigated which QoL instruments have thus far been used in 
eczema RCTs. The Global Resource of Eczema Trials (GREAT) database was searched for 
reports of eczema RCTs. Information on patient-reported outcomes, particularly QoL, was 
extracted from eligible studies. In the second systematic review, a systematical assessment of 
the measurement properties of existing measurement instruments developed and/or validated 
for the measurement of QoL in adult eczema was performed. After a systematic literature 
search in PubMed and Embase for studies on measurement properties of adult eczema QoL 
instruments, the adequacy of the measurement properties and the methodological quality was 
evaluated using the COSMIN checklist. A best evidence synthesis summarizing findings from 
different studies was the basis to assign four degrees of recommendation (A–D). The third 
systematic review aimed to systematically evaluate the measurement properties of existing 
measurement instruments developed and/or validated for the measurement of QoL in infants, 
children and adolescents with eczema. Similar to the second review, a systematic literature 
search in PubMed and Embase retrieved studies on measurement properties of eczema QoL 
instruments for infants, children and adolescents. Again, adequacy and methodological 
quality were assessed using the COSMIN checklist, with an ensuing best evidence synthesis 
as basis for further recommendations. 
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5.3 Results 
287 full texts reporting on 303 trials and 72 abstracts were eligible for the first systematic 
review. 63 of the 303 studies (20.8%) assessed QoL and used 18 named and 4 unnamed QoL 
instruments, with the most common instruments being the Dermatology Life Quality Index 
(DLQI) for adults, the Children’s Dermatology Life Quality Index (CDLQI) for children, the 
Infants’ Dermatitis Quality of Life Index (IDQoL) for infants and the Dermatitis Family 
Impact (DFI) for caregivers. The second systematic review included 15 articles reporting on 
17 QoL instruments, none of which fulfilled all requirements for recommendation. Six 
instruments were placed in category B, meaning that they have the potential to be 
recommended depending on the results of further validation studies. Three instruments had 
poor adequacy in at least one required adequacy criterion and were therefore put in category 
C. The remaining eight instruments were minimally validated and were thus placed in 
category D. In the third systematic review, 17 articles reporting on 24 QoL instruments were 
included, none of which fulfilled all required adequacy criteria. The U.S. version of the 
Childhood Atopic Dermatitis Impact Scale (CADIS) was found to have the potential to be 
recommended depending on the results of further validation studies. All other instruments 
lacked significant validation data. 
5.4 Conclusion 
In conclusion, there are two main findings of my MD thesis. Firstly, only one out five eczema 
RCTs assesses QoL. Many different instruments are used, limiting the possibilities of 
comparing and synthesizing individual trials’ findings. Secondly, no QoL instrument can 
currently be recommended for inclusion in the proposed COS until further validation data is 
available. For the time being, research should focus on the Quality of Life Index for Atopic 
Dermatitis (QoLIAD) and the DLQI for adults as well as the CADIS and self-reported 
instruments for infants, children and adolescents. 
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It is unclear which quality of life instruments have thus 
far been used in eczema trials. Therefore, we aimed to 
identify these instruments. We searched the Global Re-
source of Eczema Trials (GREAT) database for reports 
of randomized controlled trials. Information on patient-
reported outcomes, particularly quality of life, was ex-
tracted from eligible studies. Two-hundred and eighty-
seven full texts reporting on 303 trials and 72 abstracts 
were included. Of the 303 studies, 63 (20.8%) assessed 
quality of life and used 18 named and 4 unnamed instru-
ments. The Dermatology Life Quality Index (DLQI), the 
Children’s Dermatology Life Quality Index (CDLQI), 
the Infants’ Dermatitis Quality of Life Index (IDQOL), 
and the Dermatitis Family Impact (DFI) were the most 
common measures in adults, children, infants, and care-
givers, respectively. In conclusion, only about one fifth 
of eczema trials include a quality of life measure as out-
come. Many different instruments are used, limiting the 
possibilities of comparing and synthesising individual 
trials’ findings. Key words: eczema; atopic dermatitis; 
quality of life; patient-reported outcomes; HOME initia-
tive.
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Eczema (synonym: atopic dermatitis (AD)) is a common 
skin disease that affects both children and adults. It ex-
erts a negative impact on the quality of life (QoL) of the 
patients and their families and places a considerable fi-
nancial burden on patients and society (1, 2). The disease 
is characterized by a chronic or chronically relapsing 
course, with pruritus being the main symptom (3). The 
prevalence of eczema has increased over recent years (4).
Despite a multitude of available treatment options, 
important uncertainties remain in the treatment of ec-
zema requiring the conduct of high quality randomized 
controlled trials (RCTs) (5, 6). The use of non-standar-
dized and inadequately validated outcome measurement 
instruments (OMIs) in eczema trials hampers evidence-
based decision making because treatment effects may be 
over- or underestimated. Furthermore, comparison and 
evidence synthesis is rendered difficult when outcome 
measurement is not standardized.
Therefore, the Harmonising Outcome Measures for 
Eczema (HOME) initiative set out to define a core out-
come set (COS) that should be assessed in all eczema 
trials in the future (7). A COS is a consensus-derived 
minimum set of outcomes to be assessed in a specific 
situation (8). HOME agreed to consider clinical signs, 
symptoms, long term control and QoL as core outcome 
domains (9). For each of these domains an adequate 
OMI needs to be identified. For the signs domain, this 
process has been completed and the Eczema Area and 
Severity Index (EASI) has been identified as the cur-
rently most adequate measurement instrument to assess 
clinical signs in eczema (10).
To standardize processes and to provide a standard 
for COS development in dermatology, the HOME ini-
tiative has published a roadmap (11). According to this 
roadmap, the first step for each core outcome domain 
is a comprehensive review of what OMIs have actually 
been used.
QoL, as one of these core outcome domains, is usu-
ally classified as a patient-reported outcome (PRO). 
A PRO is defined as any report coming directly from 
patients, without interpretation by physicians or others, 
about how they function or feel in relation to a health 
condition and its therapy (12). Where clinical trials use 
a PRO as primary endpoint, this is a reflection of the 
importance that study authors place on PROs. Thus, 
with QoL being a PRO, we hypothesized that authors 
who used PROs as primary endpoints in eczema trials 
would also be more likely to apply QoL questionnaires. 
In accordance with the HOME roadmap (11), the 
primary aim of this systematic review was to identify 
the QoL measurement instruments used in eczema trials 
from the year 2000 onwards. We were also interested 
in whether there were any time trends in their usage. A 
secondary aim was to find out whether the considera-
tion of a PRO as a primary endpoint in eczema trials 
was related to the inclusion of a QoL instrument as an 
outcome measure. 
Eczema Trials: Quality of Life Instruments Used and Their Relation 
to Patient-Reported Outcomes. A Systematic Review
Daniel HEINL1, Joanne CHALMERS2, Helen NANKERVIS2 and Christian J. APFELBACHER1
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METHODS
Sample article selection
To obtain a comprehensive selection of eczema trials, we sear-
ched the Global Resource of Eczema Trials (GREAT) Database 
(13), which includes records of all RCTs of eczema treatments 
(14). An article was considered eligible if it was an eczema tre-
atment trial published since 2000, was indexed in the GREAT 
database by 31 May 2014 and if a full text or an abstract was av-
ailable in either English or German language. We did not consider 
any other sources of eczema trials besides the GREAT database.
Outcomes
The outcomes of interest were: i) the proportion of articles that 
assessed a QoL outcome, ii) the proportion of articles that as-
sessed a PRO, iii) whether the inclusion of a QoL measure was 
related to whether the primary endpoint was a PRO, iv) what 
QoL instruments were used, v) the number of QoL instruments 
per study and vi) the number of studies published and the pro-
portion including QoL instruments over time. 
A patient-reported outcome (PRO) was defined according to 
Patrick et al. (12) as any report coming directly from patients, 
without interpretation by physicians or others, about how they 
function or feel in relation to a health condition and its therapy. 
Any outcome used in the included studies that fulfilled this 
definition was recorded as a PRO. We did not categorize PROs 
according to content or type. The term ‘composite index’ was 
used to describe any score or index that is composed of both a 
PRO and a non-PRO part. 
Data extraction
Data extraction was carried out by D.H. To ensure consistency 
in the data extraction, guidelines on what information should 
be gathered and how this information should be evaluated was 
agreed on beforehand by D.H. and C.A. Where these guidelines 
were not applicable to certain studies, the whole team decided 
about how to evaluate the information from those studies. A 
second data extraction was performed for a random sample of 
10% of the papers by J.C. as a measure of quality assurance. 
For this sample, results were compared between the first and 
the second data extraction and discrepancies were resolved 
within the whole team. Where a resolution of a discrepancy 
within this random sample meant that changes were necessary 
to the initially extracted information by D.H., these changes 
were also made in the data extractions of the rest of the studies 
where applicable. Where the study was reported only in an 
abstract, only data on QoL was extracted.
Data analysis
Statistical data analysis was split into a descriptive and an 
analytical part.
Descriptive analysis
We determined the absolute number and the percentage of ar-
ticles assessing QoL. To get an overview of the most common 
QoL measures, we recorded which questionnaires were used 
by how many studies. Moreover, we determined the number 
of QoL instruments used per article (only regarding articles 
which assessed QoL) and explored changes in the usage of QoL 
measures over time, which we visualized in diagrams created 
with Microsoft Excel. 
We also calculated the proportion of PROs (with/without 
composite indices) in relation to all outcomes, the absolute 
number and percentage of articles assessing PROs (with/with-
out composite indices) in relation to all articles, the median 
number (and interquartile range (IQR)) of outcomes per article, 
the median number (and IQR) of PROs per article (with/without 
composite indices; only regarding articles which assess PROs) 
and the number of composite indices per article (only regarding 
articles which assess composite indices). Furthermore, we 
analysed changes in the total number of outcomes over time 
and depicted our findings in a diagram.
Analytical analysis
We hypothesized that authors who are generally in sympathy 
with the integration of PROs in eczema trials would also be 
more likely to apply QoL questionnaires. Therefore, we com-
puted the absolute and relative frequency of articles assessing 
QoL in articles with PROs as primary endpoint, in articles with 
composite indices as primary endpoint, in articles which did not 
specify their primary endpoint and in articles with non-PROs 
as primary endpoint. A chi-square test was conducted to test 
our hypothesis about the connection between a study’s primary 
endpoint and QoL assessment. The results of this chi-square test 
were presented in a contingency table. Level of significance 
was set at 5%.
For all analyses, IBM SPSS 22.0 was used. Data was extracted 
and figures were designed with Microsoft Excel 2013. We used 
EndNote X6 to manage references.
RESULTS
Our search yielded 378 papers that were published 
since 2000 and indexed in the GREAT database by no 
later than 31 May 2014. References to these papers can 
be found in Appendix S11. Nineteen articles were not 
eligible. The reasons for exclusion were: paper was 
protocol only (n = 9), no English or German abstract 
or full text was available (n = 5), paper reported on a 
study already included (n = 4), paper was conference 
publication and not available as abstract or full text 
(n = 1). Of the 359 eligible articles, we were able to 
obtain the full text for 287 papers, and an abstract only 
for the remaining 72 articles. The 287 full text papers 
reported on 303 studies. The distribution of publica-
tions over time is shown in Fig. 1. As can be seen from 
Fig. 1, 2011 saw the highest number of trials. Despite 
some minor differences, similar numbers of studies 
were found eligible for every publication year.
Descriptive analysis
Overall, only 63 (20.8%) studies assessed QoL. The 
QoL instruments that were applied in these studies are 
listed in Table I for adults and children and families, 
respectively. In adults, the Dermatology Life Quality 
Index (DLQI) (15) was the most frequently used self-
reported QoL measure; in children, the Children’s 
Dermatology Life Quality Index (CDLQI) (16) was 
the most popular self-reported questionnaire and the 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2322
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Infants’ Dermatitis Quality of Life Index (IDQOL) 
(17) was the proxy-reported instrument most often 
used. QoL of carers of children was predominantly 
assessed with the Dermatitis Family Impact (DFI) 
questionnaire (18). Altogether, 18 named and 4 unna-
med QoL questionnaires were used; of these, 4 were 
infant- or children-specific measures, 4 assessed the 
QoL of carers and 16 instruments were applicable to 
adult patients with eczema. Six instruments, 4 of which 
are validated, were eczema-specific.
Of the 63 trials that assessed QoL, we found that the 
majority of studies (n = 41, 65.1%) used only one QoL 
measurement instrument. Two QoL instruments were 
applied in 16 studies (25.4%) and the remaining 6 stu-
dies (9.5%) included 3 QoL measurement instruments. 
Analysis over time showed that although there were 
fluctuations from year to year, the proportion of trials 
that include QoL measures has remained largely static 
since 2000 (Fig. 2). For instance, none of the 22 studies 
that were published in 2005 included a QoL instrument 
whereas studies from 2006 with an inclusion rate of 
QoL measurement instruments of 31% are even above 
average. The highest percentage of studies assessing 
QoL (50%) was observed in 2014; however, this finding 
needs to be put into context as only 4 studies from 2014 
were included in total.
Similarly, we could not observe any clear trends 
towards increased or reduced usage of the most fre-
quently applied specific QoL instruments (Fig. S11). 
In most years, less than 10% of the included full texts 
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Fig. 1. Distribution of included full text studies over time.
Table I. Quality of life instruments used in adults and children and families/carers
Instrument, Ref.
Studies 
n (%), Ref. Type Full name
Adults (n = 36)
DLQI (15) 20 (56) (19–38) Dermatology-specific Dermatology Life Quality Index
Skindex-29 (39) 2 (6) (40, 41) Dermatology-specific
EDLQ (42) 1 (3) (43) Generic Everyday Life Questionnaire/Alltagsleben
EQ-5D (44) 1 (3) (45) Generic EuroQoL-5D
SF-36 (46) 1 (3) (47) Generic Short form 36
SIP (48) 1 (3) (49) Generic Sickness Impact Profile
WTP (50) 1 (3) (49) Generic Willingness To Pay
DIELH (51) 1 (3) (52) Dermatology-specific Deutsches Instrument zur Erfassung der 
Lebensqualität bei Hauterkrankungen
DLQI (modified)* (15) 1 (3) (53) Dermatology-specific Dermatology Life Quality Index
FLQA-d (54) 1 (3) (49) Dermatology-specific Freiburg Life Quality Assessment for Dermatoses
ISDL (modified)* (55) 1 (3) (36) Dermatology-specific Impact of Chronic Skin Disease on Daily Life
Self-provided* 1 (3) (56) Dermatology-specific Unnamed
Skindex-16 (57) 1 (3) (58) Dermatology-specific
Skindex-17 (59) 1 (3) (60) Dermatology-specific
EDI* (61) 1 (3) (62) Eczema-specific Eczema Disability Index
QoLIAD (63) 1 (3) (26) Eczema-specific Quality of Life Index for Atopic Dermatitis
Children and families/carers
Proxy-reported instrumentsa (n = 15)
IDQOL (17) 14 (93) (36, 64–76) Eczema-specific Infants’ Dermatitis Quality of Life Index
Self-provided* 1 (7) (77) Eczema-specific Unnamed
Self-reported instrumentsb (n = 20)
CDLQI (16) 18 (90) (28, 65, 69, 72–75, 78–88) Dermatology-specific Children’s Dermatology Life Quality Index
CDLQI (modified)* (16) 2 (10) (89, 90) Dermatology-specific Children’s Dermatology Life Quality Index
Instruments assessing the quality of life of adult carers of children with eczema (n = 20)
DFI (18) 14 (70) (45, 64–67, 69–73, 81, 86, 
87, 91)
Dermatology-specific Dermatitis Family Impact
Questionnaire by Rüden et al. (92) 3 (15) (43, 93, 94) Eczema-specific Unnamed
PIQoL-AD (95) 2 (10) (88, 96) Eczema-specific Parents’ Index of Quality of Life in Atopic Dermatitis
Self-provided* 1 (5) (83) Unknown Unnamed
*Instruments marked with an asterisk have not been validated at all.
aProxy-reported means that the (primary) caregiver of an infant fills in a questionnaire that assesses the quality of life of the infant. Proxy-reported instruments 
are often used in infants and younger children because they cannot report on their quality of life themselves due to their inability to read and a lack of 
understanding. bSelf-reported instruments are used in older children. These questionnaires are filled in by the children themselves, not by their caregiver.
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applied the DLQI (15), the IDQOL (17), the CDLQI 
(16) or the DFI (18). In 2014, 25% of the included full 
texts used the 4 instruments depicted in Fig. S11; how-
ever, this result should not be interpreted as a recent rise 
in usage of these measures since only 4 full texts from 
2014 were included in our systematic review.
For the studies which were reported in abstract form 
only, only 4 out of 72 (6%) assessed QoL. The CDLQI 
(16) was used in 2 abstracts and the DFI (18) in 1 ab-
stract. Three further QoL instruments were reported, 
but were not named.
The assessment of the full text articles revealed that 
a total of 2,633 outcomes were assessed of which 809 
(30.7%) were PROs or composite indices (i.e. a scale 
that is composed of both a PRO and a non-PRO part). 
Of these, 633 (24.0%) were PROs and 176 (6.7%) 
were composite indices. The majority of studies (281, 
92.7%) included at least one PRO and/or a composite 
index as any endpoint (primary, secondary, other). A 
total of 230 (85.9%) studies included at least one PRO, 
whereas composite indices were assessed in just over 
half of studies (164, 54.1%). 
The median number of outcomes per study was 7 
(IQR: 5–11). In studies that assessed PROs and/or 
composite indices, the median number of PROs was 2 
(IQR 1–4). The same values were found when looking 
at PROs without composite indices. For studies using 
composite indices, the vast majority of 153 (93.3%) 
studies included only one composite index, 10 studies 
(6.1%) two composite indices and only a single study 
applied 3 composite indices. Analysis over time sho-
wed that the median number of outcomes per study has 
plateaued since 2000. The highest median number of 
outcomes per study was 9.5 in 2006 whereas the lowest 
number was 5 in 2013. A median of 6 outcomes was 
found for 4 years; the same is true for a median of 7 
outcomes. In 3 years, the median number of outcomes 
per study amounted to 8.
Analytical analysis
We were able to categorise the endpoints for 302 stu-
dies: 32 studies (10.6%) chose a PRO as primary end-
point, 58 trials (19.2%) a composite index, 81 studies 
(26.8%) had a non-PRO as primary endpoint and 131 
studies (43.4%) did not specify their primary endpoint. 
The endpoint for one study could not be categorised.
There was a statistically significant association bet-
ween the type of primary endpoint (PRO, composite 
index, non-PRO, not specified) and the assessment of 
QoL (yes/no) (p = 0.002, Table II). Studies with a PRO 
as primary endpoint were most likely to measure QoL, 
followed by studies with a composite index as primary 
endpoint. Likewise, study authors that used a distinct 
non-PRO as primary endpoint were more likely to in-
clude QoL measurement than study authors that did not 
specify their primary endpoint in more detail.
DISCUSSION
QoL is considered particularly relevant for chronic skin 
diseases such as eczema. Inclusion of QoL instruments 
in RCTs is of great importance, given the fact that the 
patient’s perspective on the efficacy of a certain treat-
ment often deviates from clinicians’ assessments (97).
Our study demonstrated that the majority of studies 
(approximately 90%) include at least one PRO. This is 
in contrast to previous findings that only about 25% of 
dermatology trials included a participant efficacy out-
come (98). However, we did not apply any limitations 
concerning the type of PRO which may explain these 
differences. Despite the fact that most studies included 
a PRO, it was clear from this review that the majority 
of outcomes (approximately three-quarters) reported 
are non-PROs. 
Even though the QoL of patients and their family is 
greatly impacted by eczema, respective outcome mea-
sures often seem to only play a minor part in eczema 
trials (99). One study, however, noted a substantial in-
crease in the usage of QoL instruments in eczema trials 
from 1985 to 2010 (100). We were not able to verify 
this trend since our findings suggest that the inclusion 
of QoL measurement instruments has changed very 
little over time. A reason for this result may be that we 
looked at the relative frequency of studies assessing 
QoL instead of absolute numbers, taking into account 
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Fig. 2. Percentage of studies assessing quality of life (QoL) over time. N: 
total number of included studies in the respective year.
Table II. Association between primary endpoint and assessment 
of quality of life 
Primary endpoint
TotalPRO
Composite 
Index Non-PRO
Not 
specified
Quality of Life assessed?
Yes, n (%) 14 (43.8) 14 (24.1) 17 (21.0) 18 (13.7) 63 (20.9)
No, n (%) 18 (56.3) 44 (75.9) 64 (79.0) 113 (86.3) 239 (79.1)
Total, n (%) 32 (100) 58 (100) 81 (100) 131 (100) 302 (100)
χ2=14.556, p = 0.002. 
PRO: Patient-reported outcome.
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the larger quantity of trials in our observation period, 
compared to the observation period investigated by Re-
hal & Armstrong (100). Different time intervals in that 
study and our review may present a further explanation 
of this discrepancy since the idea of QoL in dermatology 
emerged in the early 1990s and the development of the 
first QoL instruments for dermatological conditions 
falls also in this time period. Consequently, a broader 
inclusion of QoL measurement instruments in trials 
did not start until the late 1990s. Rehal & Armstrong 
(100) reported that 14 different QoL instruments were 
used in eczema trials from 1985 to 2010. In contrast, 
we found that from 2000 to 2014, study authors applied 
22 different instruments, suggesting a growing number 
of existing QoL OMIs. Nonetheless, findings on the 
most frequently applied QoL instruments were similar 
in both reviews.
The QoL instruments that were mostly used in clinical 
trials, i.e. the DLQI (15), the IDQOL (17), the CDLQI 
(16) and the DFI (18), all have been developed at 
one academic medical centre (see http://www.cardiff.
ac.uk/dermatology/quality-of-life/). Reasons for the 
widespread use of these instruments may be that they 
are available in many language versions and that they 
are easy to use. All 4 instruments fit on one A4 page 
whereas other questionnaires are often longer. A critical 
review recommends the Skindex-29 (39) rather than the 
DLQI as dermatology-specific QoL measure (101), but 
we identified only 2 trials in which it was actually used.
With respect to the lack of “hard” outcomes such as 
mortality in eczema, QoL measures could fill this gap 
and provide the necessary evidence to judge the ef-
fectiveness and appropriateness of interventions from 
the patients’ perspective. Against this backdrop, it is 
surprising that only 1 out of 5 eczema trials include 
QoL instruments, particularly since similar figures are 
obtained for different diseases in other fields of medi-
cine. For example, one study found that 16% of drug 
clinical trials published in 2005 in 5 high quality jour-
nals included QoL measures (102). However, most of 
these studies reported on heart disease, cancer or other 
serious illnesses where “hard” outcomes are available. 
Authors of future eczema trials should therefore consi-
der the inclusion of a QoL measurement in their trials. 
We could show that authors who chose PROs as 
primary endpoints in their trials were also more likely 
to include QoL measures than researchers that decided 
to use any other endpoints. Surprisingly, this observa-
tion holds also for composite indices: A significantly 
higher proportion of studies with a composite index as 
primary endpoint assessed QoL than did studies with a 
non-PRO or a not specified endpoint. This implies that 
the measurement of QoL is not so much dependent on 
individual characteristics of a trial when opting for or 
against the inclusion of QoL instruments; instead, the 
general attitude of study authors towards PROs appears 
to determine whether or not QoL is measured as well. 
In addition, this finding may also explain why there 
was no increase in QoL measurement over time despite 
ongoing efforts to promote the use of QoL instruments. 
Moreover, there seems to be an association between 
how well researchers report on their study results and 
the measurement of QoL since authors that did not 
specify their primary endpoint were least likely to use 
QoL instruments. However, further research is war-
ranted to find out why QoL measurement instruments 
are not included in more trials.
Some further attention must also be drawn to the high 
proportion of studies that did not specify their primary 
endpoint (43.4%). In contrast, Nassar et al. (103) found 
that only 20% of the RCTs on non-neoplastic skin di-
seases that were published in 2009 did not state their 
primary outcome. However, they restricted their search 
to journals with an impact factor of at least 2. As they 
also showed that a clear definition of the primary end-
point was significantly associated with a higher journal 
impact factor, this result may present an explanation 
for our findings because we did not narrow down our 
eligibility criteria to high quality journals.
In conclusion, we could demonstrate that a high 
proportion of trials include some sort of PROs but that 
QoL was only assessed in about one fifth of all trials. 
Even though a range of QoL measurement instruments 
have been used in RCTs of eczema, most studies applied 
the DLQI (15) for adults, the CDLQI (16) for older 
children, the IDQOL (17) for infants or the DFI (18) 
for adult carers of children with eczema. 
We provide an up-to-date review on QoL OMIs used 
for eczema. A strength of this study was the use of the 
GREAT database, which searches 6 databases, including 
3 specialist databases. A recent study showed a high sen-
sitivity of the GREAT database, with 94% of trials cited 
in systematic reviews on eczema treatments listed in the 
GREAT database (104). The GREAT database therefore 
is considered a primary and comprehensive source to 
identify eczema RCTs. We did not consider any other 
study designs for inclusion in this systematic review.
Limitations of our study were the language restric-
tion to English and German and our focus on the time 
interval from 2000 to 2014. In this way, QoL ques-
tionnaires in other languages may have been missed 
or underestimated and older QoL instruments may 
be underrepresented in our review. Also, we did not 
consider ongoing trials for this review. As a result, we 
cannot rule out the possibility that different findings 
would be obtained when regarding studies that are 
currently under way.
Results on the number of reported outcomes, the 
number of reported PROs, the number of reported 
composite indices, the proportion of validated indices 
used, the assessment of adverse events and additional 
safety assessments will be reported elsewhere.
Acta Derm Venereol 96
41
601What quality of life instruments have been used in eczema trials?
The aim of this systematic review was not to critically 
appraise the measurement properties of the available 
QoL scales for eczema patients. Instead, this syste-
matic review is intended to form the basis for further 
research on the appropriateness of the mentioned QoL 
instruments for eczema patients. As the use of so many 
different QoL instruments in eczema trials limits the 
possibility to synthesize their findings in meta-analyses 
and systematic reviews, the HOME initiative aims to 
define a COS including one distinct QoL instrument. 
A critical appraisal of the measurement properties of 
existing QoL instruments is the prerequisite for doing so 
and will be subject to a further systematic review. Our 
review is the first step to reach the goal of including a 
QoL instrument in the COS.
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Abstract
Background: Eczema is a common chronic or chronically relapsing skin disease that has a substantial impact on
quality of life (QoL). By means of a consensus-based process, the Harmonising Outcome Measures in Eczema
(HOME) initiative has identified QoL as one of the four core outcome domains to be assessed in all eczema trials
(Allergy 67(9):1111-7, 2012). Various measurement instruments exist to measure QoL in adults with eczema, but
there is a great variability in both content and quality (for example, reliability and validity) of the instruments used,
and it is not always clear if the best instrument is being used.
Therefore, the aim of the proposed research is a comprehensive systematic assessment of the measurement
properties of the existing measurement instruments that were developed and/or validated for the measurement of
patient-reported QoL in adults with eczema.
Methods/Design: This study is a systematic review of the measurement properties of patient-reported measures of
QoL developed and/or validated for adults with eczema. Medline via PubMed and EMBASE will be searched using a
selection of relevant search terms. Eligible studies will be primary empirical studies evaluating, describing, or
comparing measurement properties of QoL instruments for adult patients with eczema. Eligibility assessment and
data abstraction will be performed independently by two reviewers. Evidence tables will be generated for study
characteristics, instrument characteristics, measurement properties, and interpretability. The quality of the measurement
properties will be assessed using predefined criteria. Methodological quality of studies will be assessed using the
COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. A best
evidence synthesis will be undertaken if more than one study has investigated a particular measurement property.
Discussion: The proposed systematic review will produce a comprehensive assessment of measurement properties of
existing QoL instruments in adult patients with eczema. We aim to identify one best currently available instrument to
measure QoL in eczema patients.
Systematic review registration: PROSPERO CRD42015017138.
Keywords: Eczema, Measurement instruments, Health-related quality of life, Quality of life, Validity, Reliability,
Responsiveness, Interpretability
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Background
Eczema (synonymous with atopic eczema, atopic derma-
titis) is an important medical condition not only in chil-
dren but also in adults. The prevalence of eczema in
adults is estimated at 1% to 3% [1]. Various different inter-
ventions exist, many of which have been assessed in ran-
domized controlled trials. Due to substantial variation in
eczema outcome measures in trials, interventions are not
comparable. The lack of standardization of eczema out-
come measures currently renders truly evidence-based de-
cision making difficult, if not impossible.
A multi-perspective Delphi study [2] conducted by
the initiators of the Harmonising Outcome Measures
in Eczema (HOME) initiative [3] defined clinical signs
measured by means of a physician-assessed instrument,
symptoms of eczema, and the long-term course of eczema
as the core outcome domains to be applied in all future
eczema trials. At the HOME II meeting in Amsterdam in
2011, the international community confirmed these core
outcome measures and also added quality of life (QoL) to
the core set of outcome domains [4]. The next crucial step
in the process of standardizing eczema outcome measure-
ments is to identify appropriate instruments to measure
each of the four core outcome domains of atopic eczema.
There was broad international consensus among clini-
cians, patients, and methodologists that the Outcome
Measures in Rheumatology (OMERACT) quality criteria
‘Truth, Discrimination, and Feasibility’ [5] need to be met
for eczema outcome measures to be recommended by the
HOME initiative [4].
Objectives
1. To systematically assess the measurement properties
of patient-reported measurement instruments of
QoL for adults with eczema
2. To identify outcome measurement instruments for
QoL in adults with eczema
2.a. that meet the predefined criteria to be recommended
[4,5] for the measurement of QoL in future
eczema trials
2.b.that have the potential to be recommended in
the future depending on the results of further
validation studies
2.c. that do not meet the predefined criteria to be
recommended [4,5] and therefore should not be
used any more.
3. To provide the evidence base
3.a. for an international consensus process to further
standardize the assessment of QoL in adults with
eczema in clinical trials.
3.b.for an international consensus process to
prioritize further research concerning QoL
assessment in adults with eczema.
Methods/Design
Protocol and registration
The methods for this systematic review have been devel-
oped according to recommendations from the Preferred
Reporting Items for Systematic Reviews and Meta-Analyes
Protocols (PRISMA-P) statement [6]. This protocol has
been registered in the International Prospective Register of
Systematic Reviews (PROSPERO): CRD42015017138.
Literature search
A systematic literature search will be performed in
PubMed and EMBASE. The search strategy will contain
blocks of search terms related to the following aspects:
1. construct of interest: quality of life
2. target population: (atopic) eczema (cf Table 1).
3. measurement properties: the precise PubMed search
filter for finding studies on measurement properties
developed by Terwee et al. will be used to identify
relevant articles [7]. This filter has a sensitivity of
93.1% and a precision of 9.4%.
4. interpretability
The entire search strategy is available as an Additional
file 1 to this protocol.
The systematic electronic search will be supplemented
by hand searching of reference lists of studies included
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Population Eczema (synonyms: atopic eczema, atopic
dermatitis, neurodermatitis)
Populations with other skin diseases than eczema, populations of
children with eczema, and populations of adolescents with eczema
Study design Development study, validation study Linguistic validation studies
Outcome Quality of life, health-related quality of life Signs, disease severity measure, disease control measure, biomarker,
and physiology of the skin
Type of measurement
instrument
Self-reported measurement instrument All others
Publication type Articles with available full text Abstracts
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and key articles on this topic. Furthermore, an additional
search will be performed in each database, including the
names of the instruments which are found in the initial
search. The PROQOLID (www.proqolid.org) database will
be searched.
Eligible measurement instruments
Eligible measurement instruments will include all patient-
reported measurement instruments which were designed
and/or validated to measure QoL in adults with eczema.
Eligible studies
A study will be included if it is published as a full-text
paper and concerns the development (‘development
paper’) and/or evaluation of the measurement properties
(‘validation paper’) of instruments that measure QoL or
health-related quality of life (HrQoL) in adult people
with eczema. A study with a mixed patient sample will
be eligible either if it presents a subgroup analysis for
adult patients with atopic eczema or if adult patients
with atopic eczema constitute at least 50% of the study
population. The measurement instrument must be a
self-reported questionnaire. Articles that report indir-
ect evidence, for instance, by using data obtained
within the context of a clinical trial, will not be considered
eligible. Articles assessing the measurement properties of
dermatology-specific instruments in non-eczema samples
will not be considered eligible.
Study selection
Two reviewers will independently judge titles and ab-
stracts retrieved in the literature search and, at a second
stage, full-text articles for eligibility (Table 1). Disagree-
ments will be resolved by discussion with all reviewers.
Assessment of the methodological quality of included studies
The COnsensus-based Standards for the selection of
health Measurement Instruments (COSMIN) checklist
[8-10] will be used to evaluate the methodological
quality of included studies. In the COSMIN checklist
(cf www.cosmin.nl), four domains are distinguished
(reliability, validity, responsiveness, and interpretabil-
ity) with related measurement properties and aspects
of measurement properties. These are listed in Table 2
(adapted from [8]).
For each of the measurement properties, the COSMIN
checklist consists of 5 to 18 items covering methodo-
logical standards (organized in nine boxes for the nine
measurement properties). In addition, each item can be
scored on a four-point rating scale (that is, ‘poor,’ ‘fair,’
‘good,’ ‘excellent’). Taking the lowest rating for each item
in one box, an overall quality score (‘poor,’ ‘fair,’ ‘good,’
‘excellent’) is obtained for each measurement property
separately.
The measurement property ‘criterion validity’ will not
be considered for the purpose of this systematic review
since no gold standard exists for QoL.
Data abstraction
Relevant data from all included articles will be summa-
rized in evidence tables. The evidence table will be
drafted and pilot tested. Data from each article included
will be abstracted independently by two reviewers. All
reviewers will participate in this process and will work in
pairs on defined sets of articles. Disagreements will be
resolved by discussion of all reviewers.
Evidence tables will include the following: reference,
geographical location, language, setting, study type, key
characteristics of study subjects, name of measure, do-
mains measured, number of items and (sub)scales, num-
ber and type of response categories, recall period in the
questions, scoring algorithm, time needed for adminis-
tration, mode of administration, target population for
whom the questionnaire was originally developed, how a
full copy of the questionnaire can be obtained, the in-
structions given to those who complete the question-
naire, the available versions and translations of the
questionnaire, results of the measurement properties, all
items from the COSMIN box Generalisability, and all
items from the COSMIN box Interpretability [8,9].
If general characteristics of an instrument (that is,
name of measure, number of items and (sub)scales,
number and type of response categories, recall period in
the questions, scoring algorithm, time needed for admin-
istration, mode of administration, target population for
whom the questionnaire was originally developed, how a
full copy of the questionnaire can be obtained, the in-
structions given to those who complete the question-
naire, the available versions and translations of the
questionnaire) cannot be extracted from the studies in-
cluded, the original development paper may be con-
sulted to obtain missing information.
Content comparison
An overview of the content of each instrument on item
level will be presented in order to visualize which con-
tent is covered by the different instruments. The original
development paper is going to be consulted to obtain
this information.
Quality assessment of the measurement instruments
The predefined criteria for rating the quality of measure
recommended by the COSMIN group will be used [11] (cf
Table 3). These criteria are in accordance with the OMER-
ACT filter [5] which has been adopted by the HOME ini-
tiative [4] and the criteria applied in a previous review on
atopic eczema outcome measures [12] (Table 3).
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Best evidence synthesis
If an instrument has been evaluated in different studies,
findings will be synthesized if the characteristics of the
included studies are sufficiently similar and if the results
of the studies do not show too different or conflicting
findings and if the methodological quality of the in-
cluded studies is sufficient [13]. The criteria for best evi-
dence synthesis are outlined in Table 4.
Generating recommendations for the use of QoL
measurement instruments for eczema
For each instrument identified in the review, a standard-
ized recommendation for usage or required future valid-
ation work will be made depending on the quality of the
instrument and on the methodological quality of included
studies (cf Table 5). According to the results of the HOME
II meeting [4], all three criteria of the OMERACT filter
[5], that is, truth, discrimination, and feasibility, have to be
met by an outcome measure to be recommended by the
HOME initiative.
Four categories of recommendation will be made:
1. QoL measurement instrument meets all
requirements and is recommended for use.
2. QoL measure meets two or more quality items,
but performance in all other required quality
items is unclear, so that the outcome measure
has the potential to be recommended in the
future depending on the results of further
validation studies.
Table 2 Definitions of domains, measurement properties, and aspects of measurement properties
Domain Measurement
property
Aspect of a
measurement
property
Definition
Reliability The degree to which the measurement is free from measurement error
Reliability
(extended
definition)
The extent to which scores for patients who have not changed are the same for
repeated measurement under several conditions: for example, using different sets of
items from the same HR-PROs (internal consistency) over time (test-retest) by different
persons on the same occasion (inter-rater) or by the same persons (that is, raters or
responders) on different occasions (intra-rater)
Internal
consistency
The degree of interrelatedness among the items
Reliability The proportion of total variance in the measurements which is because of ‘true’a
differences among patients
Measurement
error
The systematic and random error of a patient’s score that is not attributed to true
change of the construct to be measured
Validity The degree to which an HR-PRO instrument measures the construct(s) it purports to
measure
Content
validity
The degree to which the content of an HR-PRO instrument is an adequate reflection of
the construct to be measured
Face validity The degree to which (the items of) an HR-PRO instrument indeed looks as though they
are an adequate reflection of the construct to be measured
Construct
validity
The degree to which the scores of an HR-PRO instrument are consistent with hypotheses
(for instance with regard to internal relationships, relationships to scores of other
instruments, or differences between relevant groups) based on the assumption
that the HR-PRO instrument validly measures the construct to be measured
Structural validity The degree to which the scores of an HR-PRO instrument are an adequate reflection of
the dimensionality of the construct to be measured
Hypothesis testing Idem construct validity
Cross-cultural validity The degree to which the performance of the items on a translated or culturally adapted
HR-PRO instrument is an adequate reflection of the performance of the items of the original
version of the HR-PRO instrument
Responsiveness The ability of an HR-PRO instrument to detect change over time in the construct to be
measured
Responsiveness Idem responsiveness
Interpretabilityb The degree to which one can assign qualitative meaning - that is, clinical or commonly
understood connotations - to an instrument’s quantitative scores or changes in scores
Abbreviations: HR-PROs health related patient-reported outcomes, CTT classical test theory. aThe word ‘true’ must be seen in the context of the CTT, which states
that any observation is composed of two components - a true score and error associated with the observation. ‘True’ is the average score that would be obtained
if the scale were given an infinite number of times. It refers only to the consistency of the score and not to its accuracy [14]. bInterpretability is not considered a
measurement property but an important characteristic of a measurement instrument.
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Table 3 Quality criteria for measurement properties adapted from [11] and [15]
Property Rating Quality criteria
Reliability
Internal consistency + Cronbach’s alpha(s)≥ 0.70
? Dimensionality not known OR Cronbach’s alpha not determined
− Cronbach’s alpha(s) < 0.70
+ MIC > SDC OR MIC outside the LOA
? MIC not defined
− MIC≤ SDC OR MIC equals or inside LOA
Reliability + ICC/weighted Kappa≥ 0.70, OR Pearson’s r≥ 0.80
? Neither ICC/weighted Kappa nor Pearson’s r determined
− ICC/weighted Kappa < 0.70 OR Pearson’s r < 0.80
Validity
Content validity + All items are considered to be relevant for the construct to be measured, for the target population, and for
the purpose of the measurement, AND the questionnaire is considered to be comprehensive
? Not enough information available
− Not all items are considered to be relevant for the construct to be measured, for the target population, and
for the purpose of the measurement, OR the questionnaire is considered not to be comprehensive
Construct validity
Structural validity + Factors should explain at least 50% of the variance
? Explained variance not mentioned
− Factors explain <50% of the variance
Structural validity (IRT
methods applied)
+ Residual correlations among the items after controlling for the dominant factor <0.20 OR Q3′s < 0.37, item
scalability >0.30, IRT model fit: G2 > 0.01, no DIF for important subject characteristics (such as age, gender,
education): McFadden’s R2 < 0.02
? Important characteristics not reported
− Residual correlations among the items after controlling for the dominant factor ≥0.20 OR Q3′s≥ 0.37, item
scalability ≤0.30, IRT model fit: G2≤ 0.01, important DIF for important subject characteristics (such as age,
gender, education): McFadden’s R2≥ 0.02
Hypothesis testing + Correlation with an instrument measuring the same construct ≥0.50 OR at least 75% of the results are in accordance
with the hypotheses, AND correlation with related constructs is higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlation with an instrument measuring the same construct <0.50 OR <75% of the results are in accordance with
the hypotheses OR correlation with related constructs is lower than with unrelated constructs
Cross-cultural validity + No differences in factor structure OR no important DIF between language versions
? Multiple group factor analysis not applied AND DIF not assessed
− Differences in factor structure OR important DIF between language versions
Responsiveness
Responsiveness + Correlation with changes on instruments measuring the same construct ≥0.50 OR at least 75% of the results
are in accordance with the hypotheses OR AUC≥ 0.70, AND correlations with changes in related constructs
are higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlations with changes on instruments measuring the same construct <0.50, OR <75% of the results are in
accordance with the hypotheses, OR AUC < 0.70, OR correlations with changes in related constructs are lower
than with unrelated constructs
Interpretability + MIC calculated and anchor questions clearly described
? MIC calculated but anchor questions not clearly labelled
− MIC not reported
MIC: minimal important change, SDC: smallest detectable change, LOA: limits of agreement, ICC: intraclass correlation coefficient, AUC: area under the curve.
+positive rating, ? indeterminate rating, −negative rating.
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3. QoL measure has low quality in at least one
required quality criterion (≥1 rating of ‘minus’) and
therefore is not recommended to be used any more.
4. QoL measure has (almost) not been validated. Its
performance in all or most relevant quality items is
unclear so that it is not recommended to be used
until further validation studies clarify its quality.
Finally, we aim to identify one best (currently available)
instrument to assess QoL in adult eczema.
Discussion
The proposed systematic review will yield a comprehen-
sive assessment of measurement properties of existing
QoL instruments in adult patients with eczema. We aim
to arrive at a recommendation of one best instrument to
measure QoL in eczema patients. The processes under-
lying this systematic review are transparent and system-
atic. Quality assurance is achieved by involving two
independent reviewers at each stage. A strength of the
proposed research is the international coverage of the
contributing reviewers. This will increase the credibility
of any findings. However, coordinating work packages
between many reviewers is certainly a challenge. Whether
or not we will be able to reach the goal of recommending
one best instrument is unclear. It may well be that no in-
strument will meet all the filter criteria or that several in-
struments will meet them. In any case, the findings of this
systematic review will inform a consensus-finding process
at the fourth meeting of the HOME initiative (HOME IV)
that will take place in Malmö, Sweden, in April 2015.
Based on the findings of this work, we hope to be able
to inform group discussion and consensus voting with
the ultimate goal to endorse one instrument to be in-
cluded in the core set of outcome measurement instru-
ments for eczema. If instruments lack important
requirements, for instance, in relation to responsive-
ness or feasibility, further validation work will need to
be done before a QoL instrument can be included in
the core set.
Additional file
Additional file 1: Search strings. The search strings for Medline (via
PubMed) and EMBASE.
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Abstract
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative
has identiﬁed quality of life (QoL) as a core outcome domain to be evaluated in
every eczema trial. It is unclear which of the existing QoL instruments is most
appropriate for this domain. Thus, the aim of this review was to systematically
assess the measurement properties of existing measurement instruments developed
and/or validated for the measurement of QoL in adult eczema.
Methods: We conducted a systematic literature search in PubMed and Embase
identifying studies on measurement properties of adult eczema QoL instruments.
For all eligible studies, we assessed the adequacy of the measurement properties
and the methodological quality with the COnsensus-based Standards for the
selection of health Measurement INstruments (COSMIN) checklist. A best evi-
dence synthesis summarizing ﬁndings from different studies was the basis to
assign four degrees of recommendation (A–D).
Results: A total of 15 articles reporting on 17 instruments were included. No
instrument fulﬁlled the criteria for category A. Six instruments were placed in cat-
egory B, meaning that they have the potential to be recommended depending on
the results of further validation studies. Three instruments had poor adequacy in
at least one required adequacy criterion and were therefore put in category C.
The remaining eight instruments were minimally validated and were thus placed
in category D.
Conclusions: Currently, no QoL instrument can be recommended for use in adult
eczema. The Quality of Life Index for Atopic Dermatitis (QoLIAD) and the
Dermatology Life Quality Index (DLQI) are recommended for further validation
research.
Abbreviations
COS, Core outcome set; COSMIN, COnsensus-based Standards for the selection of health Measurement INstruments; DIF, Differential
item functioning; HOME, Harmonising Outcome Measures for Eczema; HrQoL, health-related quality of life; ICC, Intraclass Correlation
Coefficient; IRT, Item response theory; MIC, Minimal important change; MID, Minimal important difference; OMERACT, Outcome
Measures in Rheumatology; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; QoL, quality of life.
Allergy 71 (2016) 358–370 © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd358
Allergy
53
Eczema (synonymous with atopic eczema, atopic dermatitis)
is a common, chronic, relapsing skin disease that affects both
children and adults. Recent studies suggest that eczema preva-
lence rates in adults are in excess of 10% (1, 2). There are
numerous treatments for eczema, many of which have been
studied in randomized controlled trials. However, the lack of
standardization of eczema outcome measurement instruments
in clinical trials currently limits the possibility to compare and
synthesize results in order to determine the best treatments,
hampering evidence-based decision-making and rendering the
generation of treatment recommendations difﬁcult.
Therefore, the Harmonising Outcome Measures for Eczema
(HOME) initiative (www.homeforeczema.org) set out to deﬁne
a core outcome set (COS) to be applied in all future eczema
trials. A COS is an agreed minimum set of outcomes that
should be measured and reported in all clinical trials of a
speciﬁc disease or trial population (3). Clinical signs, symp-
toms, long-term control of ﬂares and quality of life (QoL) have
been identiﬁed as the core outcome domains by the HOME
initiative (4–6).
In accordance with the HOME roadmap (7), we set out to
perform a systematic review of the measurement properties
of all instruments that were developed and validated to
measure QoL in eczema patients.
Methods
Protocol and registration
This systematic review was developed in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (8). A study protocol was
published beforehand (9) and has also been registered in the
International Prospective Register of Systematic Reviews
(PROSPERO): CRD42015017138.
Literature search
On 9 January 2015, we performed a systematic literature
search in PubMed and EMBASE, as described in detail in
the previously published protocol (9).
It was supplemented by hand searching of reference lists of
included studies and key articles on this topic. We also
searched the PROQOLID database (http://www.pro
qolid.org).
Eligible studies
The eligibility criteria laid out in the protocol were applied
(9). In accordance with a consensus-based decision of the
HOME initiative (10), only disease- or dermatology-speciﬁc,
and not generic QoL measurement instruments, were eligible.
Assessment of the methodological quality of included studies
The COnsensus-based standards for the selection of health
Measurement INstruments (COSMIN) checklist was used to
evaluate the methodological quality of the included studies
(11–14).
Assessment of measurement properties and further
characteristics of QoL instruments
We assessed all measurement properties from the COSMIN
checklist in this review, with the exception of criterion valid-
ity since no gold standard exists for QoL. Interpretability
and feasibility data were collected where available. With the
exception of content comparison and instrument characteris-
tics, we regarded different language versions of the same
questionnaire separately because we consider these to be dis-
tinct instruments. Our main reason for this approach was the
fact that it cannot be assumed that different language ver-
sions of measurement instruments show the same measure-
ment properties. Strictly speaking, it is the measurements
that are valid, reliable and responsive and not the instru-
ments per se.
Content comparison
We compared the content of each instrument at content
domain level. In QoL questionnaires, subsets of items belong-
ing together based on their content are often referred to as
content domains. The original development paper for each
instrument was consulted to obtain this information. We lar-
gely adopted the domains mentioned therein.
Adequacy of the measurement properties
The predeﬁned criteria for rating the adequacy of measure-
ment properties recommended by the COSMIN group were
used in a slightly modiﬁed version (15) (Table 1). Hypothe-
sis testing was split into the aspects convergent/divergent
[deﬁned as the correlation between instruments measuring
similar/different constructs (16)] and discriminative validity
[deﬁned as the ability of a measurement instrument to dis-
tinguish between different subgroups of patients (16)]
throughout the review. Findings from both aspects were
integrated into an overall rating in the end (see also ‘Differ-
ences between protocol and review’). Where studies applied
item response theory (IRT) methods in the evaluation of
measurement properties, rather than in the development of
measurement instruments, we were able to evaluate the ade-
quacy and methodological quality for internal consistency,
construct validity, structural validity and cross-cultural
validity.
Best evidence synthesis
Where an instrument was evaluated in multiple studies, the
ﬁndings were synthesized provided the characteristics of the
included studies were sufﬁciently similar and the method-
ological quality of the included studies was sufﬁcient (18).
The criteria for best evidence synthesis are outlined in
Table 2.
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Table 1 Adequacy criteria for measurement properties adapted from (15) and (17)
Property Rating Adequacy criteria
Reliability
Internal consistency
(CTT methods applied)
+ Cronbach’s alpha(s) ≥0.70
? Cronbach’s alpha not determined
 Cronbach’s alpha(s) <0.70
Internal consistency
(IRT methods applied)
+ Person Separation Index ≥0.70
? Person Separation Index not determined
 Person Separation Index <0.70
Measurement error + MIC > SDC OR MIC outside the LoA
? MIC not defined
 MIC ≤ SDC OR MIC equals or inside LoA
Reliability + ICC/weighted Kappa ≥0.70, OR Pearson’s r ≥ 0.80
? Neither ICC/weighted Kappa, nor Pearson’s r determined
 ICC/weighted Kappa < 0.70 OR Pearson’s r < 0.80
Validity
Content validity + All items are considered to be relevant for the construct to be measured, for the target
population, and for the purpose of the measurement AND the questionnaire is considered
to be comprehensive
? Not enough information available
 Not all items are considered to be relevant for the construct to be measured, for the target
population and for the purpose of the measurement OR the questionnaire is considered not
to be comprehensive
Construct validity
Structural validity
(CTT methods applied)
+ Factors should explain at least 50% of the variance
? Explained variance not mentioned
 Factors explain < 50% of the variance
Structural validity
(IRT methods applied)
+ Residual correlations among the items after controlling for the dominant factor < 0.20 OR
Q3’s < 0.37, item scalability >0.30, IRT model fit: G2 > 0.01, no DIF for important subject
characteristics (such as age, gender, education): McFadden’s R2 < 0.02, OR no nonuniform DIF
? Important statistics not reported
 Residual correlations among the items after controlling for the dominant factor ≥0.20 OR
Q3’s ≥0.37, item scalability ≤0.30, IRT model fit: G2 ≤ 0.01, important DIF for important subject
characteristics (such as age, gender, education): McFadden’s R2 ≥ 0.02, OR nonuniform DIF
Hypothesis testing
(convergent/divergent validity)
+ Correlations with instruments measuring the same construct ≥ 0.50 OR at least 75% of the
results are in accordance with the hypotheses AND correlation with related constructs is higher
than with unrelated constructs
? Solely correlations determined with unrelated constructs
 Correlations with instruments measuring the same construct <0.50 OR < 75% of the results are
in accordance with the hypotheses OR correlation with related constructs is lower than with
unrelated constructs
Hypothesis testing
(discriminative validity)
+ Differences in scores on the measurement instrument for all evaluated patient subgroups are
statistically significant OR ≥75% of results in accordance with hypotheses
? Some differences statistically significant, others not
 Differences in scores on the measurement instrument for all evaluated patient subgroups are
not statistically significant OR <75% of results in accordance with hypotheses
Cross-cultural validity + No differences in factor structure OR no important DIF between language versions
? Multiple group factor analysis not applied AND DIF not assessed
 Differences in factor structure OR important DIF between language versions
Responsiveness
Responsiveness + Correlation with changes on instruments measuring the same construct ≥0.50 OR at least
75% of the results are in accordance with the hypotheses OR AUC ≥0.70 AND correlations
with changes in related constructs are higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
 Correlations with changes on instruments measuring the same construct <0.50 OR < 75% of
the results are in accordance with the hypotheses OR AUC < 0.70 OR correlations with
changes in related constructs are lower than with unrelated constructs
DIF, Differential item functioning; ICC, Intraclass correlation coefficient; IRT, Item response theory; LoA, Limits of agreement; MIC, Minimal
important change; SDC, Smallest detectable change; +, positive rating; ?, indeterminate rating; , negative rating.
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Generating recommendations for the use of QoL
measurement instruments for eczema
For each reviewed instrument, a standardized recommenda-
tion for usage or required future validation work was made
depending on the adequacy of the instrument and the
methodological quality of the included studies.
Four categories of recommendation were made (9):
(Α) QoL measurement instrument meets all requirements
and is recommended for use.
(Β) QoL measure meets two or more adequacy items, but
performance in all other required adequacy items is
unclear, so that the outcome measure has the potential
to be recommended in the future depending on the
results of further validation studies.
(C) QoL measure has low adequacy in at least one required
adequacy criterion (≥1 rating of ‘minus’) and therefore is
not recommended to be used any more.
(D) QoL measure has (almost) not been validated. Its per-
formance in all or most relevant adequacy items is
unclear so that it is not recommended to be used until
further validation studies clarify its adequacy.
Finally, we aimed to identify one most appropriate (cur-
rently available) instrument to assess QoL in adults with
eczema.
Differences between protocol and review
In this manuscript, we speciﬁed that generic instruments are
not eligible for our review. Unlike what was planned in the
original protocol (9), we did not perform a content compar-
ison at item level because the resulting comparison table
would have been too large and thus not informative. Instead,
we compared the content of the different QoL instruments at
content domain level.
For reasons of clarity, we decided to use the term ‘ade-
quacy of the measurement properties’ instead of ‘quality of
the measurement properties’. For studies applying IRT meth-
ods, only internal consistency, construct validity, structural
and cross-cultural validity were evaluated, if applicable. In
addition, as the review was conducted, it was clear that some
minor alterations were required to the adequacy criteria pre-
sented in Table 3 of the protocol and Table 1 of this review,
respectively:
• For internal consistency, the indeterminate rating (‘?’)
was changed from ‘Dimensionality not known OR Cron-
bach’s alpha not determined’ to ‘Cronbach’s alpha not
determined’ in order to avoid redundancy between the
adequacy criteria and the COSMIN criteria for method-
ological quality. Adequacy criteria for IRT methods were
added.
• Although the adequacy criteria for content validity refer
to a questionnaire’s target population (which may be
other than eczema), we applied the same inclusion criteria
for content validity studies like for the other measure-
ment properties, that is at least 50% eczema patients in
the sample or subgroup analysis for eczema patients pre-
sented, because we were interested in the instruments’
content validity in eczema patients.
• The IRT criteria for structural validity were amended
with information on differential item functioning (DIF)
(20). A positive rating can now also be obtained if a
study shows that there is no nonuniform DIF. Occur-
rence of nonuniform DIF results in a negative rating
according to the new criteria.
• The criteria suggested by Terwee et al. (15) for hypothe-
sis testing were only applied to convergent and diver-
gent validity. Self-developed criteria for discriminative
validity, which is another aspect of hypothesis testing,
were added. The adequacy criteria for interpretability
were omitted since interpretability is not considered to
be a formal measurement property by the COSMIN
initiative (12).
The best evidence synthesis ratings were complemented by
an indeterminate rating for strong, moderate and limited
levels of evidence each. This was done for scenarios where a
QoL instrument would obtain an indeterminate rating for a
certain measurement property. An indeterminate rating was
assigned where no clear evidence was available for either a
positive or negative rating.
In order to obtain an overall rating for hypothesis testing,
ﬁndings from best evidence synthesis for convergent/diver-
gent and discriminative validity were synthesized according
to the following criteria: in case of conﬂicting ratings, the
worse rating determined the overall rating for hypothesis
testing; if either convergent/divergent or discriminative valid-
ity obtained an indeterminate rating, the rating for the other
Table 2 Levels of evidence for the overall adequacy of a measurement property, adapted from (19)
Level Rating Criteria
Strong +++, ? (strong) or  Consistent findings in multiple studies of good methodological quality OR in one study of excellent
methodological quality
Moderate ++, ? (moderate) or  Consistent findings in multiple studies of fair methodological quality OR in one study of good
methodological quality
Limited +, ? (limited) or  One study of fair methodological quality
Conflicting +/ Conflicting findings
Unknown Weak Only studies of poor methodological quality
+, positive rating; ?, indeterminate rating; , negative rating.
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aspect of hypothesis testing determined the overall rating for
hypothesis testing.
Results
In total, we found 16 eligible articles (21–36) (Fig. 1). Of
these, we were able to obtain 15 full-text papers. One manu-
script pertaining to the Ukrainian versions of the Dermatol-
ogy Life Quality Index (DLQI) and the Skindex-16 could not
be procured and was thus excluded (25).
Most of the included studies reported on the DLQI (n = 6)
(23, 24, 28–30, 35) and the Quality of Life Index for Atopic
Dermatitis (QoLIAD, n = 3) (31, 34, 36). Two studies pre-
sented information on the Deutsches Instrument zur Erfas-
sung der Lebensqualit€at bei Hauterkrankungen (DIELH) (32,
33). Skindex-29 was evaluated in two studies (22, 26). One
study each was available for the Freiburg Life Quality
Assessment core module (FLQA-c) (21), the Freiburg Life
Quality Assessment for Dermatoses (FLQA-d) (23) and the
Impact of Chronic Skin Disease on Daily Life (ISDL) (27).
An overview of the content of these different instruments is
shown in Table 3. Symptoms and emotions are captured by
six out of seven questionnaires, whereas all other content
domains are included in a lower number of instruments.
Four instruments (DIELH, DLQI, FLQA-c, and FLQA-d)
share the most content domains, whereas the QoLIAD does
not have any content domain in common with the other QoL
instruments. Other characteristics of the included instruments
are shown in Table 4. The number of items ranges from 10
to 54. Almost all instruments use a 4- or 5-point Likert scale.
Only the ISDL applies a visual analogue scale (VAS) in addi-
tion, whereas the QoLIAD has a dichotomous response
format.
Characteristics of the included studies
Table 5 contains information on the settings and the study
populations in the included studies. All included studies
were conducted in Europe with the exception of the valida-
tion studies of the US versions of the QoLIAD and the
Skindex-29. Most studies recruited their participants in a
secondary care setting, while primary care patients were
included in only two studies. Additionally, there was signiﬁ-
cant variation with respect to sample size, with 15 patients
being the smallest and 286 patients the largest sample size
of a single study.
Validity of the instruments and recommendations
The number of studies assessing the different measurement
properties of each QoL instrument identiﬁed is given in
Table 6. From the 15 included studies, we were able to rate
the methodological quality of 67 measurement properties.
One measurement property (1%) was rated as having excel-
lent, 18 (27%) as having good, 31 (46%) as having fair and
17 (25%) as having poor methodological quality according
Table 3 Comparison of the content of the different QoL instruments on content domain level
Domain DIELH DLQI FLQA-c FLQA-d ISDL* QoLIAD Skindex-29†
Symptoms X X X X X X
Emotions X X X X X X
Activities of daily living X X X X X
Leisure X X
Work/study X X
Social life X X X X X
Treatment X X X X
Functioning X
Satisfaction X X
Stigmatization X
Illness cognitions X
Need for mental and emotional stimulation X
Need for physical and emotional stability X
Need for security X
Need to share and belong X
Esteem needs X
Need for personal development and fulfilment X
DIELH, Deutsches Instrument zur Erfassung der Lebensqualit€at bei Hauterkrankungen; DLQI, Dermatology Life Quality Index; FLQA-c,
Freiburg Life Quality Assessment core module; FLQA-d, Freiburg Life Quality Assessment for Dermatoses; ISDL, Impact of Chronic Skin
Disease on Daily Life; QoLIAD, Quality of Life Index for Atopic Dermatitis.
*The ISDL distinguishes several higher level domains that contain a number of subordinate domains each. The subordinate domains were
used for this content comparison. The exact domains are (subordinate domains in brackets): physical functioning (skin status; physical symp-
toms of itch, pain and fatigue; scratch response), psychological functioning (anxiety; negative mood; positive mood), stressors (disease
impact on daily life; stigmatization), illness cognitions (helplessness; acceptance; perceived benefits), social support (perceived support;
social network).
†Content comparison of Skindex-29 is based on dimensions empirically derived from factor analysis and not on content-related domains.
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to the COSMIN checklist. Our synthesis of the results and
level of evidence for the properties of each instrument is pre-
sented in Table 7. There was no instrument for which all
measurement properties of interest have been examined. As a
result, none of the instruments complied with all of our pre-
speciﬁed requirements of truth, discrimination and feasibility.
Detailed results for every single instrument and study
included are available as an Appendix S1 to this publication
(Tables S1–S55).
Internal consistency was good for most language versions
of the QoLIAD, with Cronbach’s a ranging from 0.88 to
0.94 (36). In a population of 146 eczema patients, the Person
Separation Index of the DLQI amounted to 0.63, resulting in
a negative rating for internal consistency (35). For all other
instruments, there was either no evidence on internal consis-
tency or only evidence from methodologically poor studies.
Measurement error was not assessed for any of the included
instruments. An indeterminate rating was found for most
language versions of the QoLIAD in terms of reliability. Of
the other instruments, reliability information was available
for the Spanish DLQI only; with an Intraclass Correlation
Coefﬁcient (ICC) of 0.77 between the two administrations,
this instrument showed good reliability (24).
There was moderate evidence of good content validity for
most QoLIAD versions. There was strong evidence that the
Italian QoLIAD has good content validity. Content validity
was found to be limited for the UK version of the DLQI in
a population of 56 eczema patients; these patients considered
the DLQI not comprehensive and found some items irrele-
vant (for instance, items 1 and 9 were not considered rele-
vant by any patient in that study) (29). Likewise, structural
validity of the UK version of the DLQI was found to be
poor due to nonuniform differential item functioning (DIF)
of items 6 and 7 with respect to gender and age, respectively.
Moreover, 2/10 items showed uniform DIF with respect to
gender, 3/10 items exhibited uniform DIF with respect to
age, and there was disease-speciﬁc DIF for 5/10 items when
patients with eczema and psoriasis were compared. Item
residual statistics were indicative of a misﬁt to the Rasch
model, although item–trait interaction suggested that the
DLQI ﬁts a Rasch model for eczema patients (35). Struc-
tural validity of the UK version of the QoLIAD as well as
of DIELH is unclear. With data available for 15/17 QoL
instruments, hypothesis testing (i.e. construct validity) was
the measurement property most frequently assessed. Good
construct validity was found for the DIELH and most
QoLIAD versions. Correlations between QoLIAD (except
Dutch and Italian) and DLQI were moderate to high
(r = 0.58–0.77) with most values being above 0.70. Similar
but lower correlations were found between QoLIAD (except
Dutch and Italian) and the Psychological General Well-
Being Schedule (PGWB) (r = 0.55–0.79) (36). Good conver-
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gent validity was also demonstrated for the UK version of
the DLQI (29). With the exception of the Dutch and the
Spanish QoLIAD versions, patients could be clearly discrimi-
nated according to perceived severity, current ﬂares of symp-
toms and general health using the QoLIAD (36). The ISDL
and the Dutch QoLIAD got negative ratings for hypothesis
testing. While convergent validity of the Dutch QoLIAD
was adequate, its discriminative validity was poor and
resulted in a negative rating (36). The English Skindex-29
(US version) had good discriminative validity (26). For the
Table 5 Important characteristics of the included development and validation studies
QoL instrument
Number of
studies
Study characteristics
Geographic
location(s) Language(s) Setting(s)
Study population
Number of participants
per study Age range (years)
DIELH 2 (32, 33) Germany German Secondary care 85 (32) ND (32)
ND (33) ND (oldest: 88) (33)
Danish DLQI 1 (30) Denmark Danish Secondary care 66 ND
English DLQI (UK) 3 (28, 29, 35) United Kingdom English (UK) Secondary care (28) 13 (28) ND (28)
Primary care (29) 56 (29) 16–53 (29)
Community (35) 146 (35) 20–82 (35)
German DLQI 1 (23) Germany German Tertiary care 80 ND
Spanish DLQI 1 (24) Spain Spanish Secondary care 114 ND
FLQA-c 1 (21) Germany German Tertiary care 253 17–75
FLQA-d 1 (23) Germany German Tertiary care 80 ND
ISDL 1 (27) Netherlands Dutch Secondary care 128 16–77
Dutch QoLIAD 1 (36) Netherlands Dutch Secondary care 15 (item generation) ND
20 (field testing) ND
46 (validation) 16–67
English
QoLIAD (UK)
2 (34, 36) United Kingdom English (UK) Community (34) 146 (34) 20–82 (34)
Community and
secondary care (36)
36 (item generation) (36) ND (36)
21 (field testing) (36) ND (36)
Community (36) 286 (validation) (36) 16–86 (36)
English
QoLIAD (US)
1 (36) United States
of America
English (US) ND ND (item generation) ND
Secondary care 20 (field testing) ND
178 (validation) 16–78
French QoLIAD 1 (36) France French ND ND (item generation) ND
Secondary care ND (field testing) ND
Community 213 (validation) 18–86
German QoLIAD 1 (36) Germany German ND ND (item generation) ND
Secondary care 17 (field testing) ND
Community and
secondary care
187 (validation) 17–77
Italian QoLIAD 1 (36) Italy Italian Secondary care 14 (item generation) ND
15 (field testing)
Spanish QoLIAD 1 (31, 36)* Spain Spanish ND (36) ND (item generation) (36) ND (36)
Community and
secondary care (36)
20 (field testing) (36) ND (36)
Secondary
care (31, 36)
83 (validation) (31, 36) 16–81 (31, 36)
English
Skindex-29 (US)
1 (26) United States
of America
English (US) Primary and
secondary care
103 ND
German Skindex-29 1 (22) Germany German Tertiary care 76 ND
DIELH, Deutsches Instrument zur Erfassung der Lebensqualit€at bei Hauterkrankungen; DLQI, Dermatology Life Quality Index; FLQA-c, Frei-
burg Life Quality Assessment core module; FLQA-d, Freiburg Life Quality Assessment for Dermatoses; ISDL, Impact of Chronic Skin Dis-
ease on Daily Life; ND, Not described; QoLIAD, Quality of Life Index for Atopic Dermatitis; UK, United Kingdom; US, United States (of
America).
*Two articles on the Spanish QoLIAD were included but regarded as one study due to duplicate publication. From de Lucas 2003, only
validation data not presented in Whalley 2004 were taken into account.
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remaining questionnaires, hypothesis testing assessments
either led to an indeterminate rating or were conducted
methodologically poorly.
Responsiveness in eczema patients was investigated for
only three questionnaires, but only the Spanish DLQI was
proven responsive (24).
Values for the minimal important change (MIC) or mini-
mal important difference (MID) were not available for any
of the included questionnaires. Data on ﬂoor and ceiling
effects (i.e. ≥15% of patients having the lowest/the highest
score) were available from one study for the QoLIAD. Only
the US version of the QoLIAD showed some ﬂoor effects
with 17.1% and 18.5% of respondents having the lowest
score for visits 1 and 2, respectively. No ﬂoor or ceiling
effects were observed for the other QoLIAD versions (36). In
a sample of 56 eczema patients, the English DLQI (UK)
exhibited no ceiling effects (29). Likewise, there were no ﬂoor
or ceiling effects in the 13 eczema patients taking part in the
development study of the English DLQI (UK) (28). Comple-
tion time for the Spanish QoLIAD was found to be 5 min or
less (36).
Discussion
In this systematic review, the measurement properties of
seven different adult eczema QoL instruments were evalu-
ated. None of these instruments fulﬁlled all predeﬁned ﬁlter
criteria for truth, discrimination and feasibility, indicating the
need for further validation work.
Currently, no QoL instrument can be highly recom-
mended. In general, more validation research on all QoL
questionnaires included in this review would be desirable.
The QoLIAD (36) in several language versions was placed
in category B, meaning that it has the potential to be rec-
ommended in the future depending on the results of further
validation studies. The same is true for the Spanish language
version of the DLQI (24), although less information is avail-
able for this instrument compared to the QoLIAD. For the
majority of the questionnaires, that is DIELH (33), Danish
DLQI (30), German DLQI (23), FLQA-c (21), FLQA-d (23),
Italian QoLIAD (36), English Skindex-29 (US) (26) and
German Skindex-29 (22), further usage cannot be recom-
mended until more validation data are available since the
performance of these instruments is largely unclear. Three
instruments, the English DLQI (UK version) (28), ISDL (27)
and Dutch QoLIAD (36), were found to have low adequacy
in at least one required adequacy criterion and therefore are
considered problematic for further use in eczema patients.
The QoLIAD, in several language versions, is a valid and
internally consistent QoL instrument applying a needs-based
model. According to this model, QoL is determined by an
individual’s ability and capacity to satisfy their needs, with
high QoL when most needs and lowest QoL when few or
none of the needs are met. Consequently, instruments based
on this model assess the overall impact of a disease and its
treatment. This is also reﬂected by the fact that the
QoLIAD is the only instrument that does not have any con-
tent domain in common with the other instruments. As aT
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result, the QoLIAD may not cover some of the aspects that
clinicians might consider important in clinical practice.
Floor or ceiling effects of the 25-item questionnaire were
almost not observed and it was quickly completed.
Although good construct validity was shown for most lan-
guage versions of the QoLIAD, the negative rating for
hypothesis testing for the Dutch QoLIAD indicates that the
QoLIAD’s construct validity should be further examined.
Reliability, structural validity and cross-cultural validity of
the QoLIAD are unclear and should also be further investi-
gated. Measurement error and responsiveness of the
QoLIAD have not yet been investigated. Moreover, inter-
pretability data (i.e. deﬁnition and ranges of the QoLIAD
that represent mild, moderate and severe QoL impairments
in eczema) are not available.
The Spanish DLQI is a 10-item QoL instrument that was
shown reliable and responsive in eczema patients. The valid-
ity of this DLQI version has not yet been tested. Even
though plenty of information concerning ﬂoor and ceiling
effects as well as other interpretability data is available for
other language versions of the DLQI in populations other
than eczema, respective data of the Spanish DLQI obtained
in eczema patients are not available.
We found the English (UK) version of the DLQI to have
poor internal consistency, content and structural validity in
eczema patients. Thus, the English DLQI (UK version) is
not suggested to assess QoL in eczema patients. Likewise,
the ISDL and the Dutch version of the QoLIAD are not
suggested for use either because of a lack of construct
validity.
As we included a number of instruments that are dermatol-
ogy-speciﬁc and thus were not speciﬁcally developed for
patients with eczema, content validity of those instruments in
eczema patients is of great importance. Dermatology-speciﬁc
instruments are more likely to miss issues that eczema
patients consider important simply because they were devel-
oped for patients with skin disease in general. Whereas good
content validity was shown for the QoLIAD, an eczema-spe-
ciﬁc instrument, content validity of the included dermatol-
ogy-speciﬁc instruments in eczema patients was almost not
investigated. One study found limited content validity of the
English DLQI (UK) in eczema patients. This ﬁnding chal-
lenges the applicability of the DLQI to eczema patients and
raises the question whether other language versions of this
instrument may have better content validity. Particularly for
the Spanish DLQI, shown to be adequately reliable and
responsive, a thorough examination of its content validity in
eczema patients is needed.
As most data on interpretability were not gathered in
eczema samples, only little information on interpretability
was available for the included instruments. For instance, a
MIC of four points has been proposed for the DLQI, but the
corresponding studies did not meet our eligibility criteria (41,
42). Banding systems to assign clinical meaning to the scores
have been suggested both for the DLQI (43) and the Skin-
dex-29 (44–46), but none of these studies was found eligible.
Thus, future validation studies should also look at inter-
pretability in eczema patients.
Strengths and limitations of this review
We registered and published a protocol prior to our system-
atic review and highlighted differences between the protocol
and ﬁnal review. A validated, precise search ﬁlter was used
to identify all possibly eligible articles of any language
indexed in PubMed, EMBASE or both (47). Aiming to ﬁnd
the best evidence for eczema patients, we used predeﬁned
and strict eligibility criteria. We applied the COSMIN check-
list to rate the study quality and gather information on inter-
pretability and feasibility (11–14). At least two reviewers
were involved in every step of the review process to assure
quality. Frequent discussions took place within the research
team in order to resolve discrepancies.
A potential limitation of our systematic review is that we
only searched PubMed and EMBASE, thus possibly missing
articles listed elsewhere. However, we were not able to ﬁnd
any further eligible articles through a thorough hand search.
We were not able to retrieve one eligible article providing
information on the measurement properties of the Ukrainian
versions of the Skindex-16 and the DLQI (25).
Recommendations to researchers, clinicians and decision-
makers
This review suggests that currently only the QoLIAD and the
DLQI have the potential to be recommended for use depend-
ing on the results of further validation studies. These valida-
tion studies should investigate several language versions of
the QoLIAD and the DLQI, also including the versions that
were found inadequate for use in eczema patients in order to
possibly conﬁrm the ﬁndings of previous studies, thus
strengthening the evidence base for the recommendations pre-
sented in this systematic review. The Dutch QoLIAD, the
ISDL and the UK version of the DLQI are not suggested for
use in eczema trials unless future validation studies show – in
contrast to the existing evidence – adequate measurement
properties for these instruments.
Clinicians and researchers should include a QoL measure-
ment instrument in every future eczema trial because QoL is
one of the core outcome domains of the proposed COS. As
no instrument for measuring adult QoL in eczema trials can
be highly recommended at the moment, the HOME initiative
suggests using any QoL instrument that is at least valid, reli-
able and feasible in eczema patients (48). Unfortunately, we
found in our review that currently no such instrument is
available. An ideal solution to this quandary does not exist.
Clinicians and researchers need to balance validity, reliability
and feasibility. We suggest that researchers should include
one of the two instruments from category B, i.e. the
QoLIAD or the DLQI, in their trials.
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Abstract
Background: Eczema is a common chronic or chronically relapsing, inflammatory skin disease that exerts a
substantial negative impact on quality of life (QoL). The Harmonising Outcome Measures for Eczema (HOME)
initiative has used a consensus-based process which identified QoL as one of the four core outcome domains to be
assessed in all eczema clinical trials. A number of measurement instruments exist to measure QoL in infants, children,
and adolescents with eczema, and there is a great variability in both content and quality of the instruments used.
Therefore, the objective of the proposed research is to comprehensively and systematically assess the measurement
properties of the existing measurement instruments that were developed and/or validated for the measurement of
patient-reported QoL in infants, children, and adolescents with eczema.
Methods/design: This study is a systematic review of the measurement properties of patient-reported measures of
QoL developed and/or validated for infants, children, and adolescents with eczema. A systematic literature search will
be carried out in MEDLINE via PubMed and EMBASE using a selection of relevant search terms. Eligible studies will be
primary empirical studies evaluating, describing, or comparing measurement properties of QoL instruments for infants,
children, and adolescents with eczema. Two reviewers will independently perform eligibility assessment and data
abstraction. Evidence tables will be used to record study characteristics, instrument characteristics, measurement
properties, and interpretability. The adequacy of the measurement properties will be assessed using predefined criteria.
The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist will be used
to evaluate the methodological quality of included studies. A best evidence synthesis will be undertaken if more than
one study has examined a particular measurement property.
Discussion: The proposed systematic review will yield a comprehensive assessment of measurement properties of
existing QoL instruments in infants, children, and adolescents with eczema. The results will serve as a basis to
recommend a QoL measurement instrument for infants, one for children, and one for adolescents for use in future
clinical trials.
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Keywords: Eczema, Atopic dermatitis, Measurement instruments, Health-related quality of life, Quality of life, Validity,
Reliability, Responsiveness, Interpretability
* Correspondence: christian.apfelbacher@klinik.uni-regensburg.de
1Medical Sociology, Department of Epidemiology and Preventive Medicine,
University of Regensburg, Regensburg, Germany
8Division of Public Health and Primary Care, Brighton and Sussex Medical
School, Falmer, UK
Full list of author information is available at the end of the article
© 2016 Heinl et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Heinl et al. Systematic Reviews  (2016) 5:25 
DOI 10.1186/s13643-016-0202-z
66
Background
Eczema (synonymous with atopic eczema, atopic derma-
titis) represents the most common chronic disease in chil-
dren in many countries [1]. Its main symptom is persistent
pruritus [2]. The disease has a negative impact on the qual-
ity of life (QoL) of the patients and their families [3, 4].
Despite the fact that various interventions exist for eczema,
uncertainties concerning the best treatment options re-
main. A major reason for this situation is the inconsistent
use of varying eczema outcome measures in randomized
controlled trials, making the comparison of interventions
across these trials in systematic reviews and meta-analyses
difficult. Thus, outcome measures in clinical trials of
(pediatric) eczema patients need to be improved [5].
An internationally acknowledged way to ameliorate
this unsatisfying situation is the development of a core
outcome set (COS) [6]. The Harmonising Outcome
Measures for Eczema (HOME) initiative [7] aims to de-
velop a COS for eczema. Clinical signs measured by
means of a physician-assessed instrument, symptoms,
long-term control of eczema flares, and QoL were
agreed on as the core outcome domains to be assessed
in all future eczema trials [8, 9]. There was broad inter-
national consensus among clinicians, patients, and
methodologists that the Outcome Measures in Rheuma-
tology (OMERACT) quality criteria “truth, discrimin-
ation, and feasibility” [10] need to be met for eczema
outcome measures to be recommended by the HOME
initiative [9]. The next crucial step in the process of
standardizing eczema outcome measurements is now
the identification of appropriate instruments to measure
each of the four core outcome domains of atopic eczema
[11]. For adult QoL measurement instruments, this has
already been undertaken, using methods similar to this
proposed review [12]. The results have been published
[13]. As the methodology of this systematic review will
be in large parts identical to the one applied in the re-
view on adult QoL instruments, content and wording of
this protocol are very similar to the published protocol
of the review on adult QoL instruments [12]. This pertains
specifically to the methods section. To ensure transpar-
ency, differences in the methodology of both reviews are
highlighted in the “Differences between this review and
previously suggested methodology” section.
Objectives
1. To systematically assess the measurement properties
of patient- or parent-reported measurement instru-
ments of QoL for infants, children, and adolescents
with eczema
2. To identify outcome measurement instruments for
QoL in infants, children, and adolescents with
eczema
a. That meet the predefined criteria to be
recommended [10, 9] for the measurement of
QoL in future eczema trials
b. That have the potential to be recommended in
the future depending on the results of further
validation studies
c. That do not meet the predefined criteria to be
recommended [10, 9] and therefore should not be
used any more
3. To provide the evidence base for an international
consensus process
a. To further standardize the assessment of QoL in
infants, children, and adolescents with eczema in
clinical trials
b. To prioritize further research concerning QoL
assessment in infants, children, and adolescents
with eczema
Methods/design
Protocol and registration
The methods for this systematic review have been devel-
oped according to the recommendations from the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols (PRISMA-P) statement [14],
and a populated PRISMA-P checklist is available as an
Additional file 1 to this protocol. This protocol has been
registered in the International Prospective Register of
Systematic Reviews (PROSPERO): CRD42015023483.
Literature search
A systematic literature search will be performed in
PubMed and EMBASE. The search strategy will contain
blocks of search terms related to the following aspects:
1. Construct of interest: quality of life
2. Target population: (atopic) eczema (Table 1)
3. Measurement properties: the precise PubMed search
filter for finding studies on measurement properties
developed by Terwee et al. will be used to identify
relevant articles [15]. This filter has a sensitivity of
93.1 % and a precision of 9.4 %
4. Interpretability
The search will not be restricted with respect to the
publication time of retrieved studies. The entire search
strategy is available as an Additional file 2 to this protocol.
The systematic electronic search will be supplemented by
hand searching of reference lists of studies included and
key articles on this topic. Furthermore, an additional
search will be performed in each database, including the
names of the instruments which are found in the initial
search. The PROQOLID (www.proqolid.org) database, an
online database of QoL instruments, will be searched. The
initial search in PubMed and EMBASE will be carried out
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on a single day that will be reported in the final review,
whereas the hand searching process will be performed
during the eligibility assessment of articles, which may
take several weeks. The additional search of each database
will be done, after the eligibility assessment has been com-
pleted, on a single day.
Eligible studies
A study will be included if it is published as a full-text
paper and concerns the development (“development
paper”) and/or evaluation of the measurement properties
(“validation paper”) of instruments that measure QoL or
health-related quality of life (HrQoL) in infants, children,
and adolescents with eczema. Measurement instruments
that assess both the QoL of children and caregivers will be
included if separate scores for the QoL of the child and
for the QoL of the caregiver can be calculated. Generic
QoL measurement instruments for infants, children, and
adolescents and measurement instruments assessing solely
the QoL of caregivers will not be considered eligible. The
HOME initiative decided in 2011 that generic QoL meas-
urement instruments are not eligible for the COS [16].
QoL measurement instruments for caregivers will be in-
vestigated in a separate review. To be eligible, at least
50 % of a study’s population must consist of eczema pa-
tients younger than 16 years of age. A study with a mixed
patient sample will be eligible either if it presents a sub-
group analysis for infants, children, and adolescents with
eczema or if infants, children, and adolescents with
eczema constitute at least 50 % of the study population.
The measurement instrument must be a self- or proxy-
reported questionnaire. Articles that report indirect
evidence, for instance, by using data obtained within
the context of a clinical trial, will not be considered
eligible. Articles assessing the measurement properties
of dermatology-specific instruments in non-eczema
samples will not be considered eligible.
Study selection
Two reviewers will independently judge titles and ab-
stracts retrieved in the literature search and, at a sec-
ond stage, full-text articles for eligibility (Table 1).
Disagreements will be resolved by consensus-seeking
discussions within the research team.
Data extraction
Relevant data from all included articles will be summa-
rized in evidence tables. The evidence tables drafted for
the adults’ review [12] will be slightly adapted. Data from
each article included will be extracted independently
by two reviewers. Reviewers will work in pairs on
defined sets of articles. Disagreements will be resolved
by consensus-seeking discussions within the research
team.
Evidence tables will include the following: reference,
geographical location, language, setting, study type, key
characteristics of study subjects, name of measurement
instruments, domains measured, number of items and
(sub)scales, number and type of response categories, re-
call period in the questions, scoring algorithm, time
needed for administration, mode of administration, tar-
get population for whom the questionnaire was origin-
ally developed, how a full copy of the questionnaire can
be obtained, the instructions given to those who
complete the questionnaire, the available versions and
translations of the questionnaire, results of the measure-
ment properties, all items from the COnsensus-based
Standards for the selection of health Measurement IN-
struments (COSMIN) box Generalisability, and all items
from the COSMIN box Interpretability [17, 18].
If general characteristics of an instrument (that is,
name of measurement instrument, number of items and
(sub)scales, number and type of response categories,
recall period in the questions, scoring algorithm, time
needed for administration, mode of administration,
target population for whom the questionnaire was
originally developed, how a full copy of the question-
naire can be obtained, the instructions given to those
who complete the questionnaire, the available versions
and translations of the questionnaire) cannot be
extracted from the studies included, the original
development paper may be consulted to obtain miss-
ing information.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Population Eczema (synonyms: atopic eczema, atopic dermatitis,
neurodermatitis); populations younger than 16 years of age
Populations with other skin diseases than eczema, populations of
adults with eczema, carers of infants/children with eczema
Study design Development study, validation study Linguistic validation studies
Outcome Quality of life, health-related quality of life Signs, disease severity measure, disease control measure,
biomarker, physiology of the skin
Type of
measurement
instrument
Self- or proxy-reported measurement instrument All others
Publication type Articles with available full text Abstracts
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Content comparison
An overview of the content of each instrument on con-
tent domain level will be presented in order to visualize
the content covered by the different instruments. The
original development paper will be consulted to obtain
this information.
Assessment of the methodological quality of included
studies
The COSMIN checklist [17–19] will be used to evaluate
the methodological quality of included studies. In the
COSMIN checklist (www.cosmin.nl), four domains are
distinguished (reliability, validity, responsiveness, and in-
terpretability) with related measurement properties and
aspects of measurement properties. These are listed in
Table 2 (adapted from Mokkink LB et al. [18]).
For each measurement property, the COSMIN checklist
consists of 5 to 18 items covering methodological stan-
dards (organized in nine boxes for the nine measurement
properties). In addition, each item can be scored on a 4-
point rating scale (that is, “poor,” “fair,” “good,” “excellent”).
Taking the lowest rating for each item in one box, an over-
all quality score (“poor,” “fair,” “good,” “excellent”) is
obtained for each measurement property separately [20].
Assessment of measurement properties and further
characteristics of QoL instruments
We will assess all measurement properties from the
COSMIN checklist in this review, with the exception of
the measurement property “criterion validity,” which will
not be considered for the purpose of this systematic re-
view, since there is no gold standard for QoL. Data on
interpretability and feasibility will be collected where
presented. With the exception of content comparison
and instrument characteristics, we will regard different
language versions of the same questionnaire separately
throughout the review. Our principal reason for doing
so is the fact that it is problematic to assume that differ-
ent language versions of measurement instruments ex-
hibit the same measurement properties. Strictly
speaking, it is the measurements themselves that are
valid, reliable, and responsive and not the instruments
per se.
Assessment of the adequacy of the measurement
instruments
The predefined criteria for rating the adequacy of the
measurement instruments recommended by the COS-
MIN group will be used in a slightly modified version
[21] (Table 3). These criteria are in accordance with the
OMERACT filter [10], which has been adopted by the
HOME initiative [9] and applied in a previous review on
atopic eczema outcome measures [22]. The measure-
ment property “hypothesis testing” will be split into the
aspects convergent/divergent (defined as the correlation
between instruments measuring similar/different con-
structs [23]) and discriminative validity (defined as the
ability of a measurement instrument to distinguish be-
tween different subgroups of patients [23]) for this re-
view. An overall rating for hypothesis testing will be
obtained from both aspects in the end (see “Generating
recommendations for the use of QoL measurement in-
struments for eczema” section). Where studies apply
item response theory (IRT) methods in the evaluation of
measurement properties, rather than in the development
of measurement instruments, we will be able to assess
the adequacy and methodological quality of internal
consistency, construct validity, structural validity, and
cross-cultural validity.
Best evidence synthesis
If an instrument has been evaluated in multiple stud-
ies, findings will be synthesized if the characteristics
of the included studies are sufficiently similar, if the
results of the studies do not show significantly differ-
ent or conflicting findings, and if the methodological
quality of the included studies is sufficient [24]. The
criteria for best evidence synthesis are outlined in
Table 4.
Generating recommendations for the use of QoL
measurement instruments for eczema
For each instrument identified in the review, a standard-
ized recommendation for usage or required future valid-
ation work will be made depending on the
methodological quality of included studies and on the
adequacy of the instrument (Table 5). According to the
results of the HOME II meeting [9], all three criteria of
the OMERACT filter [10], that is, truth, discrimination,
and feasibility, have to be met by an outcome measure
to be recommended by the HOME initiative. Although
convergent/divergent and discriminative validity will be
regarded separately throughout the review, the findings
for these two aspects of hypothesis testing will be syn-
thesized according to the following criteria: in case of
conflicting ratings, the worse rating determines the over-
all rating for hypothesis testing; if one of the aspects ob-
tains an indeterminate rating, the rating for the other
aspect determines the overall rating for hypothesis
testing.
Four categories of recommendation will be made:
A. QoL measurement instrument meets all
requirements and is recommended for use.
B. QoL measure meets two or more adequacy items,
but performance in all other required adequacy
items is unclear, so that the outcome measure has
the potential to be recommended in the future
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Table 2 Definitions of domains, measurement properties, and aspects of measurement properties
Domain Measurement property Aspect of a measurement
property
Definition
Reliability The degree to which the measurement is free from measurement error.
Reliability (extended definition) The extent to which scores for patients who have not changed is the same for repeated measurement
under several conditions: for example, using different sets of items from the same HR-PROs (internal
consistency), over time (test-retest) by different persons on the same occasion (inter-rater) or by the
same persons (i.e., raters or responders)
on different occasions (intra-rater).
Internal consistency The degree of interrelatedness among the items.
Reliability The proportion of total variance in the measurements which is because of “true”a differences
among patients.
Measurement error The systematic and random error of a patient’s score that is not attributed to true change of the
construct to be measured.
Validity The degree to which an HR-PRO instrument measures the construct(s) it purports to measure.
Content validity The degree to which the content of an HR-PRO instrument is an adequate reflection of the construct
to be measured.
Face validity The degree to which (the items of) an HR-PRO instrument indeed looks as though they are an adequate
reflection of the construct to be measured.
Construct validity The degree to which the scores of an HR-PRO instrument are consistent with hypotheses (for instance
with regard to internal relationships, relationships to scores of other instruments, or differences between
relevant groups) based on the assumption that the HR-PRO instrument validly measures the construct
to be measured.
Structural validity The degree to which the scores of an HR-PRO instrument are an adequate reflection of the dimensionality
of the construct to be measured.
Hypothesis testing Idem construct validity.
Cross-cultural validity The degree to which the performance of the items on a translated or culturally adapted HR-PRO instrument
are an adequate reflection of the performance of the items of the original version of the HR-PRO instrument.
Responsiveness The ability of an HR-PRO instrument to detect change over time in the construct to be measured.
Responsiveness Idem responsiveness.
Interpretabilityb The degree to which one can assign qualitative meaning—that is, clinical or commonly understood
connotations—to an instrument’s quantitative scores or changes in scores.
HR-PROs health-related patient-reported outcomes, CTT classical test theory
aThe word “true” must be seen in the context of the CTT, which states that any observation is composed of two components—a true score and error associated with the observation. “True” is the average score that
would be obtained if the scale were given an infinite number of times. It refers only to the consistency of the score and not to its accuracy [26]
bInterpretability is not considered a measurement property but an important characteristic of a measurement instrument
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Table 3 Adequacy criteria for measurement properties adapted from [21] and [27]
Property Rating Adequacy criteria
Reliability
Internal consistency (CTT methods applied) + Cronbach’s alpha(s) ≥0.70
? Cronbach’s alpha not determined
− Cronbach’s alpha(s) <0.70
Internal consistency (IRT methods applied) + Person Separation Index ≥0.70
? Person Separation Index not determined
− Person Separation Index <0.70
Measurement error + MIC > SDC OR MIC outside the LoA
? MIC not defined
− MIC ≤ SDC OR MIC equals or inside LoA
Reliability + ICC/weighted Kappa ≥0.70, OR Pearson’s r≥ 0.80
? Neither ICC/weighted Kappa, nor Pearson’s r determined
− ICC/weighted Kappa <0.70 OR Pearson’s r < 0.80
Validity
Content validity + All items are considered to be relevant for the construct to be measured, for the
target population, and for the purpose of the measurement AND the questionnaire
is considered to be comprehensive
? Not enough information available
− Not all items are considered to be relevant for the construct to be measured, for the
target population, and for the purpose of the measurement OR the questionnaire is
considered not to be comprehensive
Construct validity
Structural validity (CTT methods applied) + Factors should explain at least 50 % of the variance
? Explained variance not mentioned
− Factors explain <50 % of the variance
Structural validity (IRT methods applied) + Residual correlations among the items after controlling for the dominant factor
<0.20 OR Q3’s <0.37, item scalability >0.30, IRT model fit: G2 >0.01, no DIF for
important subject characteristics (such as age, gender, education): McFadden’s
R
2 <0.02, OR no non-uniform DIF
? Important statistics not reported
− Residual correlations among the items after controlling for the dominant factor
≥0.20 OR Q3’s ≥0.37, item scalability ≤0.30, IRT model fit: G2 ≤0.01, important DIF
for important subject characteristics (such as age, gender, education): McFadden’s
R
2
≥0.02, OR non-uniform DIF
Hypothesis testing (convergent/divergent validity) + Correlations with instruments measuring the same construct ≥0.50 OR at least 75 %
of the results are in accordance with the hypotheses AND correlation with related
constructs is higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlations with instruments measuring the same construct <0.50 OR <75 % of the
results are in accordance with the hypotheses OR correlation with related constructs
is lower than with unrelated constructs
Hypothesis testing (discriminative validity) + Differences in scores on the measurement instrument for all evaluated patient
subgroups are statistically significant OR ≥75 % of results in accordance with
hypotheses
? Some differences statistically significant, others not
− Differences in scores on the measurement instrument for all evaluated patient
subgroups are not statistically significant OR <75 % of results in accordance
with hypotheses
Cross-cultural validity + No differences in factor structure OR no important DIF between language versions
? Multiple group factor analysis not applied AND DIF not assessed
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depending on the results of further validation
studies.
C. QoL measure has low adequacy in at least one
required adequacy criterion (≥1 rating of “minus”)
and therefore is not recommended to be used
anymore.
D. QoL measure has (almost) not been validated. Its
performance in all or most relevant adequacy items
is unclear so that it is not recommended to be used
until further validation studies clarify its adequacy.
Finally, we aim to identify one best (currently available)
instrument to assess QoL in infants, one best (currently
available) instrument to assess QoL in children, and one
best (currently available) instrument to assess QoL in
adolescents with eczema.
Differences between this review and previously
suggested methodology
We refined our eligibility criteria and made clear that
generic QoL instruments will not be eligible for this re-
view [12]. As this review will focus on infants, children,
and adolescents, proxy-reported instruments will also be
included.
Because interpretability and feasibility of a QoL instru-
ment are very important for researchers and clinicians,
we emphasized that corresponding information will be
collected where presented. We also decided to regard
different language versions of the same QoL instrument
separately; this approach was also used in our previous
review on adult QoL instruments [13] but initially not
specified in the pertaining protocol. Content comparison
of the included instruments will be done on content do-
main level instead of item level because a comparison
table on item level would become unclear and confusing
due to the multitude of data shown. Moreover, we de-
cided to use the term “adequacy of the measurement
properties” instead of “quality of the measurement prop-
erties.” For studies applying IRT methods, only internal
consistency, construct validity, structural validity, and
cross-cultural validity will be assessed, where applicable.
Important changes concern the adequacy criteria out-
lined in Table 3:
 For internal consistency, the indeterminate rating
(“?”) was changed from “Dimensionality not known
OR Cronbach’s alpha not determined” to
“Cronbach’s alpha not determined” in order to avoid
an overlap between the adequacy criteria and the
COSMIN criteria for methodological quality.
Adequacy criteria for studies using IRT methods
were added.
 The IRT criteria for structural validity were
enhanced with criteria on differential item
functioning (DIF) [25]. If a study shows that there is
no non-uniform DIF, this can now also result in a
positive rating. Non-uniform DIF will be rated nega-
tively according to the new criteria.
Table 3 Adequacy criteria for measurement properties adapted from [21] and [27] (Continued)
− Differences in factor structure OR important DIF between language versions
Responsiveness
Responsiveness + Correlation with changes on instruments measuring the same construct ≥0.50
OR at least 75 % of the results are in accordance with the hypotheses OR AUC
≥0.70 AND correlations with changes in related constructs are higher than with
unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlations with changes on instruments measuring the same construct <0.50
OR <75 % of the results are in accordance with the hypotheses OR AUC <0.70
OR correlations with changes in related constructs are lower than with unrelated
constructs
MIC minimal important change, SDC smallest detectable change, LoA limits of agreement, ICC intraclass correlation coefficient, AUC area under the curve, +
positive rating, ? indeterminate rating, − negative rating
Table 4 Levels of evidence for the overall adequacy of a measurement property adapted from [28]
Level Rating Criteria
Strong +++, ? (strong) or −−− Consistent findings in multiple studies of good methodological quality OR in one study
of excellent methodological quality
Moderate ++, ? (moderate) or −− Consistent findings in multiple studies of fair methodological quality OR in one study of
good methodological quality
Limited +, ? (limited) or − One study of fair methodological quality
Conflicting +/− Conflicting findings
Unknown ? Only studies of poor methodological quality
+ positive rating, ? indeterminate rating, − negative rating
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 Hypothesis testing was split into its two aspects
convergent/divergent and discriminative validity,
with separate criteria for each aspect, resulting in an
overall rating for hypothesis testing in the end.
 The criteria developed by Terwee et al. for
hypothesis testing will only be applied to convergent
and divergent validity. For discriminative validity,
another aspect of hypothesis testing, self-developed
criteria were added. As the COSMIN initiative does
not consider interpretability to be a formal measure-
ment property, the adequacy criteria for interpret-
ability were omitted [18].
An indeterminate rating for strong, moderate, and lim-
ited levels of evidence was added to the best evidence
synthesis ratings each. This was done for scenarios
where a QoL instrument would obtain an indeterminate
rating for a certain measurement property. An indeter-
minate rating will be assigned to a measurement prop-
erty if there is no clear evidence for either a positive or
negative rating.
Discussion
The proposed systematic review will yield a comprehen-
sive assessment of measurement properties of existing
QoL instruments in infants, children, and adolescents
with eczema. We aim to arrive at a recommendation of
one best instrument for infants, one best instrument for
children, and one best instrument for adolescents, re-
spectively. Rigorous and appropriate methods are vital to
obtain meaningful, scientifically acknowledged results
that form the basis to put forward such recommenda-
tions [6]. With good reason, researchers and clinicians
demand that the development of a COS for eczema
must adhere to high standards. We have made various
efforts to satisfy these expectations. Firstly, the processes
underlying this systematic review are transparent and
systematic. Secondly, the involvement of at least two re-
viewers at each stage will assure quality of and reduce
variability in the assessments. Another strength of the
proposed research is the use of well-established methods
and criteria, such as the COSMIN checklist, that have
been successfully applied in a considerable number of
previous systematic reviews. Furthermore, the inter-
national coverage of the contributing reviewers will
increase the credibility of any findings.
In addition to the results obtained by best evidence
synthesis, the feasibility of a questionnaire, e.g., number
of items and time needed for administration, is another
essential requirement for recommendation. This is also
reflected by the fact that all three criteria of the OMER-
ACT filter, i.e., truth, discrimination, and feasibility, need
to be met by an outcome measure to be recommended
by the HOME initiative [9, 10]. Truth and discrimination
are reflected by the results from best evidence synthesis.
Although there are no adequacy criteria for feasibility,
information on feasibility will be collected throughout
the review process and will be considered for the
conclusions of our systematic review. Sufficient feasi-
bility of a questionnaire is important for its inclusion
in the proposed COS and the widespread implemen-
tation in future eczema trials.
Moreover, we may consider the popularity of a QoL
instrument as an additional parameter for recommenda-
tion if several instruments are placed in category A and
a decision to recommend one of them based solely on
best evidence synthesis is not possible. A potential bene-
fit of well-known and frequently applied QoL instru-
ments could be that more data on the questionnaire’s
feasibility and interpretability of its scores may be avail-
able compared to less popular instruments.
Whether or not we will be able to reach the goal of
recommending one best instrument for each age group
is unclear. It may well be that several instruments will
meet the OMERACT filter criteria. If instruments lack
important requirements, for instance, in relation to re-
sponsiveness or measurement error, they will not comply
with the OMERACT filter criteria, and additional valid-
ation studies will need to be carried out before these
instruments can be included in the COS. As a result, it
could happen that our systematic review will only be
able to identify priorities for further validation work
Table 5 Adequacy criteria required for recommendation of QoL measures for eczema
Adequacy item (name) Inclusion in OMERACT filter Required rating for recommendation
Content validity Truth +
Structural validity Truth +
Hypotheses testing Truth +
Cross-cultural validity Truth +
Internal consistency Discrimination +
Reliability Discrimination +
Measurement error Discrimination +
Responsiveness Discrimination +
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instead of putting forward a clear recommendation for a
certain QoL measurement instrument. Nonetheless, the
findings of this systematic review will inform a
consensus-finding process at the fifth meeting of the
HOME initiative (HOME V) that will take place in São
Paulo, Brazil, in 2017. Based on the findings of this
work, we hope to be able to inform group discussion
and consensus voting with the ultimate goal to endorse
one instrument for each age group to be included in the
core set of outcome measurement instruments for eczema.
Additional files
Additional file 1: PRISMA-P 2015 checklist. The completed PRISMA-P
checklist for this protocol.
Additional file 2: Search strings. The search strings for MEDLINE
(via PubMed) and EMBASE.
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Summary
Background Quality of life (QoL) is one of the core outcome domains identified by
the Harmonising Outcome Measures for Eczema (HOME) initiative to be assessed
in every eczema trial. There is uncertainty about the most appropriate QoL
instrument to measure this domain in infants, children and adolescents.
Objectives To systematically evaluate the measurement properties of existing mea-
surement instruments developed and/or validated for the measurement of QoL
in infants, children and adolescents with eczema.
Methods A systematic literature search in PubMed and Embase, complemented by
a thorough hand search of reference lists, retrieved studies on measurement
properties of eczema QoL instruments for infants, children and adolescents. For
all eligible studies, we judged the adequacy of the measurement properties and
the methodological study quality with the COnsensus-based Standards for the
selection of health Measurement INstruments (COSMIN) checklist. Results from
different studies were summarized in a best-evidence synthesis and formed the
basis to assign four degrees of recommendation.
Results Seventeen articles, three of which were found by hand search, were
included. These 17 articles reported on 24 instruments. No instrument can be
recommended for use in all eczema trials because none fulfilled all required ade-
quacy criteria. With adequate internal consistency, reliability and hypothesis test-
ing, the U.S. version of the Childhood Atopic Dermatitis Impact Scale (CADIS), a
proxy-reported instrument, has the potential to be recommended depending on
the results of further validation studies. All other instruments, including all self-
reported ones, lacked significant validation data.
Conclusions Currently, no QoL instrument for infants, children and adolescents
with eczema can be highly recommended. Future validation research should pri-
marily focus on the CADIS, but also attempt to broaden the evidence base for the
validity of self-reported instruments.
What’s already known about this topic?
• Most eczema trials include the Infants’ Dermatitis Quality of Life Index (IDQoL) or
the Children’s Dermatology Life Quality Index (CDLQI) as quality of life (QoL)
measurement instruments.
© 2016 British Association of Dermatologists878 British Journal of Dermatology (2017) 176, pp878–889
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• It is unclear which instruments are most appropriate to measure QoL in infants,
children and adolescents with eczema.
What does this study add?
• Most QoL instruments for infants, children and adolescents with eczema are poorly
validated, indicating a clear need for further validation work.
Affecting more than 10% of infants and children, eczema (syn-
onyms: ‘atopic eczema’, ‘atopic dermatitis’) is one of the most
common chronic diseases in children in many countries.1–3 A
high eczema prevalence is also observed in adolescence,2 with a
substantial risk of the disease persisting into adulthood.4 Despite
a multitude of treatment options, evidence-based decision-mak-
ing based on systematic reviews and meta-analyses is hampered
due to the heterogeneity of outcome measurement instruments
used, particularly in randomized controlled trials.
Therefore, the Harmonising Outcome Measures for Eczema
(HOME) initiative (www.homeforeczema.org) aims to
develop a core outcome set (COS) for use in all future eczema
trials. A COS is a minimum set of outcomes that should be
measured and reported in all clinical trials of a specific disease
or trial population.5 The core outcome domains suggested by
the HOME initiative are clinical signs, symptoms, long-term
control of flares and quality of life (QoL).6–8
Following the HOME roadmap,9 we performed a systematic
review of the measurement properties of all instruments that
were developed and validated to measure QoL in infants, chil-
dren and adolescents with eczema. For adults, this step has
already been completed.10
Material and methods
Protocol and registration
This systematic review was developed in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement.11 A completed PRISMA checklist
is available as an online appendix to this publication (see
Appendix SA1; Supporting Information). The study
protocol was published12 and registered in the International
Prospective Register of Systematic Reviews (PROSPERO):
CRD42015023483.
Literature search
A systematic literature search in PubMed and EMBASE was
conducted on 18 June 2015. The entire search strategy is
shown in detail in the study protocol.12 Hand searching of the
PROQOLID database (http://www.proqolid.org) and reference
lists of included studies and key articles on QoL in infants,
children and adolescents with eczema complemented the sys-
tematic search.
Eligible studies
We applied the eligibility criteria presented in the protocol.12
Briefly, the study population of eligible development and vali-
dation studies of dermatology- or eczema-specific QoL instru-
ments had to consist of at least 50% of patients with eczema
younger than 16 years of age, or studies had to present sub-
group analyses for this patient group.
Content comparison
The content of the included instruments was compared at the
content domain level based on information from the original
development paper.
Assessment of the methodological quality of included
studies
We used the COnsensus-based Standards for the selection of
health Measurement INstruments (COSMIN) checklist to judge
the methodological quality of the included studies (www.cos-
min.nl).13–16 This checklist consists of 5–18 items per mea-
surement property covering methodological standards; the
compliance with these standards is rated on a four-point rat-
ing scale (‘poor’, ‘fair’, ‘good’, ‘excellent’). The lowest rating
for any item pertaining to a certain measurement property
determines the overall rating for this measurement property.
Assessment of measurement properties and further
characteristics of quality of life instruments
With the exception of criterion validity, all measurement
properties from the COSMIN checklist were evaluated in this
systematic review. Where available, interpretability and feasi-
bility data were collected. Because we view them as distinct
instruments, different language versions of the same question-
naire were considered separately throughout this review
except for content comparison and instrument characteristics.
Assessment of the adequacy of the measurement
properties
To evaluate the adequacy of the investigated measurement
properties, we applied the corresponding predefined criteria
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recommended by the COSMIN group in a slightly modified
version (see Table SA1 in Appendix SA2; Supporting Informa-
tion).17,18 The specific changes we made to these criteria are
explained in the protocol.12 Where studies used item response
theory (IRT) methods in the assessment of measurement prop-
erties instead of the development of measurement instruments,
we assessed the adequacy and methodological quality of inter-
nal consistency, construct validity, structural validity and
cross-cultural validity.
Best-evidence synthesis
Findings on the same instrument from multiple studies were
synthesized if the characteristics of the included studies were
sufficiently similar, the results did not show considerably dif-
ferent or conflicting findings and the methodological quality
of the included studies was adequate.19 Criteria for best-evi-
dence synthesis are found in Table SA2 (in Appendix SA2;
Supporting Information).20
Generating recommendations for the use of quality of
life measurement instruments for eczema
Depending on the adequacy of each instrument and the
methodological quality of the included studies, a standardized
recommendation for usage and necessary future validation
work was made for each investigated instrument.
Four categories of recommendation were made:12
A QoL measurement instrument meets all requirements
and is recommended for use.
B QoL measure meets two or more adequacy criteria, but
performance in all other required adequacy criteria is
unclear, so that the outcome measure has the potential to
be recommended in the future depending on the results of
further validation studies.
C QoL measure has low adequacy in at least one required
adequacy criterion (≥ 1 rating of ‘minus’) and therefore is
not recommended to be used anymore.
D QoL measure has (almost) not been validated. Its perfor-
mance in all or most relevant adequacy criteria is unclear
so that it is not recommended to be used until further vali-
dation studies clarify its adequacy.
Finally, we aimed to identify one best (currently available)
instrument to assess QoL in infants, one best (currently avail-
able) instrument to assess QoL in children, and one best (cur-
rently available) instrument to assess QoL in adolescents with
eczema.
Results
Seventeen articles were included (Fig. 1).21–37 One paper
complying with the inclusion criteria presented only summary
information, making analyses of the evaluated questionnaires
and measurement properties impossible; the paper was conse-
quently excluded.38 Another paper containing data on the
content validity of the Childhood Impact of Atopic Dermatitis
(CIAD) did not formally meet the inclusion criteria and was
thus excluded.39 However, read in conjunction with the eligi-
ble development article of the CIAD,34 information on content
validity could be extracted from that excluded paper and was
therefore considered for this review.
Most included studies reported on the Children’s Dermatol-
ogy Life Quality Index (CDLQI, n = 6)22,29–31,33,36 and the
Infants’ Dermatitis Quality of Life Index (IDQoL,
n = 6).21,24,25,29,32,37 Three studies evaluated the Childhood
Atopic Dermatitis Impact Scale (CADIS)26,27,35 and two studies
assessed the DISABKIDS Atopic Dermatitis Module (DISABKIDS-
ADM).23,28 Information on the CIAD was available from two
studies,34,39 but only one of them met the inclusion criteria.34
A comparison of the content covered by these five instru-
ments is presented in Table SA3 (in Appendix SA2; Supporting
Information). The CDLQI and the IDQoL are the most similar
in content out of the five instruments. Table 1 shows other
general characteristics of the included instruments. The CADIS,
CIAD and IDQoL are proxy-reported, whereas the CDLQI is
completed by the children themselves. The questionnaire DIS-
ABKIDS-ADM is available both in a self- and a proxy-reported
version. Only the CDLQI is a dermatology-specific instrument;
all others are eczema-specific. The lowest number of items in
a questionnaire is seven, the highest 45. Four of the five ques-
tionnaires apply a 4- or 5-point Likert scale; only the CIAD
uses a dichotomous response format.
Characteristics of the included studies
An overview of settings and study populations in the included
studies is shown in Table 2. Most studies were conducted in
secondary/tertiary care settings in Europe. Sample sizes ranged
from eight to 370 patients.
Validity of the instruments and recommendations
In total, we were able to rate the methodological quality of
84 measurement properties. Two measurement properties
(2%) had good, 18 (21%) had fair and 64 (76%) had poor
methodological quality. Detailed results for every instrument
and study investigated in this systematic review can be found
in Supplementary Tables S1–S80 (found in the Detailed Results
SR1; Supporting Information).
Proxy-reported instruments
Table SA4 (in Appendix SA2; Supporting Information) shows
the number of studies assessing the different measurement
properties of each included proxy-reported QoL instrument.
The results of best-evidence synthesis and the degree of rec-
ommendation for each proxy-reported instrument are found
in Table 3. There was no instrument for which all relevant
measurement properties have been investigated. Hence, there
was also no instrument that fulfilled all prespecified require-
ments of truth, discrimination and feasibility.
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With Cronbach’s a ranging from 076 to 093 for its sub-
scales, internal consistency of the U.S. version of the CADIS
was found to be adequate.26 Most language versions of the
CIAD also demonstrated good internal consistency, with Cron-
bach’s a values between 072 and 085.34 For the other
instruments, internal consistency assessment was either con-
ducted methodologically poorly or was not done at all. Mea-
surement error was not investigated for any of the proxy-
reported instruments included. Good reliability was shown for
the U.S. version of the CADIS, with intraclass correlation coef-
ficients (ICC) of 089–095 for the domain scores and 096
for the total score between the two administrations.27 An ICC
of 089 was found for the Dutch IDQoL, proving this instru-
ment to be adequately reliable.37 While three language
versions of the CIAD obtained an indeterminate rating for reli-
ability, there was either no evidence or evidence only from
methodologically poor studies for the other instruments.
Data on content validity could be extracted for the U.S. ver-
sion of the CADIS, the U.K. version of the IDQoL and all lan-
guage versions of the CIAD. However, all content validity
assessments were conducted methodologically poorly. No clear
rating could be assigned for the IRT methods used to investi-
gate structural validity of the U.S. version of the CIAD.34
Hypothesis testing was the measurement property most fre-
quently evaluated, with information available for 14 of the 16
proxy-reported instruments. The two Italian CADIS versions
correlated well with other QoL instruments; for instance,
Spearman’s correlation coefficients of 074 with the IDQoL
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and 068 with the Dermatitis Family Impact were found for
the long-version Italian CADIS.35 Discriminative validity of the
U.S. version of the CADIS was proven adequate because the
instrument could differentiate patients according to severity as
measured by the SCORing Atopic Dermatitis (SCORAD)
index.27 Convergent validity of the U.K. version of the IDQoL
was assessed in a study of fair methodological quality, but
resulted in an indeterminate adequacy rating as only
correlations with unrelated constructs were determined.32
Evidence on hypothesis testing for the remaining
questionnaires was available from methodologically poor
studies only.21,24,28,29,34,37 Likewise, we could not draw a
conclusion on cross-cultural validity, which was assessed for
the long version of the Italian CADIS and four language
versions of the CIAD, due to poor methodological study
quality.34,35
Responsiveness in patients with eczema was investigated for
only three questionnaires, but these assessments were of poor
methodological quality.25,27,32,34
Values for the minimal important change (MIC), the mini-
mal important difference (MID) or validated banding systems
are not available for the IDQoL.40 Evidence from several
included validation studies suggests that the IDQoL does not
exhibit floor and ceiling effects (i.e. ≥ 15% of patients having
the lowest/highest possible score).24,29,32,37 We could not
find information on the interpretability of the other proxy-
reported questionnaires. Completion time of the CADIS
amounted to approximately 6 min in one study.26
Table 1 Characteristics of the different instruments
Characteristic CADIS CDLQI CIAD DISABKIDS-ADM IDQoL
Target population Children with eczema
aged 0–6 years (and
their parents)
Children with skin
disease aged
4–16 years
Children with eczema Children and
adolescents with
eczema
Infants with eczema
aged under 4 years
Mode of
administration
Proxy-reporteda Self-reportedb Proxy-reporteda Self- or proxy-
reportedb
Proxy-reporteda
Number of items 45/41/33c 10 9/7d 12 10
Number of subscales 5 6 ND 2 8
Number/type of
response categories
5-point Likert scale 4-point Likert scale Dichotomous (true/
not true)
5-point Likert scale
(and ‘not
applicable’)
4-point Likert scale
Scoring algorithm Calculation of domain
scores by summing
up item scores of all
items in one
domain; calculation
of a total score by
summing up scores
of all items in the
questionnaire
Calculation of a sum
score, range 0–30
ND Calculation of a mean
standardized score
for each dimension,
range 0–100
Calculation of a sum
score, range 0–30
Recall period in
the items
4 weeks 1 week None (‘at the
moment’)
ND 1 week
Administration costs No administration
costs43
No charge for
nonfunded studies;
$1150 per patient
for pharmaceutical
companies51
ND ND No charge for use
in nonfunded
studies and routine
clinical practice;
$1150 per patient
for pharmaceutical
companies52
Available translations English (U.S.), Italian,
Japanese43
More than 5051 Dutch, English (U.K.),
English (U.S.),
French, German
Brazilian Portuguese,
other languagese
More than 2052
CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, Children’s Dermatology Life Quality Index; CIAD, Childhood Impact of Atopic
Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, Infants’ Dermatitis Quality of Life Index; ND, not described.
a‘Proxy-reported’ means that the (primary) caregiver of an infant fills in a questionnaire that assesses the quality of life of the infant. Proxy-
reported instruments are often used with infants and younger children because they cannot report on their quality of life themselves due to
their inability to read and a lack of understanding. b‘Self-reported’ instruments are used with older children and adolescents. These question-
naires are filled in by the children/adolescents themselves, not by their caregiver. c45 items in the original version, 41 items in the long Ital-
ian version, 33 items in the short Italian version (Italian versions include fewer items as some were found to misfit in factor analysis). dNine
items in each of the Dutch, English (U.K.), French and German versions; seven items in the English (U.S.) version. The European versions
and the U.S. questionnaire have six items in common (of these, three are used as link items). eNo description given regarding which lan-
guage versions were tested in the European validation study.
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Table 2 Important characteristics of the included development and validation studies
QoL instrument
Number
of studies
Geographic
location(s) Language(s) Setting(s)
Study population
Number of
participants
per study Age range
English CADIS (U.S.) 226,27 U.S.A. English (U.S.) Secondary/tertiary care 270 15–714 months
Italian CADIS (long
version)
135 Italy Italian Secondary/tertiary care 135 2–72 months
Italian CADIS (short
version)
135 Italy Italian Secondary/tertiary care 135 2–72 months
Danish CDLQI 130 Denmark Danish Secondary/tertiary care 35 ND
English CDLQI (U.K.) 131 U.K. English (U.K.) Secondary/tertiary care 47 ND (mean  SD:
92  36 years)
Malay CDLQI 122 Malaysia Bahasa Malaysia Secondary/tertiary care 33 ND (youngest:
7 years)
Serbian CDLQI 133 Serbia Serbian Secondary/tertiary care 64 4–16 years
Spanish CDLQI
(Mexico)
136 Mexico Mexican Spanish Secondary/tertiary care 64 8–16 years
Swedish CDLQI 129 Sweden Swedish Secondary/tertiary care 50 5–15 years
Dutch CIAD 134,39,a Netherlands Dutch Secondary/tertiary care
and community39
15 (item
generation)39
ND39
20 (field testing)39 ND39
Clinical trial34,b 4834 ND34
English CIAD (U.K.) 134,39,a U.K. English (U.K.) Secondary/tertiary care
and community39
35 (item
generation)39
ND39
20 (field testing)39 ND39
Clinical trial34,b 2134 ND34
English CIAD (U.S.) 134,39,a U.S.A. English (U.S.) Secondary/tertiary care
and community39
2039 ND39
Clinical trial34,b 24334 ND (mean  SD:
48  216
months)34
French CIAD 134,39,a France French Secondary/tertiary care
and community39
1939 ND39
Clinical trial34,b 5234 ND34
German CIAD 134,39,a Germany German Secondary/tertiary care
and community39
1939 ND39
Clinical trial34,b 8734 ND34
Italian CIAD 139,a Italy Italian Secondary/tertiary care
and community
15 (item generation) ND
8 (field testing) ND
Spanish CIAD 139,a Spain Spanish Secondary/tertiary care
and community
20 ND
DISABKIDS-ADM
(unknown language)
123 ND
(two
European
countries)
ND ND 29 ND
Portuguese
DISABKIDS-ADM
(Brazil, proxy-
reported version)
128 Brazil Brazilian
Portuguese
Secondary/tertiary care 52 8–18 years
Portuguese
DISABKIDS-ADM
(Brazil, self-reported
version)
128 Brazil Brazilian
Portuguese
Secondary/tertiary care 52 8–18 years
Arabic IDQoL 121 Saudi Arabia Arabic Secondary/tertiary care 370 ND (mean  SD:
88  99
months)
(continued)
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Self-reported instruments
Table SA5 (in Appendix SA2; Supporting Information) shows
the number of studies assessing the different measurement
properties of each included self-reported QoL instrument. The
results of best evidence synthesis and the degree of recom-
mendation for each self-reported instrument are found in
Table 4. There was no instrument for which all relevant mea-
surement properties have been investigated. Hence, there was
also no instrument that fulfilled all prespecified requirements
of truth, discrimination and feasibility.
Internal consistency assessments were available for four
included self-reported QoL instruments, but all were conducted
methodologically poorly. Measurement error was not evaluated
for any self-reported instrument included. Both the Malay and
the Mexican Spanish CDLQI were assigned an indeterminate rat-
ing for reliability, whereas this measurement property was not
investigated for any other included self-reported instrument.
Content validity was investigated only for the unknown lan-
guage version of the DISABKIDS-ADM, but the methodological
study quality was poor.23 Information on structural validity of
the included self-reported instruments was not available. Data
on hypothesis testing was available for all instruments except
the unknown language version of the DISABKIDS-ADM. We
found an intermediate rating for discriminative validity of the
Swedish CDLQI because the instrument was able to differenti-
ate patients according to age, but could not distinguish
patients with eczema only from patients with eczema and
another allergic comorbidity.29 The assessments of construct
validity of all other questionnaires were of poor methodologi-
cal quality. Cross-cultural validity was not assessed for any
self-reported QoL instrument included.
An investigation of responsiveness was available for the Dan-
ish CDLQI only, but was conducted methodologically poorly.30
Little information on interpretability is available for the self-
reported QoL instruments. No floor and ceiling effects were
found for the CDLQI in an analysis of 50 Swedish children
with eczema.29 Similarly, the CDLQI showed no floor and
ceiling effects in the 47 children participating in its develop-
ment study.31 A recent meta-analysis provides an overview of
CDLQI scores in different conditions, enabling comparisons of
scores of patients with eczema with those of patients suffering
from other diseases and helping to interpret patients’ CDLQI
scores.41 Values for the MIC/MID for the CDLQI in patients
with eczema, as well as interpretability data for the DISAB-
KIDS-ADM, could not be found.
Discussion
This systematic review assessed the measurement properties of
five different QoL instruments for use in infants, children and
adolescents with eczema. None of these instruments complied
with all prespecified filter criteria of truth, discrimination and
feasibility, clearly indicating that more validation work is
required.
The strengths of this systematic review include a registered
and published protocol, the application of a validated, precise
search filter42 and of predefined eligibility criteria, and the use
of the COSMIN checklist13–16 to judge the methodological
quality of the included studies. Every step of the review pro-
cess was carried out by at least two reviewers. Furthermore,
one reviewer (D.H.) was involved in every step of the review
to ensure consistency among the participating reviewers. Dis-
crepancies were resolved by frequent discussions within the
whole team.
A limitation of this review is the fact that only PubMed and
Embase were searched. A thorough hand search of reference
lists of included studies, important reviews and the
Table 2 (continued)
QoL instrument
Number
of studies
Geographic
location(s) Language(s) Setting(s)
Study population
Number of
participants
per study Age range
Dutch IDQoL 137 Netherlands Dutch Primary care 66 05–835 months
English IDQoL (U.K.) 225,32 U.K. English (U.K.) Secondary/tertiary care25 20325 1–53 months25
Secondary/tertiary care and
community32
89 (validation)32 ND (mean: 2016
months)32
Secondary/tertiary care32 92 (development)32 ND32
Italian IDQoL 124 Italy Italian Secondary/tertiary care 21 12–48 months
Swedish IDQoL 129 Sweden Swedish Secondary/tertiary care 28 24–48 months
CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, Children’s Dermatology Life Quality Index; CIAD, Childhood Impact of Atopic
Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, Infants’ Dermatitis Quality of Life Index; ND, not described;
QoL, quality of life. aThe study by McKenna et al.39 from 2005 did not formally meet the inclusion criteria. However, read in conjunction
with the eligible 2007 CIAD development article by McKenna et al.,34 information on content validity of the CIAD could be extracted from
the 2005 article. As a result, only the article by McKenna et al.34 from 2007 was formally included, but information from the 2005 article
was also taken into consideration for content validity assessment. bThese studies were conducted in the context of a clinical trial. No further
information on the participating health service providers was presented, which is why it was not possible to group these study populations
into one of the three categories of community, primary care or secondary/tertiary care.
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PROQOLID database retrieved 10 articles of interest not found
in our initial systematic search, three of which were judged
eligible and included. Another limitation may be that we
could not consider responsiveness results of the CIAD obtained
in the whole European sample because the paper provided no
corresponding country-specific data. Also, information on dis-
criminative validity of the CIAD could not be considered
because the specific P-values were not presented by McKenna
et al.34
Of all the instruments reviewed, only the U.S. version of
the CADIS26 reached category B, hence having the potential to
be recommended in the future depending on the results of
further validation studies. All other questionnaires were placed
in category D; their future use cannot be endorsed until fur-
ther validation data is available.
The CADIS, intended for use in patients with eczema
0–6 years of age, is an internally consistent, reliable question-
naire with adequate construct validity. Its conceptual framework
is based on a literature review and directed focus sessions with
experts and parents. Compared with the other included instru-
ments, the CADIS is unique in that it assesses both the QoL of
the affected infant or child and the QoL of their parents.
Although the instrument provides a total score, separate scores
for the domains relating to the child’s QoL can also be calcu-
lated. Results from both the infant- or child-related domains
and the parent-related domains were considered for this system-
atic review. The 45-item questionnaire was completed quickly.
A disadvantage of the CADIS is that only three validated lan-
guage versions of the instrument are currently available, with a
validation study of a Spanish version being prepared for publica-
tion (personal communication; see reference list for details).43
The validation article of the Japanese CADIS version, recently
published,44 was not investigated in this systematic review
because it was not yet available when our systematic review was
conducted. It will be taken into account in the first update to
this systematic review. Measurement error and structural valid-
ity of the CADIS have not yet been investigated. Moreover,
future studies of improved methodological quality should look
at content validity, cross-cultural validity, responsiveness and
interpretability of the CADIS.
The major finding of this systematic review is that nearly all
existing QoL instruments for infants, children and adolescents
with eczema are lacking significant validation data and were
hence classified in category D. One reason for this is that 76%
of the measurement properties were investigated in a method-
ologically poor manner, compared with 25% in our preceding
systematic review assessing the measurement properties of
adult eczema QoL instruments.10 Part of this difference can be
attributed to a stricter approach in judging whether hypothe-
ses were formulated a priori when assessing hypothesis testing
and responsiveness (item 4 in COSMIN box F, item 8 in COS-
MIN box I) in this review compared with the afore-mentioned
review of adult eczema QoL instruments. However, only 16
of the 32 COSMIN boxes of hypothesis testing and responsive-
ness rated as ‘poor’ in this systematic review would obtain a
better COSMIN rating if a less strict approach concerning
hypotheses formulation were applied, still leaving 57%
methodologically poorly investigated measurement properties
in total. This result suggests that the methodological study
quality is indeed worse than in the previous review on adult
eczema QoL instruments.
In addition to insufficient or methodologically poor valida-
tion of most instruments included, interpretability data is also
lacking. A MID of 25 points on the CDLQI has been found in
Table 4 Summary of measurement properties of self-reported QoL instruments for infants, children and adolescents with eczema
Measurement property
Danish
CDLQI
English
CDLQI
(U.K.)
Malay
CDLQI
Serbian
CDLQI
Spanish
CDLQI
(Mexico)
Swedish
CDLQI
DISABKIDS-
ADM (unknown
language)
Portuguese
DISABKIDS-ADM
(Brazil, self-reported version)
Internal consistency / / Weak Weak Weak / / Weak
Measurement error / / / / / / / /
Reliability / / ? (limited) / ? (limited) / / /
Content validity / / / / / / Weak /
Structural validity / / / / / / / /
Hypothesis testing Weak Weak Weak Weak Weak ? (limited) / Weak
Cross-cultural validity / / / / / / / /
Responsiveness Weak / / / / / / /
Recommendation D D D D D D D D
CDLQI, Children’s Dermatology Life Quality Index; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; QoL, quality of life. Recommen-
dations are defined as follows: A, QoL measurement instrument meets all requirements and is recommended for use; B, QoL measure meets
two or more adequacy items, but performance in all other required adequacy items is unclear, so that the outcome measure has the potential
to be recommended in the future depending on the results of further validation studies; C, QoL measure has low adequacy in at least one
required adequacy criterion (≥ 1 rating of ‘minus’) and therefore is not recommended to be used anymore; D, QoL measure has (almost)
not been validated. Its performance in all or most relevant adequacy items is unclear so that it is not recommended to be used until further
validation studies clarify its adequacy. ? (limited), intermediate rating indicating intermediate measurement property; Weak, measurement
property was assessed only in studies of poor methodological quality (please refer to Table SA2 for further details in the Supporting Informa-
tion);/, not assessed.
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patients with psoriasis,45 but corresponding data for patients
with eczema do not exist. Similarly, a banding system to help
in interpreting CDLQI scores has been developed,46 but the
study did not meet our eligibility criteria because it reported
on general dermatology patients in abstract form only. Inter-
pretability in patients with eczema is an important topic that
future validation studies should address.
Only two of the five included instruments are self-reported
by the affected children. While proxy-reported measures,
including the CADIS, may be particularly useful in infants and
younger children, they are not suitable for older children and
adolescents. As both the CDLQI and the DISABKIDS-ADM were
placed in category D, there is currently no self-reported QoL
instrument for paediatric eczema that can be recommended
for use. CDLQI and DISABKIDS-ADM are also intended for use
in adolescents. However, it has been argued that factors influ-
encing adolescents’ QoL are fundamentally different from
those observed in children and adults, leading to the develop-
ment of the adolescent-specific Skindex-Teen.47 The develop-
ment study of this questionnaire was not eligible for this
review, though. Future validation studies of self-reported QoL
instruments should therefore investigate whether they are suit-
able for adolescents with eczema as well, or if separate instru-
ments for this age group are needed.
Currently, only the CADIS has the potential to be recom-
mended for use depending on the results of further validation
studies. These validation studies should include all existing lan-
guage versions of the CADIS and specifically examine measure-
ment error, content validity, structural validity, cross-cultural
validity, responsiveness and interpretability. If these studies find
favourable measurement properties of the CADIS, it should be
translated and validated in more languages to increase interna-
tional applicability. As the IDQoL is the QoL instrument most
often used in eczema trials involving infants,48 it seems also
advisable to undertake further validation work for this question-
naire. Additionally, future validation research should focus on
self-reported QoL instruments for children and adolescents with
eczema included in this review (CDLQI and DISABKIDS-ADM).
For the time being, as none of the investigated QoL instruments
can be highly recommended, we suggest using the proxy-
reported CADIS for infants and younger children with eczema
until formal consensus is reached by the HOME initiative. For
older children and adolescents with eczema, there is currently
no valid, reliable and feasible self-reported instrument. Trials in
this age group should include the QoL instrument that in their
authors’ opinion is best suited for children and adolescents with
eczema. In older adolescents, the two QoL instruments for
adults with eczema placed in category B in a previous systematic
review,10 the Quality of Life Index for Atopic Dermatitis
(QoLIAD)49 and the Dermatology Life Quality Index (DLQI),50
may be applicable.
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9. Anhang 
Nachfolgend finden sich unterstützende Materialien zu den von mir veröffentlichten Artikeln 
(z. B. Tabellen, Abbildungen), die von den jeweiligen Journals nicht gedruckt veröffentlicht, 
sondern als Online-Appendizes zur Verfügung gestellt wurden. 
9.1 Anhang 1 
zu Heinl D, Chalmers J, Nankervis H, Apfelbacher CJ. Eczema Trials: Quality of Life 
Instruments Used and Their Relation to Patient-Reported Outcomes. A Systematic Review. 
Acta Derm Venereol. 2016; 96: 596-601.  
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Fig. S1. Percentage of included full texts using one of the 4 most frequently applied quality of life (QoL) instruments 
over time. DLQI: Dermatology Life Quality Index; IDQOL: Infants’ Dermatitis Quality of Life Index; CDLQI: 
Children’s Dermatology Life Quality Index; DFI: Dermatitis Family Impact.
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9.2 Anhang 2 
zu Apfelbacher CJ, Heinl D, Prinsen CA, Deckert S, Chalmers J, Ofenloch R, Humphreys R, 
Sach T, Chamlin S, Schmitt J. Measurement properties of adult quality-of-life measurement 
instruments for eczema: protocol for a systematic review. Syst Rev. 2015;4(1):48. 
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Search string Medline (via PubMed) 
 
#1 (modified precision search terms by Terwee et al. 2009)  
 
(instrumentation[sh] OR Validation Studies[pt] OR “reproducibility of results”[MeSH Terms] 
OR reproducib*[tiab] OR “psychometrics”[MeSH] OR psychometr*[tiab] OR 
clinimetr*[tiab] OR clinometr*[tiab] OR “observer variation”[MeSH] OR observer 
variation[tiab] OR “discriminant analysis” [MeSH] OR reliab*[tiab] OR valid*[tiab] OR 
coefficient[tiab] OR “internal consistency”[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR 
alphas[tiab])) OR “item correlation”[tiab] OR “item correlations”[tiab] OR “item 
selection”[tiab] OR “item selections”[tiab] OR “item reduction”[tiab] OR “item 
reductions”[tiab] OR agreement[tw] OR precision[tw] OR imprecision[tw] OR “precise 
values”[tw] OR test-retest[tiab] OR (test[tiab] AND retest[tiab]) OR (reliab*[tiab] AND 
(test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-rater[tiab] OR 
intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR 
intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR 
intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR intertechnician[tiab] 
OR intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-
examiner[tiab] OR intraexaminer[tiab]) OR (intra-examiner[tiab] OR interassay[tiab] OR 
inter-assay[tiab] OR intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-
individual[tiab] OR intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] 
OR inter-participant[tiab] OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] 
OR kappa’s[tiab] OR kappas[tiab] OR “coefficient of variation”[tiab] OR repeatab*[tw] OR 
((replicab*[tw] OR repeated[tw]) AND (measure[tw] OR measures[tw] OR findings[tw] OR 
result[tw] OR results[tw] OR test[tw] OR tests[tw])) OR generaliza*[tiab] OR 
generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND correlation*[tiab]) OR 
discriminative[tiab] OR “known group” [tiab] OR “factor analysis”[tiab] OR “factor 
analyses”[tiab] OR “factor structure”[tiab] OR “factor structures”[tiab] OR 
dimensionality[tiab] OR subscale*[tiab] OR “multitrait scaling analysis”[tiab] OR “multitrait 
scaling analyses”[tiab] OR “item discriminant”[tiab] OR “interscale correlation”[tiab] OR 
“interscale correlations”[tiab]) OR ((error[tiab] OR errors[tiab]) AND (measure*[tiab] OR 
correlat*[tiab] OR evaluat*[tiab] OR accuracy[tiab] OR accurate[tiab] OR precision[tiab] OR 
mean[tiab])) OR “individual variability”[tiab] OR “interval variability”[tiab] OR “rate 
variability”[tiab] OR “variability analysis”[tiab] OR (uncertainty[tiab] AND 
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(measurement[tiab] OR measuring[tiab])) OR “standard error of measurement”[tiab] OR 
sensitiv*[tiab] OR responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR “minimal 
detectable concentration”[tiab] OR interpretab*[tiab] OR (small*[tiab] AND (real[tiab] OR 
detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR “meaningful change”[tiab] OR 
“minimal important change”[tiab] OR “minimal important difference”[tiab]) OR (“minimally 
important change”[tiab] OR “minimally important difference”[tiab] OR “minimal detectable 
change”[tiab] OR “minimal detectable difference”[tiab] OR “minimally detectable 
change”[tiab] OR “minimally detectable difference”[tiab] OR “minimal real change”[tiab] 
OR “minimal real difference”[tiab] OR “minimally real change”[tiab] OR “minimally real 
difference”[tiab] OR “ceiling effect” [tiab] OR “floor effect”[tiab] OR “Item response 
model”[tiab] OR IRT[tiab] OR Rasch[tiab] OR “Differential item functioning”[tiab] OR 
DIF[tiab] OR “computer adaptive testing”[tiab] OR “item bank”[tiab] OR “cross-cultural 
equivalence”[tiab] OR accepta*[tiab] OR “ease of use”[tiab] OR practica*[tiab] OR 
feasib*[tiab]) 
 
 
 
#2  
 
(“addresses”[Publication Type] OR “biography”[Publication Type] OR “case 
reports”[Publication Type] OR “comment”[Publication Type] OR “directory”[Publication 
Type] OR “editorial”[Publication Type] OR “festschrift”[Publication Type] OR 
“interview”[Publication Type] OR “lectures”[Publication Type] OR “legal cases”[Publication 
Type] OR “legislation”[Publication Type] OR “letter”[Publication Type] OR 
“news”[Publication Type] OR “newspaper article”[Publication Type] OR “patient education 
handout”[Publication Type] OR “popular works”[Publication Type] OR 
“congresses”[Publication Type] OR “consensus development conference”[Publication Type] 
OR “consensus development conference, nih”[Publication Type] OR “practice 
guideline”[Publication Type]) NOT (“animals”[MeSH Terms] NOT “humans”[MeSH 
Terms]) 
 
 
#3: #1 NOT #2 
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#4 
 
(quality of life[MH] OR quality of life[TW] OR health status[MH] OR health status[TW] OR 
"activities of daily living"[MH] OR activities of daily living[TW] OR life quality* OR daily 
life[TW]OR health level[TW] OR level of health[TW] OR patient reported outcome[TW] OR 
Skindex[TW] OR Eczema Disability Index[TW]) 
 
AND 
 
#5 
("dermatitis, atopic"[MeSH] OR atopic dermatitis[tiab] OR atopic eczema[tiab] OR 
eczema[MeSH] OR eczema[tiab] OR "neurodermatitis"[MeSH] OR Neurodermatitis[tiab] 
OR skin diseases[MH] OR skin disease*[tiab] OR dermatology[tiab]) 
 
 
#3 AND #4 AND #5 
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Search string Embase 
 
#1  
exp instrumentation/ or exp validation study/ or exp reproducibility/ or reproducib$.mp. or 
exp psychometry/ or psychometr$.mp. or clinimetr*.mp. or clinometr$.mp. or exp observer 
variation/ or observer variation.mp. or exp discriminant analysis/ or exp reliability/ or 
reliab$.mp. or exp Validity/ or valid$.mp. or coefficient.mp. or internal consistency.mp. or 
(cronbach$ and (alpha or alphas)).mp. or item correlation.mp. or item correlations.mp. or item 
selection.mp. or item selections.mp. or item reduction.mp. or item reductions.mp. or 
agreement.mp. or precision.mp. or imprecision.mp. or precise values.mp. or (test-retest or 
(test and retest) or (reliab$ and (test or retest)) or stability or interrater or inter-rater or 
intrarater or intra-rater or intertester or inter-tester or intratester or intra-tester or interobserver 
or inter-observer or intraobserver or intra-observer or intertechnician or intertechnician or 
intratechnician or intra-technician or interexaminer or inter-examiner or intraexaminer or 
intra-examiner or interassay or inter-assay or intraassay or intra-assay or interindividual or 
inter-individual or intraindividual or intra-individual or interparticipant or inter-participant or 
intraparticipant or intra-participant or kappa or kappa$ or coefficient of variation or repeatab$ 
or ((replicap$ or repeated) and (measure or measures or findings or result or results or test or 
tests))).mp. or (generaliza$ or generalisa$ or concordance or (intraclass and correlation$) or 
discriminative or known group or factor analysis or factor analyses or factor structure or 
factor structures or dimensionality or subscale$ or multitrait scaling analysis or multitrait 
scaling analyses or item discriminant or interscale correlation or interscale correlations or 
((error or errors) and (measure$ or correlat$ or evaluat$ or accuracy or accurate or precision 
or mean)) or individual variability or interval variability or rate variability or variability 
analysis or (uncertainty and (measurement or measuring)) or standard error of measurement 
or sensitiv$ or responsive$ or (limit and detection) or minimal detectable concentration or 
interpretab$ or (small$ and (real or detectable) and (change or difference)) or meaningful 
change or minimal important change or minimal important difference or minimally important 
change or minimally important difference or minimal detectable change or minimal detectable 
difference or minimally detectable change or minimally detectable difference or minimal real 
change or minimal real difference or minimally real change or minimally real difference).mp. 
or (ceiling effect or floor effect or Item response model or IRT or Rasch or Differential item 
functioning or DIF or computer adaptive testing or item bank or cross-cultural equivalence or 
practica$ or feasib$).mp. 
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#2 (Conference Abstract or Conference Paper or Conference Review or Editorial or Erratum 
or Letter or Note).pt. 
 
 
#3:  #1 NOT #2 
 
 
#4 
quality of life/ or quality of life.mp. or health status/ or health status.mp. or daily life activity/ 
or activities of daily living.mp. or life quality$.mp. or daily life.mp. or health level.mp. or 
level of health.mp. or health status/ or patient reported outcome.mp. or Skindex.mp. or 
Eczema Disability Index.mp. 
 
#5 
exp Atopic Dermatitis/ or dermatitis, atopic.mp. or atopic dermatitis.mp. or exp eczema/ or 
atopic eczema.mp. or eczema, atopic.mp. or exp NEURODERMATITIS/ or 
neurodermatitis.mp. or skin disease/ or skin disease.mp. or dermatology/ or dermatology.mp. 
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9.3 Anhang 3 
zu Heinl D, Prinsen CAC, Deckert S, Chalmers JR, Drucker AM, Ofenloch R, Humphreys R, 
Sach T, Chamlin SL, Schmitt J, Apfelbacher C. Measurement properties of adult quality-of-
life measurement instruments for eczema: a systematic review. Allergy. 2016; 71: 358-370.  
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Abbreviations and symbols used 
 
+ positive rating 
? indeterminate rating 
- negative rating 
AD = atopic dermatitis; AE = atopic eczema; ANOVA = analysis of variance; COSMIN = COnsensus-
based Standards for the selection of health status Measurement INstruments; DIELH = Deutsches 
Instrument zur Erfassung der Lebensqualität; DIF = Differential item functioning; DLQI = Dermatology 
Life Quality Index; EASI = Eczema Area and Severity Index; GWBI = General Well-Being Index; INVAS = 
Investigator overall assessment of disease severity; QoL = quality of life; MCS = Mental component 
score ; NL = Netherlands; PCS = Physical component score; PGI = Patient-Generated Index; PGWB = 
Psychological General Well-Being Index; PRUVAS = subjective measure of pruritus severity; PTVAS = 
subjective measure of eczema severity; SCORAD = SCORing Atopic Dermatitis; SF-36 = Short form 36; 
TCS = topical corticosteroids; UK = United Kingdom; US = United States of America  
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1. Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH) 
 
Table E1: Structural validity of the DIELH 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(E1) 
Principal components analysis within the single 
diagnostic groups (including AE) performed; questions 
were included if they did not load >0.7 on more than one 
factor 
Not given ? 
Number of AE 
patients 
unknown 
fair 
Conclusion: One study assessed structural validity of the DIELH and indicated unclear structural validity as a QoL instrument for eczema 
 Structural validity of the DIELH as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
Table E2: Discriminative validity of the DIELH 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E2) 
Comparison of the sum scores of different 
diagnostic groups (Kruskal-Wallis test); 
hypothesis: Patients with chronic 
inflammatory dermatoses (like AE) have an 
higher impact on QoL 
Median total score for AE 75.5 
(highest value of all diagnostic 
groups); statistically significant 
(p<0.0001) 
+ 85 AE patients fair 
Conclusion: One study assessed discriminative validity of the DIELH and indicated adequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the DIELH as a measurement of QoL: adequate 
 Quality of evidence: fair  
1
1
2
 
4 
 
2. Dermatology Life Quality Index (DLQI) – Danish version 
 
Table E3: Convergent/divergent validity of the Danish DLQI 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E3) 
Spearman correlation 
coefficients between DLQI 
and 8 dimensions/PCS/MCS of 
the SF-36; Spearman 
correlation coefficients 
between DLQI, PRUVAS, 
PTVAS and INVAS; Wilcoxon 
rank scores between DLQI and 
SCORAD 
The spearman correlation coefficients 
between DLQI and 8 dimensions/PCS/MCS of 
the SF-36 range between -0.54 (General 
health) and -0.11 (Bodily pain); most 
correlations <0.5 
Spearman correlation coefficients for DLQI 
were 0.62 with PRUVAS, 0.81 with PTVAS and 
0.82 with INVAS. 
DLQI was significantly (P < 0.0001) associated 
with objective SCORAD. 
- 
66 patients 
with eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the Danish DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the Danish DLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
 
 
 
1
1
3
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Table E4: Discriminative validity of the Danish DLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E3) 
Discriminative was assessed 
(using Wilcoxon rank scores) 
by seeing how well the QOL 
measures could discriminate 
between groups of 
participants according to 
clinical assessed SCORAD 
Differences in DLQI scores between patients 
with mild and moderate AD (according to 
objective SCORAD) were statistically 
significant (P<0.0001). 
+ 
66 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the Danish DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the Danish DLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
1
4
 
6 
 
3. Dermatology Life Quality Index (DLQI) – English version (UK) 
 
Table E5: Internal consistency of the English DLQI (UK) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E4) Person Separation Index (PSI) 
0.63 for eczema patients (considered low by 
the author) 
- 
146 patients 
with eczema 
good 
Conclusion: One study assessed internal consistency of the UK version of the DLQI and indicated inadequate internal consistency as a QoL instrument for 
eczema 
 Internal consistency of the English DLQI (UK) as a measurement of QoL: inadequate 
 Quality of evidence: good 
 
Table E6: Content validity of the English DLQI (UK) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E5) 
Comparison of the 
areas/activities in the DLQI 
and those that were 
mentioned by the patients in 
the PGI; hypothesis: patients 
would include a broader 
range of affected areas in 
their responses to the PGI 
than those included in the 
DLQI 
36 patients (64%) mentioned areas or 
activities not part of the DLQI, 20 patients 
identified only areas included in the DLQI; 
DLQI item 1 not mentioned by any patient 
- 
56 patients 
with eczema 
fair 
Conclusion: One study assessed content validity of the UK version of the DLQI and indicated inadequate content validity as a QoL instrument for eczema 
 Content validity of the English DLQI (UK) as a measurement of QoL: inadequate 
 Quality of evidence: fair 
 
1
1
5
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Table E7: Structural validity of the English DLQI (UK) 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(E4) 
Examination of overall fit to 
the Rasch model by reference 
to the overall item-trait 
iŶteractioŶ χ²-fit value and via 
Item and Person interaction 
statistics; examination of DIF 
by ANOVA of standardized 
residuals. 
DLQI does not fit a Rasch model for the overall 
sample, but fits a Rasch model for AD patients 
(item-trait interaction = 0.460); item residual 
statistics indicative of model misfit for the AD 
patients; 5/10 items showed DIF for different 
parameters (age and/or gender) in the AD 
sample. 5/10 items showed disease-specific 
DIF in the overall sample. 
A single item (item 4, P=0.048) showed misfit 
to the model. Items 4 (P=0.010) and 7 
(P=0.043) showed uniform DIF by gender, and 
item 6 (P=0.012) exhibited nonuniform DIF by 
gender. Items 2 
(P=0.010), 4 (P=0.020), 7 (P<0.001), and 10 
(P=0.028) showed uniform DIF by age, and 
item 7 (p<0.001) showed 
nonuniform DIF by age. 
- 
292 patients 
(overall 
sample, 146 
psoriasis, 146 
eczema) 
146 patients 
(eczema 
sample) 
good 
Conclusion: One study assessed structural validity of the UK version of the DLQI and indicated inadequate structural validity as a QoL instrument for eczema 
 Structural validity of the English DLQI (UK) as a measurement of QoL: inadequate 
 Quality of evidence: good 
 
 
 
 
 
1
1
6
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Table E8: Convergent/divergent validity of the English DLQI (UK) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E5) 
Correlation between DLQI and 
PGI and individual DLQI 
questions were calculated. 
The mean PGI scores of 
those who scored 0 on items 
of the DLQI were compared, 
using a t-test, with the 
scores of those who scored 1-
3 in each item of the DLQI. 
Calculation of correlations 
between the DLQI and the 
costs of eczema; hypothesis: 
patients with poor QoL incur 
high total costs, health service 
costs and personal costs 
Total correlation between DLQI and PGI -0.52 
(p<0.001) --> positive rating; Questions 1-5 of 
the DLQI were correlated with the PGI but 
only question 2 had a correlation of >0.5. 
Questions 6-10 were not statistically 
significant correlated. 
Correlations between DLQI and total costs -
0.34 (p<0.01); correlation between DLQI and 
health service costs -0.47 (p<0.001); no 
correlation with personal costs 
Positive rating because correlation with a QoL 
measure (PGI) is higher than these 
correlations 
+ 
56 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the UK version of the DLQI and indicated adequate convergent validity as QoL instrument for 
eczema 
 Convergent/divergent validity of the English DLQI (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
1
1
7
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Table E9: Discriminative validity of the English DLQI (UK) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E6) 
Comparison of DLQI scores 
between patients with atopic 
eczema, pruritus and psoriasis 
with patients with acne, basal 
cell carcinoma and viral warts 
Scores for patients with atopic eczema, 
generalized pruritus and psoriasis were higher 
than for patients with acne, basal cell 
carcinoma and viral warts (P<0.001) 
+ 
13 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the UK version of the DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the English DLQI (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
1
8
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4. Dermatology Life Quality Index (DLQI) – German version 
 
Table E10: Discriminative validity of the German DLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E7) 
Discriminative validity: 
Comparison of mean and 
subscale scores between 
patients with psoriasis and 
AD; t-test to determine 
statistical significance 
Differences in mean score statistically 
significant (p<0.01); Differences in all subscale 
scores statistically significant except for 
leisure/sport and relationships 
? 
80 patients 
with eczema  
poor 
Conclusion: One study assessed discriminative validity of the German DLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the German DLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 119
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5. Dermatology Life Quality Index (DLQI) – Spanish version 
 
Table E11: Reliability of the Spanish DLQI 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E8) 
Test retest using Intraclass 
Correlation Coefficient (ICC) 
between two administrations 
ICC between the two administrations was 0.77 
(95% CI) for eczema patients 
+ 
45 patients 
with eczema  
fair 
Conclusion: One study assessed reliability of the Spanish DLQI and indicated adequate reliability as a QoL instrument for eczema 
 Reliability of the Spanish DLQI as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E12: Responsiveness of the Spanish DLQI 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(E8) 
Change in scores over three 
visits after starting TCS 
V1 = 4.53, V2 = 2.80, V3 = 1.64. Change 
between V1 and V3 was statistically significant 
(p=<0.001); change between V1 and V2 not 
statistically significant 
? 
69 patients 
with eczema  
fair 
(E8) 
Sensitivity to change - effect 
size (ES) statistic 
ES for change in overall DLQI score between 
visits 1 and 3 was 0.82. 
+ 
69 patients 
with eczema 
fair 
Conclusion: One study assessed responsiveness of the Spanish DLQI and indicated adequate responsiveness as a QoL instrument for eczema 
 Responsiveness of the Spanish DLQI as a measurement of QoL: adequate 
 Quality of evidence: fair 
1
2
0
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6. Freiburg Life Quality Assessment – core module (FLQA-c) 
 
Table E13: Convergent/divergent validity of the FLQA-c 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E9) 
FLQA scores compared to 
SCORAD severity scores using 
Pearson correlation 
coefficient 
Low and moderate correlations between 
severity score and FLQA scales; between r = 
14 and r = 34 in atopic dermatitis patients 
(p108, 2nd column) 
? 
253 patients 
with eczema  
fair 
Conclusion: One study assessed convergent/divergent validity of the FLQA-c and indicated unclear convergent validity as a QoL instrument for eczema 
 Convergent/divergent validity of the FLQA-c as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
Table E14: Discriminative validity of the FLQA-c 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E9) 
Comparison of scores 
between AD and psoriasis 
patients (ANOVA for 
independent samples) 
Differences between AD and psoriasis patients 
statistically significant (p<0.001) for 5/6 
subscales 
? 
253 patients 
with eczema  
fair 
Conclusion: One study assessed discriminative validity of the FLQA-c and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the FLQA-c as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
1
2
1
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Table E15: Responsiveness of the FLQA-c 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(E9) 
Comparison of patient scores 
after 4 weeks of treatment 
(paired t-test) 
Changes in scores on all subscales statistically 
significant (p<0.001) for AD patients 
+ 
Number of AD 
patients 
unknown 
poor 
Conclusion: One study assessed responsiveness of the FLQA-c, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the FLQA-c as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
2
2
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7. Freiburg Life Quality Assessment for Dermatoses (FLQA-d) 
 
Table E16: Discriminative validity of the FLQA-d 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E7) 
Comparison of subscale 
scores between patients with 
psoriasis and AD; t-test to 
determine statistical 
significance 
Differences in all subscale scores statistically 
significant (p<0.01) except for social life and 
treatment --> 4/6 statistically significant 
different --> indeterminate rating (in contrast 
to DLQI no data on mean scores) 
? 
80 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the FLQA-d, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the FLQA-d as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
2
3
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8. Impact of Chronic Skin Disease on Daily Life (ISDL) 
 
Table E17: Internal consistency of the ISDL 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E10) 
Cronbach's alpha but poorly 
described 
Ranged from 0.64 - 0.93 + 
128 patients 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table E18: Content validity of the ISDL 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E10) 
Items based on literature had 
to be relevant for the 
construct to be measured; 
health professionals and 
patients with chronic skin 
diseases evaluated the initial 
item pool, resulting in 30 
eligible items 
Normal distributions of all items in pilot study ? 
Item 
generation: 
unknown 
 
Pilot study: 65 
psoriasis and 
77 AD patients 
poor 
Conclusion: One study assessed content validity of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
1
2
4
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Table E19: Convergent/divergent validity of the ISDL 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E10) 
Convergent validity of ISDL 
assessed with patients rating 
of disease activity on a 4-point 
Likert scale (extent and 
severity of skin involvement 
of main disease characteristics 
for each body area), DLQI, 
anxiety scale (SCL), depression 
scale (SCL) and neuroticism 
scale (EPQ). Calculated 
Pearson's correlation 
coefficient. 
Too many individual results to list. Moderate 
(0.30-0.50) to relatively high (>0.50) 
correlations in expected directions. More 
correlations <0.5 than above 0.5, see table 3 
in paper. 
- 
128 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the ISDL and indicated inadequate convergent validity as a QoL instrument for eczema 
 Convergent/divergent validity of the ISDL as a measurement of QoL: inadequate 
 Quality of evidence: fair 
 
Table E20: Discriminative validity of the ISDL 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E10) 
Comparison of scores of AD 
and psoriasis patients 
AD patients had significantly higher scores for 
itch (t=3.27, p<0.001), scratch response 
(conscious t=4.95, p<0.001; automatic t=6.40, 
p<0.001) and daily-life impact (t=4.14, 
p<0.001); differences in scores on all other 
subscales not statistically significant 
? 
128 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
2
5
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Table E21: Responsiveness of the ISDL 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(E10) 
Effect study of 5-session of 
cognitive behavioural group 
therapy programme where 
patients learn to cope with 
itch and reduce scratching to 
assess sensitivity to change. 
Physical functioning: skin status (t=3.85), itch 
(t=5.07), conscious scratching (t=5.47), 
automatic scratching (t=4.80) - all p<0.001, 
pain (t=3.62, p<0.01), fatigue (t=1.89, p<0.07). 
Daily life impact: t=4.31, p<0.001, helplessness 
(t=2.70, p<0.01), acceptance (t= -3.52, 
p<0.01), perceived benefits (t= -3.59, p<0.01), 
anxiety (t=2.43, p=0.02). No significant 
changes for negative and positive mood, 
stigmatization and social support. So 11/16 
showed some correlation. 
? 
49 patients 
with eczema 
poor 
Conclusion: One study assessed responsiveness of the ISDL, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the ISDL as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
2
6
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9. Quality of Life Index for Atopic Dermatitis (QoLIAD) – Dutch version 
 
Table E22: Internal consistency of the Dutch QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.88 (time 1) and 0.89 (time 2) + 
39 patients 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the Dutch QoLIAD, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Dutch QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table E23: Reliability of the Dutch QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.80 ? 
17 patients 
with eczema 
poor 
Conclusion: One study assessed reliability of the Dutch QoLIAD, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the Dutch QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
 
1
2
7
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Table E24: Content validity of the Dutch QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Interviews (15 NL, 65 total) to 
explore the effect AD has on 
the patient to generate 
wording for items. Tested for 
cultural applicability across 
countries. Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42. Final version had 
25 items - fit to Rasch model. Local 
dependency between items was minimal - 
minimal item redundancy 
+ 
Item 
generation 
and selection: 
15 patients 
with eczema 
 
Field testing: 
20 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the Dutch QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the Dutch QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: good 
 
 
 
 
 
 
 
 
1
2
8
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Table E25: Convergent/divergent validity of the Dutch QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
SpearŵaŶ’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.79 
(time 1) and 0.58 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.63 (time 
1) and 0.47 (time 2). 
+ 
39 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the Dutch QoLIAD and indicated adequate convergent validity as a QoL instrument for eczema 
 Convergent/divergent validity of the Dutch QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E26: Discriminative validity of the Dutch QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Dutch measure was not statistically significant 
for all 3 assessment groups. May be due to 
small sample size in Netherlands. 
- 
39 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the Dutch QoLIAD and indicated inadequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the Dutch QoLIAD as a measurement of QoL: inadequate 
 Quality of evidence: fair 
1
2
9
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10. Quality of Life Index for Atopic Dermatitis (QoLIAD) – English version (UK) 
 
Table E27: Internal consistency of the English QoLIAD (UK) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.91 (time 1) and 0.94 (time 2) + 
269 patients 
with eczema 
fair 
(E12) 
Internal consistency was 
assessed using Person 
Separation Index (PSI) 
The PSI given in table 2 indicate there is a 
good level of internal reliability as they were 
greater than 0.7 (0.91 for initial fit of QoLIAD 
and 0.82 when 2 items removed). 
+ 
146 patients 
with eczema 
good 
Conclusion: Two studies assessed internal consistency of the UK version of the QoLIAD and indicated adequate internal consistency as a QoL instrument for 
eczema 
 Internal consistency of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair to good 
 
Table E28: Reliability of the English QoLIAD (UK) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.86 ? 
269 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the UK version of the QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the English QoLIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
1
3
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Table E29: Content validity of the English QoLIAD (UK) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Interviews (36 UK, 65 total) to 
explore the effect AD has on 
the patient to generate 
wording for items. Tested for 
cultural applicability across 
countries. Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items. Final 
version had 25 items - fit to Rasch model. 
Local dependency between items was minimal 
- minimal item redundancy 
+ 
Item 
generation 
and selection: 
36 patients 
with eczema 
 
Field testing: 
21 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the UK version of the QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: good 
 
 
 
 
 
 
 
 
1
3
1
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Table E30: Structural validity of the English QoLIAD (UK) 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(E12) 
Examination of overall fit to 
the Rasch model by reference 
to the overall item-trait 
iŶteractioŶ χ²-fit value and via 
Item and Person interaction 
statistics; examination of DIF 
by ANOVA of standardized 
residuals. 
QoLIAD fits the Rasch model (item-trait 
interaction = 0.28), although there is evidence 
for marginal multidimensionality. No clear 
item misfit found. Authors do not refer to DIF 
in the results section (except for disease, but 
not statement whether DIF was uniform or 
non-uniform) 
? 
146 patients 
with eczema 
good 
Conclusion: One study assessed structural validity of the UK version of the QoLIAD and indicated unclear structural validity as a QoL instrument for eczema 
 Structural validity of the English QoLIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: good 
 
 
 
 
 
 
 
 
 
1
3
2
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Table E31: Convergent/divergent validity of the English QoLIAD (UK) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
Spearman’s rank correlation 
coefficients 
Correlations between QoLIAD and DLQI 0.69 
(time 1) and 0.77 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.55 (time 
1) and 0.55 (time 2). 
+ 
269 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the UK version of the QoLIAD and indicated adequate convergent validity as a QoL instrument 
for eczema 
 Convergent/divergent validity of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
1
3
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Table E32: Discriminative validity of the English QoLIAD (UK) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001 for 
severity and general health, p<0.01 for flares) 
+ 
269 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the UK version of the QoLIAD and indicated adequate discriminative validity as a QoL instrument for 
eczema 
 Discriminative validity of the English QoLIAD (UK) as a measurement of QoL: adequate 
 Quality of evidence: fair 
1
3
4
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11. Quality of Life Index for Atopic Dermatitis (QoLIAD) – English version (US) 
 
Table E33: Internal consistency of the English QoLIAD (US) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.93 (time 1) and 0.92 (time 2) + 
170 patients 
with eczema 
fair 
Conclusion: One study assessed internal consistency of the US version of the QoLIAD and indicated adequate internal consistency as a QoL instrument for 
eczema 
 Internal consistency of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E34: Reliability of the English QoLIAD (US) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.90 ? 
170 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the US version of the QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the English QoLIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
 
1
3
5
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Table E35: Content validity of the English QoLIAD (US) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Tested for cultural 
applicability across countries. 
Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items Final 
version had 25 items - fit to Rasch model. 
Local dependency between items was minimal 
- minimal item redundancy 
+ 
Item 
generation 
and selection: 
not described 
 
Field testing: 
20 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the US version of the QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: good 
 
 
 
 
 
 
 
 
 
1
3
6
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Table E36: Convergent/divergent validity of the English QoLIAD (US) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
SpearŵaŶ’s raŶk correlatioŶ 
coefficients 
Correlations between QoLIAD and DLQI 0.74 
(time 1) and 0.75 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.55 (time 
1) and 0.67 (time 2). 
+ 
170 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the US version of the QoLIAD and indicated adequate convergent validity as a QoL instrument 
for eczema 
 Convergent/divergent validity of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
1
3
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Table E37: Discriminative validity of the English QoLIAD (US) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001 for 
severity and general health, p<0.01 for flares) 
+ 
170 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the US version of the QoLIAD and indicated adequate discriminative validity as a QoL instrument for 
eczema 
 Convergent validity of the English QoLIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
 
1
3
8
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12. Quality of Life Index for Atopic Dermatitis (QoLIAD) – French version 
 
Table E38: Internal consistency of the French QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.90 (time 1) and 0.92 (time 2) + 
200 patients 
with eczema 
fair 
Conclusion: One study assessed internal consistency of the French  QoLIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the French QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E39: Reliability of the French QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.89 ? 
200 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the French  QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the French QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
 
 
1
3
9
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Table E40: Convergent/divergent validity of the French QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
SpearŵaŶ’s raŶk correlatioŶ 
coefficients 
Correlations between QoLIAD and DLQI 0.65 
(time 1) and 0.71 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.63 (time 
1) and 0.66 (time 2). 
+ 
200 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the French  QoLIAD and indicated adequate convergent validity as a QoL instrument for 
eczema 
 Convergent/divergent validity of the French QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
1
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Table E41: Discriminative validity of the French QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001) 
+ 
200 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the French  QoLIAD and indicated adequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the French QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
1
4
1
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13. Quality of Life Index for Atopic Dermatitis (QoLIAD) – German version 
 
Table E42: Internal consistency of the German QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.91 (time 1) and 0.92 (time 2) + 
178 patients 
with eczema 
fair 
Conclusion: One study assessed internal consistency of the German  QoLIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table E43: Reliability of the German QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.86 ? 
178 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the German  QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the German QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
 
 
1
4
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Table E44: Content validity of the German QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Tested for cultural 
applicability across countries. 
Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items. Final 
version had 25 items - fit to Rasch model. 
Local dependency between items was minimal 
- minimal item redundancy 
+ 
Item 
generation 
and selection: 
not described 
 
Field testing: 
17 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the German  QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: good 
 
 
 
 
 
 
 
 
 
1
4
3
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Table E45: Convergent/divergent validity of the German QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
SpearŵaŶ’s raŶk correlatioŶ 
coefficients 
Correlations between QoLIAD and DLQI 0.70 
(time 1) and 0.73 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.64 (time 
1) and 0.68 (time 2). 
+ 
178 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the German  QoLIAD and indicated adequate convergent validity as a QoL instrument for 
eczema 
 Convergent/divergent validity of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
1
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Table E46: Discriminative validity of the German QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Differences in scores for all 3 assessment 
groups statistically significant (p<0.001) 
+ 
178 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the German  QoLIAD and indicated adequate discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the German QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
1
4
5
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14. Quality of Life Index for Atopic Dermatitis (QoLIAD) – Italian version 
 
Table E47: Content validity of the Italian QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Interviews (14 Italy, 65 total) 
to explore the effect AD has 
on the patient to generate 
wording for items. Tested for 
cultural applicability across 
countries. Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42 items. 
+ 
Item 
generation 
and selection: 
14 patients 
with eczema 
 
Field testing: 
15 patients 
with eczema 
excellent 
Conclusion: One study assessed content validity of the Italian  QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the Italian QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: excellent 
1
4
6
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15. Quality of Life Index for Atopic Dermatitis (QoLIAD) – Spanish version 
 
Table E48: Internal consistency of the Spanish QoLIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(E11) Cronbach's coefficient 0.88 (time 1) and 0.90 (time 2) + 
80 patients 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the Spanish  QoLIAD, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Spanish QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table E49: Reliability of the Spanish QoLIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(E11) 
Test-retest. Patients 
completed the QoLIAD twice, 
2 weeks apart. 
Spearman's correlation coefficient = 0.88 ? 
80 patients 
with eczema 
fair 
Conclusion: One study assessed reliability of the Spanish  QoLIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the Spanish QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
 
 
1
4
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Table E50: Content validity of the Spanish QoLIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(E11) 
Tested for cultural 
applicability across countries. 
Patients completed 
questionnaire and 
interviewed to identify and 
remove problematic items. 
Field testing to further reduce 
items. 
All needs affected by AD identified (not listed 
here) resulting in 76 item scale. 20 removed 
and 11 modified after cross cultural validation 
to yield a 56 item version for field testing. At 
the field testing stage 14 items were removed 
and two modified leaving 42. Final version had 
25 items - fit to Rasch model. Local 
dependency between items was minimal - 
minimal item redundancy 
+ 
Item 
generation 
and selection: 
not described 
 
Field testing: 
20 patients 
with eczema 
good 
Conclusion: One study assessed content validity of the Spanish  QoLIAD and indicated adequate content validity as a QoL instrument for eczema 
 Content validity of the Spanish QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: good 
 
 
 
 
 
 
 
 
 
1
4
8
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Table E51: Convergent/divergent validity of the Spanish QoLIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Patients completed the 
QoLIAD, DLQI and 
PGWB/GWBI (general) twice, 
2 weeks apart. Assessed 
correlation between scales. 
Ranges predicted 0.6-0.8 for 
DLQI and 0.5-0.7 for 
PGWB/GWBI using 
SpearŵaŶ’s raŶk correlatioŶ 
coefficients 
Correlations between QoLIAD and DLQI 0.76 
(time 1) and 0.75 (time 2).  Correlations 
between QoLIAD and PGWB/GWBI 0.79 (time 
1) and 0.76 (time 2). 
+ 
80 patients 
with eczema 
fair 
Conclusion: One study assessed convergent/divergent validity of the Spanish  QoLIAD and indicated adequate convergent validity as a QoL instrument for 
eczema 
 Convergent/divergent validity of the Spanish QoLIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
 
 
 
 
 
 
 
1
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Table E52: Discriminative validity of the Spanish QoLIAD 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E11) 
Assessed ability of scale to 
discriminate between i) 
patient perceived severity 
(mild / moderate and 
quite/very severe AD, ii) flare 
or no flare and iii) patient 
perceived general health 
(excellent, good, fair or poor) 
Spanish measure was not statistically 
significant for flare. Differences on scores 
between the two other assessment groups 
were statistically significant (p<0.001) 
? 
80 patients 
with eczema 
fair 
(E13) 
Calculated differences in 
scores, compared QoLIAD and 
body parts affected 
(face/hands, face, hands), 
QoLIAD and treatment 
because of the symptoms; 
tested for statistical 
significance using Mann-
Whitney-U and Kruskal-Wallis 
test; no hypotheses 
QoLIAD and body parts: p=0.004 for face 
affected, p=0.114 for face/hands, p=0.052 for 
hands --> QoLIAD could distinguish patients 
whose face was affected 
QoLIAD and treatment: p=0.392 
1/4 statistically significant 
? 
79 patients 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the Spanish QoLIAD and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the Spanish QoLIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
 
 
1
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16. Skindex-29 – English version (US) 
 
Table E53: Convergent/divergent validity of the English Skindex-29 (US) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(E14) 
Determination of correlations 
between scores on the 
instrument and physician's 
judgment of severity of the 
skin disease using Pearson's 
correlation coefficients 
Significant correlation with the emotion scale 
(r=0.29, P<0.01); correlations for the two 
other scales not statistically significant 
? 
102 patients 
with eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the English Skindex-29 (US), but due to poor methodological study quality no conclusion can 
be drawn  
 Convergent/divergent validity of the English Skindex-29 (US) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
 
 
 
 
 
1
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Table E54: Discriminative validity of the English Skindex-29 (US) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E14) 
Comparison of scales scores 
of eczema patients with 
patients with isolated lesions 
(benign growths, 
nonmelanoma skin cancer) 
using the Wilcoxon rank-sum 
test 
Hypothesis: Patients with 
inflammatory dermatoses 
would have higher scale 
scores than patients with 
isolated lesions 
Mean scores of patients with eczema were 
significantly higher than those with benign 
skin lesions or nonmelanoma skin cancer 
(P<0.001) for all 3 subscales 
+ 
102 patients 
with eczema 
good 
Conclusion: One study assessed discriminative validity of the English Skindex-29 (US) and indicated adequate discriminative validity as a QoL instrument for 
eczema 
 Discriminative validity of the English Skindex-29 (US) as a measurement of QoL: adequate 
 Quality of evidence: good 
1
5
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17. Skindex-29 – German version 
 
Table E55: Discriminative validity of the German Skindex-29 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(E15) 
Pearson correlation 
coefficients for each Skindex-
29 subscale with EASI scores 
Correlation between EASI/Skindex-29: 
functioning 0.73, emotion 0.61, symptoms 
0.72 (all statistically significant) 
? 
13 patients 
with eczema 
poor 
(E15) 
Pearson correlation 
coefficients for each Skindex-
29 subscale with self-ratings 
of skin symptoms, itch and 
sleep disturbance 
Correlation between patient ratings of 
severity and Skindex-29: functioning 0.54-
0.59, emotion 0.35-0.40, symptoms 0.62-0.71 
(all statistically significant) 
? 
63 patients 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the German  Skindex-29 and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the German Skindex-29 as a measurement of QoL: unclear 
 Quality of evidence: fair 
1
5
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Search string Medline (via PubMed) 
 
#1 (modified precision search terms by Terwee et al. 2009)  
 
(instrumentation[sh] OR Validation Studies[pt] OR “reproducibility of results”[MeSH Terms] 
OR reproducib*[tiab] OR “psychometrics”[MeSH] OR psychometr*[tiab] OR 
clinimetr*[tiab] OR clinometr*[tiab] OR “observer variation”[MeSH] OR observer 
variation[tiab] OR “discriminant analysis” [MeSH] OR reliab*[tiab] OR valid*[tiab] OR 
coefficient[tiab] OR “internal consistency”[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR 
alphas[tiab])) OR “item correlation”[tiab] OR “item correlations”[tiab] OR “item 
selection”[tiab] OR “item selections”[tiab] OR “item reduction”[tiab] OR “item 
reductions”[tiab] OR agreement[tw] OR precision[tw] OR imprecision[tw] OR “precise 
values”[tw] OR test-retest[tiab] OR (test[tiab] AND retest[tiab]) OR (reliab*[tiab] AND 
(test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-rater[tiab] OR 
intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR 
intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR 
intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR intertechnician[tiab] 
OR intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-
examiner[tiab] OR intraexaminer[tiab]) OR (intra-examiner[tiab] OR interassay[tiab] OR 
inter-assay[tiab] OR intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-
individual[tiab] OR intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] 
OR inter-participant[tiab] OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] 
OR kappa’s[tiab] OR kappas[tiab] OR “coefficient of variation”[tiab] OR repeatab*[tw] OR 
((replicab*[tw] OR repeated[tw]) AND (measure[tw] OR measures[tw] OR findings[tw] OR 
result[tw] OR results[tw] OR test[tw] OR tests[tw])) OR generaliza*[tiab] OR 
generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND correlation*[tiab]) OR 
discriminative[tiab] OR “known group” [tiab] OR “factor analysis”[tiab] OR “factor 
analyses”[tiab] OR “factor structure”[tiab] OR “factor structures”[tiab] OR 
dimensionality[tiab] OR subscale*[tiab] OR “multitrait scaling analysis”[tiab] OR “multitrait 
scaling analyses”[tiab] OR “item discriminant”[tiab] OR “interscale correlation”[tiab] OR 
“interscale correlations”[tiab]) OR ((error[tiab] OR errors[tiab]) AND (measure*[tiab] OR 
correlat*[tiab] OR evaluat*[tiab] OR accuracy[tiab] OR accurate[tiab] OR precision[tiab] OR 
mean[tiab])) OR “individual variability”[tiab] OR “interval variability”[tiab] OR “rate 
variability”[tiab] OR “variability analysis”[tiab] OR (uncertainty[tiab] AND 
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(measurement[tiab] OR measuring[tiab])) OR “standard error of measurement”[tiab] OR 
sensitiv*[tiab] OR responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR “minimal 
detectable concentration”[tiab] OR interpretab*[tiab] OR (small*[tiab] AND (real[tiab] OR 
detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR “meaningful change”[tiab] OR 
“minimal important change”[tiab] OR “minimal important difference”[tiab]) OR (“minimally 
important change”[tiab] OR “minimally important difference”[tiab] OR “minimal detectable 
change”[tiab] OR “minimal detectable difference”[tiab] OR “minimally detectable 
change”[tiab] OR “minimally detectable difference”[tiab] OR “minimal real change”[tiab] 
OR “minimal real difference”[tiab] OR “minimally real change”[tiab] OR “minimally real 
difference”[tiab] OR “ceiling effect” [tiab] OR “floor effect”[tiab] OR “Item response 
model”[tiab] OR IRT[tiab] OR Rasch[tiab] OR “Differential item functioning”[tiab] OR 
DIF[tiab] OR “computer adaptive testing”[tiab] OR “item bank”[tiab] OR “cross-cultural 
equivalence”[tiab] OR accepta*[tiab] OR “ease of use”[tiab] OR practica*[tiab] OR 
feasib*[tiab]) 
 
 
 
#2  
 
(“addresses”[Publication Type] OR “biography”[Publication Type] OR “case 
reports”[Publication Type] OR “comment”[Publication Type] OR “directory”[Publication 
Type] OR “editorial”[Publication Type] OR “festschrift”[Publication Type] OR 
“interview”[Publication Type] OR “lectures”[Publication Type] OR “legal cases”[Publication 
Type] OR “legislation”[Publication Type] OR “letter”[Publication Type] OR 
“news”[Publication Type] OR “newspaper article”[Publication Type] OR “patient education 
handout”[Publication Type] OR “popular works”[Publication Type] OR 
“congresses”[Publication Type] OR “consensus development conference”[Publication Type] 
OR “consensus development conference, nih”[Publication Type] OR “practice 
guideline”[Publication Type]) NOT (“animals”[MeSH Terms] NOT “humans”[MeSH 
Terms]) 
 
 
#3: #1 NOT #2 
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#4 
 
(quality of life[MH] OR quality of life[TW] OR health status[MH] OR health status[TW] OR 
"activities of daily living"[MH] OR activities of daily living[TW] OR life quality* OR daily 
life[TW]OR health level[TW] OR level of health[TW] OR patient reported outcome[TW] OR 
CDLQI[TW] OR IDQOL[TW]) 
 
 
#5 
("dermatitis, atopic"[MeSH] OR atopic dermatitis[tiab] OR atopic eczema[tiab] OR 
eczema[MeSH] OR eczema[tiab] OR "neurodermatitis"[MeSH] OR Neurodermatitis[tiab] 
OR skin diseases[MH] OR skin disease*[tiab] OR dermatology[tiab]) 
 
#3 AND #4 AND #5 
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Search string Embase 
 
#1  
exp instrumentation/ or exp validation study/ or exp reproducibility/ or reproducib$.mp. or 
exp psychometry/ or psychometr$.mp. or clinimetr*.mp. or clinometr$.mp. or exp observer 
variation/ or observer variation.mp. or exp discriminant analysis/ or exp reliability/ or 
reliab$.mp. or exp Validity/ or valid$.mp. or coefficient.mp. or internal consistency.mp. or 
(cronbach$ and (alpha or alphas)).mp. or item correlation.mp. or item correlations.mp. or item 
selection.mp. or item selections.mp. or item reduction.mp. or item reductions.mp. or 
agreement.mp. or precision.mp. or imprecision.mp. or precise values.mp. or (test-retest or 
(test and retest) or (reliab$ and (test or retest)) or stability or interrater or inter-rater or 
intrarater or intra-rater or intertester or inter-tester or intratester or intra-tester or interobserver 
or inter-observer or intraobserver or intra-observer or intertechnician or intertechnician or 
intratechnician or intra-technician or interexaminer or inter-examiner or intraexaminer or 
intra-examiner or interassay or inter-assay or intraassay or intra-assay or interindividual or 
inter-individual or intraindividual or intra-individual or interparticipant or inter-participant or 
intraparticipant or intra-participant or kappa or kappa$ or coefficient of variation or repeatab$ 
or ((replicap$ or repeated) and (measure or measures or findings or result or results or test or 
tests))).mp. or (generaliza$ or generalisa$ or concordance or (intraclass and correlation$) or 
discriminative or known group or factor analysis or factor analyses or factor structure or 
factor structures or dimensionality or subscale$ or multitrait scaling analysis or multitrait 
scaling analyses or item discriminant or interscale correlation or interscale correlations or 
((error or errors) and (measure$ or correlat$ or evaluat$ or accuracy or accurate or precision 
or mean)) or individual variability or interval variability or rate variability or variability 
analysis or (uncertainty and (measurement or measuring)) or standard error of measurement 
or sensitiv$ or responsive$ or (limit and detection) or minimal detectable concentration or 
interpretab$ or (small$ and (real or detectable) and (change or difference)) or meaningful 
change or minimal important change or minimal important difference or minimally important 
change or minimally important difference or minimal detectable change or minimal detectable 
difference or minimally detectable change or minimally detectable difference or minimal real 
change or minimal real difference or minimally real change or minimally real difference).mp. 
or (ceiling effect or floor effect or Item response model or IRT or Rasch or Differential item 
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functioning or DIF or computer adaptive testing or item bank or cross-cultural equivalence or 
practica$ or feasib$).mp. 
 
#2 (Conference Abstract or Conference Paper or Conference Review or Editorial or Erratum 
or Letter or Note).pt. 
 
 
#3:  #1 NOT #2 
 
 
#4 
quality of life/ or quality of life.mp. or health status/ or health status.mp. or daily life activity/ 
or activities of daily living.mp. or life quality$.mp. or daily life.mp. or health level.mp. or 
level of health.mp. or health status/ or patient reported outcome.mp. or CDLQI.mp. or 
IDQOL.mp. 
 
#5 
exp Atopic Dermatitis/ or dermatitis, atopic.mp. or atopic dermatitis.mp. or exp eczema/ or 
atopic eczema.mp. or eczema, atopic.mp. or exp NEURODERMATITIS/ or 
neurodermatitis.mp. or skin disease/ or skin disease.mp. or dermatology/ or dermatology.mp. 
 
#3 AND #4 AND #5 
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9.5 Anhang 5 
zu Heinl D, Prinsen CAC, Sach T, Drucker AM, Ofenloch R, Flohr C, Apfelbacher C. 
Measurement properties of quality-of-life measurement instruments for infants, children and 
adolescents with eczema: a systematic review. Br J Dermatol. 2017; 176: 878-89. 
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Online Appendix SA1: Tables pertaining to the British Journal of 
Dermatology puďliĐation ͞Measurement properties of quality-of-
life measurement instruments for infants, children and adolescents 
with eczema: a systematic review͟ 
Supplementary Table SA1. Adequacy criteria for measurement properties adapted from 
Terwee et al.
S1
 and PROMIS Methodology
S2
 
Property  Rating Adequacy criteria 
Reliability   
Internal consistency (CTT 
methods applied) 
+ 
? 
- 
CroŶďaĐh's alpha;sͿ ш Ϭ.ϳϬ 
CroŶďaĐh’s alpha not determined 
Cronbach's alpha(s) < 0.70 
Internal consistency (IRT 
methods applied) 
+ 
? 
- 
Person Separation Index ш 0.70 
Person Separation Index not determined 
Person Separation Index < 0.70 
Measurement error + 
? 
- 
MIC > SDC OR MIC outside the LoA 
MIC not defined 
MIC <= SDC OR MIC equals or inside LoA 
Reliability + 
? 
- 
ICC/weighted Kappa >=Ϭ.ϳϬ, OR PearsoŶ’s r >= Ϭ.ϴϬ 
Neither ICC/weighted Kappa, Ŷor PearsoŶ’s r 
determined 
ICC/weighted Kappa < Ϭ.ϳϬ OR PearsoŶ’s r < Ϭ.ϴϬ 
Validity   
Content validity + 
 
 
 
? 
- 
All items are considered to be relevant for the 
construct to be measured, for the target population, 
and for the purpose of the measurement AND the 
questionnaire is considered to be comprehensive  
Not enough information available  
Not all items are considered to be relevant for the 
construct to be measured, for the target population, 
and for the purpose of the measurement OR the 
questionnaire is considered not to be comprehensive 
Construct validity   
Structural validity 
(CTT methods applied) 
+ 
? 
- 
Factors should explain at least 50% of the variance 
Explained variance not mentioned 
Factors explain < 50% of the variance 
Structural validity (IRT 
methods applied) 
+ 
 
 
 
 
? 
- 
Residual correlations among the items after controlling 
for the dominant factor < 0.20 OR Q3's < 0.37, item 
scalability >0.30, IRT model fit: G2 >0.01, no DIF for 
important subject characteristics (such as age, gender, 
education): McFadden's R2 < 0.02, OR no non-uniform 
DIF 
Important statistics not reported 
Residual correlations among the items after controlling 
for the doŵiŶaŶt faĐtor ш Ϭ.ϮϬ OR Qϯ's ш Ϭ.ϯϳ, iteŵ 
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sĐalaďilitǇ чϬ.ϯϬ, IRT ŵodel fit: GϮ чϬ.Ϭϭ, iŵportaŶt DIF 
for important subject characteristics (such as age, 
geŶder, eduĐatioŶͿ: MĐFaddeŶ's RϮ шϬ.ϬϮ, OR non-
uniform DIF 
Hypothesis testing 
(convergent/divergent 
validity) 
+ 
 
 
 
? 
- 
Correlations with instruments measuring the same 
construct >=0.50 OR at least 75% of the results are in 
accordance with the hypotheses AND correlation with 
related constructs is higher than with unrelated 
constructs 
Solely correlations determined with unrelated 
constructs 
Correlations with instruments measuring the same 
construct < 0.50 OR < 75% of the results are in 
accordance with the hypotheses OR correlation with 
related constructs is lower than with unrelated 
constructs 
Hypothesis testing 
(discriminative validity) 
+ 
 
 
? 
- 
Differences in scores on the measurement instrument 
for all evaluated patient subgroups are statistically 
significant OR ш75% of results in accordance with 
hypotheses 
Some differences statistically significant, others not 
Differences in scores on the measurement instrument 
for all evaluated patient subgroups are not statistically 
significant OR <75% of results in accordance with 
hypotheses 
Cross-cultural validity + 
 
? 
 
- 
No differences in factor structure OR no important DIF 
between language versions 
Multiple group factor analysis not applied AND DIF not 
assessed 
Differences in factor structure OR important DIF 
between language versions 
Responsiveness   
Responsiveness + 
 
 
 
 
? 
- 
Correlation with changes on instruments measuring 
the saŵe ĐoŶstruĐt ш Ϭ.5Ϭ OR at least ϳ5% of the 
results are in accordance with the hypotheses OR AUC 
ш Ϭ.ϳϬ AND ĐorrelatioŶs with ĐhaŶges iŶ related 
constructs are higher than with unrelated constructs 
Solely correlations determined with unrelated 
constructs 
Correlations with changes on instruments measuring 
the same construct < 0.50 OR < 75% of the results are 
in accordance with the hypotheses OR AUC < 0.70 OR 
correlations with changes in related constructs are 
lower than with unrelated constructs 
Abbreviations: AUC, area under the curve; CTT, classical test theory; DIF, differential item 
functioning; ICC, intraclass correlation coefficient; LoA, limits of agreement; MIC, minimal 
important change; SDC, smallest detectable change.  
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+ positive rating, ? indeterminate rating, - negative rating 
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Supplementary Table SA2. Levels of evidence for the overall adequacy of a measurement 
property adapted from Schellingerhout et al.
S3
 
Level Rating Criteria 
Strong +++, ? (strong) or --- Consistent findings in 
multiple studies of good 
methodological quality OR in 
one study of excellent 
methodological quality 
Moderate ++, ? (moderate) or -- Consistent findings in 
multiple studies of fair 
methodological quality OR in 
one study of good 
methodological quality 
Limited +, ? (limited) or - One study of fair 
methodological quality 
Conflicting +/- Conflicting findings 
Unknown  ? Only studies of poor 
methodological quality  
+ positive rating, ? indeterminate rating, - negative rating 
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Supplementary Table SA3. Comparison of the content of the different QoL instruments on 
content domain level 
Domain CADIS
a
 CDLQI CIAD
b
 
DISABKIDS-
ADM
c IDQoL 
Symptoms X X   X 
Emotions  X    
Difficulties with mood     X 
Activities of daily living X X   X 
Leisure  X   X 
Sleep  X   X 
Social/family life  X   X 
Treatment  X   X 
Behaviour X     
Impact    X  
Stigmatization    X  
a
The CADIS also contains the following content domains related to parental QoL: family and social function, sleep, emotions. 
b
No content domains for the CIAD were presented in the development article. 
c
Content comparison of DISABKIDS-ADM is based on dimensions empirically derived from factor analysis and not on content-related 
domains. 
Abbreviations: CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, ChildreŶ’s DerŵatologǇ Life QualitǇ IŶdeǆ; CIAD, Childhood Impact 
of Atopic Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, IŶfaŶts’ Derŵatitis QualitǇ of Life IŶdeǆ; QoL, quality of 
life.  
  
  
 
Supplementary Table SA4. Number of studies assessing the measurement properties of proxy-reported QoL instruments for infants, children 
and adolescents with eczema 
Measurement 
property 
English 
CADIS 
(US) 
Italian 
CADIS 
(long 
version) 
Italian 
CADIS 
(short 
version) 
Dutch 
CIAD 
English 
CIAD 
(UK) 
English 
CIAD 
(US) 
French 
CIAD 
German 
CIAD 
Italian 
CIAD 
Spanish 
CIAD 
Portuguese 
DISABKIDS-
ADM (Brazil, 
proxy-reported 
version) 
Arabic 
IDQoL 
Dutch 
IDQoL 
English 
IDQoL 
(UK) 
Italian 
IDQoL 
Swedish 
IDQoL 
Internal 
consistency 
1
S4
 1
S5
 1
S5
 1
S6
 1
S6
 1
S6
 1
S6
 1
S6
 / / 1
S7
 1
S8
 / / 1
S9
 / 
Measurement 
error 
/ / / / / / / / / / / / / / / / 
Reliability 1
S10
 1
S5
 1
S5
 1
S6
 1
S6
 1
S6
 1
S6
 1
S6
 / / / / 1
S11
 1
S12
 1
S9
 / 
Content validity 1
S4
 / / 1
S13
 1
S13
 1
S13
 1
S13
 1
S13
 1
S13
 1
S13
 / / / 1
S12
 / / 
Structural validity / 1
S5
 / / / 1
S6
 / / / / / / / / / / 
Hypothesis 
testing 
1
S10
 1
S5
 1
S5
 1
S6
 1
S6
 1
S6
 1
S6
 1
S6
 / / 1
S7
 1
S8
 1
S11
 2
S12,S14
 1
S9
 1
S15
 
Cross-cultural 
validity 
/ 1
S5
 / 1
S6
 1
S6
 / 1
S6
 1
S6
 / / / / / / / / 
Responsiveness 1
S10
 / / / / 1
S6
 / / / / / / / 2
S12,14
 / / 
Abbreviations: CADIS, Childhood Atopic Dermatitis Impact Scale; CIAD, Childhood Impact of Atopic Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, IŶfaŶts’ Derŵatitis QualitǇ of Life IŶdeǆ; QoL, 
quality of life; UK, United Kingdom; US, United States (of America). 
  
1
6
9
 
170 
 
 
Supplementary Table SA5. Number of studies assessing the measurement properties of 
self-reported QoL instruments for infants, children and adolescents with eczema 
Measurement 
property 
Danish 
CDLQI 
English 
CDLQI 
(UK) 
Malay 
CDLQI 
Serbian 
CDLQI 
Spanish 
CDLQI 
(Mexico) 
Swedish 
CDLQI 
DISABKIDS-
ADM 
(unknown 
language) 
Portuguese 
DISABKIDS-ADM 
(Brazil, self-
reported version) 
Internal consistency / / 1
S16
 1
S17
 1
S18
 / / 1
S7
 
Measurement error / / / / / / / / 
Reliability / / 1
S16
 / 1
S18
 / / / 
Content validity / / / / / / 1
S19
 / 
Structural validity / / / / / / / / 
Hypothesis testing 1
S20
 1
S21
 1
S16
 1
S17
 1
S18
 1
S15
 / 1
S7
 
Cross-cultural validity / / / / / / / / 
Responsiveness 1
S20
 / / / / / / / 
Abbreviations: CDLQI, ChildreŶ’s DerŵatologǇ Life QualitǇ IŶdeǆ; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; QoL, quality of 
life; UK, United Kingdom; 
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Abbreviations and symbols used 
 
+ positive rating 
? indeterminate rating 
- negative rating 
AD = atopic dermatitis; ANVOCA = analysis of covariance; ANOVA = analysis of variance; CADIS = 
Childhood Atopic Dermatitis Impact Scale; CDLQI = ChildreŶ’s DerŵatologǇ Life QualitǇ IŶdeǆ; CIAD = 
Childhood Impact of Atopic Dermatitis; COSMIN = COnsensus-based Standards for the selection of 
health Measurement INstruments; DFI = Dermatitis Family Impact; DIF = Differential item 
functioning; DISABKIDS-ADM = DISABKIDS Atopic Dermatitis Module; EASI = Eczema Area and 
Severity Index; FDI = Family Dermatitis Impact (identic with DFI); ICC = Intraclass Correlation 
Coefficient; IDQoL = IŶfaŶts’ Derŵatitis QualitǇ of Life IŶdeǆ; INVAS = Investigator overall assessment 
of disease severity; QoL = quality of life; MCS = Mental component score ; NL = Netherlands; PAGS = 
parental severity assessment; PCS = Physical component score; PGWB = Psychological General Well-
Being Index; PRUVAS = subjective measure of pruritus severity; PTVAS = subjective measure of 
eczema severity; R&L = Rajka & Langeland; SCORAD = SCORing Atopic Dermatitis; TIS = Three Item 
Severity Score; UK = United Kingdom; US = United States of America  
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1. Childhood Atopic Dermatitis Impact Scale (CADIS) – English version (US) 
 
Table S1: Internal consistency of the English  version (US)  of the CADIS 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S1) 
Calculation of Cronbach's alpha 
for every subscale 
Cronbach's alpha ranged from 0.76-0.93 for 
the subscales 
+ 
270 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed internal consistency of the English version (US) of the CADIS and indicated adequate internal consistency as a QoL instrument 
for eczema  
 Internal consistency of the English version (US) of the CADIS as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S2: Reliability of the English version (US) of the CADIS 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S2) 
Completion of the CADIS at enrollment and 48 
hours later; Calculation of the Intraclass 
Correlation Coefficient of Reliability for each 
domain score and for the total score 
ICC total score: 0.96 
ICC domain scores: 0.89-0.95 
+ 
41 parents of 
children with 
AD 
fair 
Conclusion: One study assessed reliability of the English version (US) of the CADIS and indicated adequate reliability as a QoL instrument for eczema  
 Reliability of the English version (US) of the CADIS as a measurement of QoL: adequate 
 Quality of evidence: fair  
 
 
1
7
5
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Table S3: Content validity of the English version (US) of the CADIS 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S1) 
Parents of young children with 
AD involved in construction of a 
conceptual framework (together 
with expert clinicians and 
published work); pilot test of 
initial version with 20 parents of 
AD children 
Parents: 453 mentions of the ways that AD 
bothers their child and 410 mentions of the 
ways that AD bothers them; all mentions 
noted by more than 7% of the parents 
were included in the CADIS; removal of 
four items considered ambiguous, biased, 
or wordy (by the investigators) 
? 
Construction 
of conceptual 
framework: 
unknown 
Pilot study: 20 
parents of 
children with 
AD 
poor 
Conclusion: One study assessed content validity of the English version (US) of the CADIS, but due to poor methodological study quality no conclusion can be 
drawn  
 Content validity of the English version (US) of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S4: Convergent/divergent validity of the English version (US) of the CADIS 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S2) 
Calculation of the correlation 
between CADIS scores and SCORAD 
total and objective scores and ratings 
of pruritus and sleep loss using 
Spearman's correlation coefficients 
CADIS/total SCORAD: 0.48-0.65; 
CADIS/objective SCORAD: 0.42-0.53; 
subjective criteria (pruritus and sleep 
loss): 0.46-0.72 
? 
270 parents of 
children with 
AD 
poor 
Conclusion: One study assessed convergent/divergent validity of the English version (US) of the CADIS, but due to poor methodological study quality no 
conclusion can be drawn  
 Convergent/divergent validity of the English version (US) of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
1
7
6
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Table S5: Discriminative validity of the English version (US) of the CADIS 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S2) 
Comparison of CADIS scores 
between patients of three severity 
groups based on their objective 
SCORAD score using ANOVA 
Scores from all 5 CADIS domains 
significantly differentiated patients at 
each clinical severity level (P<0.001); all 
pairwise comparisons significant (P<0.05) 
+ 
270 parents of 
children with 
AD 
fair 
Conclusion: One study assessed discriminative validity of the English version (US) of the CADIS and indicated adequate discriminative validity as a QoL 
instrument for eczema  
 Discriminative validity of the English version (US) of the CADIS as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S6: Responsiveness of the English version (US) of the CADIS 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(S2) 
Comparison of CADIS scores 
between patients that were 
improved, the same, or worsened 
after 4 weeks according to a global 
question about their skin 
condition; ANOVA 
CADIS domains significantly differentiated 
patients from the three groups (P<0.001); 
improved subjects had significantly better 
scores than the other 2 groups on all 
domains (P<0.05); no significant 
difference between improved and 
worsened subjects (P>0.05) 
? 
228 parents of 
children with 
AD 
poor 
Conclusion: One study assessed responsiveness of the English version (US) of the CADIS, but due to poor methodological study quality no conclusion can be 
drawn  
 Responsiveness of the English version (US) of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
7
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2. Childhood Atopic Dermatitis Impact Scale (CADIS) – Italian long version 
 
Table S7: Internal consistency of the Italian long version of the CADIS 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S3) Calculation of Cronbach's alpha 
ItaliaŶ loŶg ǀersioŶ: α for total score Ϭ.ϵϱ; α 
for subscales ranging from 0.77-0.95 
+ 
135 parents of 
children with 
AD 
poor 
Conclusion: One study assessed internal consistency of the Italian long version of the CADIS, but due to poor methodological study quality no conclusion can 
be drawn  
 Internal consistency of the Italian long version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S8: Reliability of the Italian long version of the CADIS 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S3) 
Test-retest interval 48 
hours; calculation of 
Spearman's correlation 
coefficients for each 
subscale and the total score 
Italian long version: correlations for total scale 
0.92; 0.90 for Child Symptoms; 0.80 for Child 
Activity Limitations and Behavior; 0.73 for 
Family and Social Function; 0.87 for Parent 
EŵotioŶ aŶd PareŶt Sleep ;for all: P≤Ϭ.ϬϬϭͿ 
? 
66 parents of 
children with 
AD 
poor 
Conclusion: One study assessed reliability of the Italian long version of the CADIS, but due to poor methodological study quality no conclusion can be drawn  
 Reliability of the Italian long version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor  
 
 
1
7
8
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Table S9: Structural validity of the Italian long version of the CADIS 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(S3) 
Two separate exploratory factor analysis 
(principal axis factoring) for child-related 
and parent-related scales, respectively; 
initial minimum loading for an item 0.32; 
later, for item reduction purposes, items 
with loadings below 0.50 were dropped 
Child-related items: 2 factors 
accounted for 43.9% of the total 
variance 
Parent-related items: 3 factors 
accounted for 43.7% of the total 
variance 
Several items were eliminated (see 
cross-cultural validity for details). 
- 
135 parents of 
children with 
AD 
poor 
Conclusion: One study assessed structural validity of the Italian long version of the CADIS, but due to poor methodological study quality no conclusion can be 
drawn  
 Structural validity of the Italian long version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor  
 
 
 
 
 
 
 
 
 
1
7
9
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Table S10: Convergent/divergent validity of the Italian long version of the CADIS 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S3) 
Calculation of Spearman's 
correlation coefficients between 
each CADIS domain score and 
objective, subjective and total 
SCORAD scores, total IDQoL, 
CDLQI and DFI scores; 
Hypothesis: higher correlations 
between CADIS and QoL 
instruments (IDQoL, CDLQI, DFI) 
than between CADIS and 
SCORAD 
Italian CADIS, long version (total score): 
CADIS/oSCORAD 0.38, CADIS/subjective 
SCORAD 0.57, CADIS/total SCORAD 0.44, 
CADIS/IDQoL 0.74, CADIS/CDLQI 0.58, 
CADIS/DFI 0.68 
Italian CADIS, long version (domain scores): 
CADIS/oSCORAD 0.27-0.37, 
CADIS/subjective SCORAD 0.31-0.58, 
CADIS/total SCORAD 0.32-0.44, 
CADIS/IDQoL 0.40-0.75, CADIS/CDLQI 0.38-
0.60, CADIS/DFI 0.51-0.62 
+ 
SCORAD: 135 
parents of 
children with 
AD; IDQoL: 
102 parents; 
CDLQI: 33 
parents; DFI: 
126 parents 
fair 
Conclusion: One study assessed convergent/divergent validity of the Italian long version of the CADIS and indicated adequate convergent validity as a QoL 
instrument for eczema  
 Convergent/divergent validity of the Italian long version of the CADIS as a measurement of QoL: adequate 
 Quality of evidence: fair  
 
 
 
 
 
 
 
1
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Table S11: Discriminative validity of the Italian long version of the CADIS 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S3) 
Comparison of CADIS 
scores of different 
patient severity 
groups according to 
SCORAD using ANOVA 
Kruskal-Wallis test for difference between the 
different severity groups was significant for all CADIS 
doŵaiŶs ;loŶg aŶd short ǀersioŶ; P≤Ϭ.ϬϭͿ; pairǁise 
comparisons all significant except 4: moderate/severe 
AD in Child Activity Limitations and Behavior and in 
the Parent Emotions domain; mild/moderate in Family 
and Social Function and Parent Sleep Domains 
? 
135 parents of 
children with 
AD 
poor 
Conclusion: One study assessed discriminative validity of the Italian long version of the CADIS, but due to poor methodological study quality no conclusion can 
be drawn  
 Discriminative validity of the Italian long version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor  
 
 
 
 
 
 
 
 
 
1
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Table S12: Cross-cultural validity of the Italian long version of the CADIS 
Author 
Cross-cultural validity 
Method Result Interpretation Study base COSMIN score 
(S3) 
Two separate 
exploratory 
factor analysis 
(principal axis 
factoring) for 
child-related 
and parent-
related scales, 
respectively 
Child-related items: 1 item from Child Symptoms loaded on 
both factors --> attributed to Activity Limitations and 
Behavior; 2 items from Activity Limitations and Behavior 
loaded on Child Symptoms, 1 loaded on both factors; 2 items 
from Activity Limitations and Behavior did not reach an 
acceptable loading on any factor and were excluded. Further 2 
child-related items excluded after examination of the rotated 
factor matrix because of inadequate factor loadings. 
Parent-related items: 1 item from Parent Emotions scale 
loaded on Family and Social Function scale; 1 item from 
Parent Emotion scale eliminated (no acceptable loading on 
any factor). 1 item from Family and Social Function scale 
loaded on Parent sleep, 1 item loaded on both factors, and 1 
was eliminated (no acceptable loading on any factor). 
Subsequent examination of the pattern matrix led to the 
elimination of 6 family-related items. 
Summary: 4 items loaded on factors different from the 
original version; 3 items loaded on two factors; 4 items 
reached no acceptable loading on any factor --> 11/45 items 
worked differently compared to the original version; 8 items 
eliminated in subsequent analysis 
- 
135 parents of 
children with 
AD 
poor 
Conclusion: One study assessed cross-cultural validity of the Italian long version of the CADIS, but due to poor methodological study quality no conclusion can 
be drawn  
 Cross-cultural validity of the Italian long version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor  
1
8
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3. Childhood Atopic Dermatitis Impact Scale (CADIS) – Italian short version 
 
Table S13: Internal consistency of the Italian short version of the CADIS  
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S3) 
Calculation of Cronbach's 
alpha 
ItaliaŶ short ǀersioŶ: α for total scale Ϭ.ϵϬ; α 
for subscales ranging from 0.72-0.89 
+ 
135 parents of 
children with 
AD 
poor 
Conclusion: One study assessed internal consistency of the Italian short version of the CADIS, but due to poor methodological study quality no conclusion can 
be drawn 
 Internal consistency of the Italian short version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S14: Reliability of the Italian short version of the CADIS 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S3) 
Test-retest interval 48 hours; 
calculation of Spearman's 
correlation coefficients for 
each subscale and the total 
score 
Italian short version: correlations for total 
scale 0.91; 0.91 for Child Symptoms; 0.78 for 
Child Activity Limitations and Behavior; 0.85 
for Parent Emotions; 0.67 for Family and 
Social Function; 0.87 for Parent Sleep (for all: 
P≤Ϭ.ϬϬϭͿ 
? 
66 parents of 
children with 
AD 
poor 
Conclusion: One study assessed reliability of the Italian short version of the CADIS, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the Italian short version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
1
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Table S15: Convergent/divergent validity of the Italian short version of the CADIS 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S3) 
Calculation of Spearman's 
correlation coefficients between 
each CADIS domain score and 
objective, subjective and total 
SCORAD scores, total IDQoL, 
CDLQI and DFI scores; 
Hypothesis: higher correlations 
between CADIS and QoL 
instruments (IDQoL, CDLQI, DFI) 
than between CADIS and 
SCORAD 
Italian CADIS, short version (total score): 
CADIS/oSCORAD 0.38, CADIS/subjective 
SCORAD 0.56, CADIS/total SCORAD 0.44, 
CADIS/IDQoL 0.74, CADIS/CDLQI 0.56, 
CADIS/DFI 0.66 
Italian CADIS, short version (domain 
scores): CADIS/oSCORAD 0.24-0.39, 
CADIS/subjective SCORAD 0.24-0.57, 
CADIS/total SCORAD 0.28-0.45, 
CADIS/IDQoL 0.32-0.74, CADIS/CDLQI 0.37-
0.63, CADIS/DFI 0.46-0.61 
+ 
SCORAD: 135 
parents of 
children with 
AD; IDQoL: 
102 parents; 
CDLQI: 33 
parents; DFI: 
126 parents 
fair 
Conclusion: One study assessed convergent/divergent validity of the Italian short version of the CADIS and indicated adequate convergent validity as a QoL 
instrument for eczema  
 Convergent/divergent validity of the Italian short version of the CADIS as a measurement of QoL: adequate 
 Quality of evidence: fair  
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Table S16: Discriminative validity of the Italian short version of the CADIS 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S3) 
Comparison of CADIS 
scores of different 
patient severity 
groups according to 
SCORAD using ANOVA 
Kruskal-Wallis test for difference between the 
different severity groups was significant for all CADIS 
doŵaiŶs ;loŶg aŶd short ǀersioŶ; P≤Ϭ.ϬϭͿ; pairǁise 
comparisons all significant except 4: moderate/severe 
AD in Child Activity Limitations and Behavior and in 
the Parent Emotions domain; mild/moderate in Family 
and Social Function and Parent Sleep Domains 
? 
135 parents of 
children with 
AD 
poor 
Conclusion: One study assessed discriminative validity of the Italian short version of the CADIS, but due to poor methodological study quality no conclusion can 
be drawn  
 Discriminative validity of the Italian short version of the CADIS as a measurement of QoL: unclear 
 Quality of evidence: poor  
1
8
5
 
14 
 
4. Children’s Dermatology Life Quality Index (CDLQI) – Danish version 
 
Table S17: Convergent/divergent validity of the Danish CDLQI 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S4) 
Calculation of Spearman's 
correlation coefficient to determine 
the relationship between CDLQI and 
patient visual analogue scale for 
pruritus (PRUVAS), patient overall 
assessment visual analogue scale 
(PTVAS), investigator overall 
assessment visual analogue scale 
(INVAS) and physical component 
score (PCS) and mental component 
score (MCS) of SF-36 
CDLQI/PCS: -0.90 (P<0.05) 
CDLQI/MCS: 0.52 (not significant) 
CDLQI/PRUVAS: 0.60 (P<0.0001) 
CDLQI/PTVAS: 0.75 (P<0.0001) 
CDLQI/INVAS: 0.71 (P<0.0001) 
+ 
PCS/MCS: 6 children 
with AD aged 14-16 
years 
PRUVAS/PTVAS/INVAS: 
35 children with AD 
and 7 controls aged 3-
14 years 
poor 
Conclusion: One study assessed convergent/divergent validity of the Danish CDLQI, but due to poor methodological study quality no conclusion can be drawn  
 Convergent/divergent validity of the Danish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
 
 
1
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Table S18: Discriminative validity of the Danish CDLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S4) 
Comparison of scores of patients 
with mild and moderate AD 
according to SCORAD using 
Wilcoxon rank scores 
Patients with moderate AD had 
significantly higher CDLQI scores than 
patients with mild eczema (P<0.0001) 
+ 
35 children 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the Danish CDLQI, but due to poor methodological study quality no conclusion can be drawn  
 Discriminative validity of the Danish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S19: Responsiveness of the Danish CDLQI 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(S4) 
CDLQI compared at visit 1 and 
visit 2 (6 months later) 
Visit 1: mean = 8; Visit 2: mean = 3. Statistical 
testing not reported. 
? 
35 children 
with eczema 
poor 
Conclusion: One study assessed responsiveness of the Danish CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the Danish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
 
 
1
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5. Children’s Dermatology Life Quality Index (CDLQI) – English version (UK) 
 
Table S203: Discriminative validity of the English CDLQI (UK) 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S5) 
Comparison of scores of patients with 
eczema, psoriasis and acne with those 
of patients with moles and naevi 
Scores for eczema, psoriasis and acne 
all significantly higher than those for 
moles and naevi (P<0.002) 
+ 
47 children 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the UK version of the CDLQI, but due to poor methodological study quality no conclusion can be 
drawn 
 Discriminative validity of the English CDLQI (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
8
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6. Children’s Dermatology Life Quality Index (CDLQI) – Malay version 
 
Table S21: Internal consistency of the Malay CDLQI 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S6) Calculation of Cronbach's alpha α=Ϭ.ϵϮ + 33 children 
with AD 
poor 
Conclusion: One study assessed internal consistency of the Malay CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Malay CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S22: Reliability of the Malay CDLQI 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S6) 
Calculation of Spearman's correlation 
coefficient to determine relationship 
between mean scores on the CDLQI at 
administration 1 and 2; Kappa analysis of 
agreement (not mentioned if a weighted 
kappa ǀalue ǁas calculatedͿ; Δt = Ϯ ǁeeks 
r=0.74; "average of moderate 
agreement" according to kappa 
(estimate not presented) 
? 
33 children 
with AD 
fair 
Conclusion: One study assessed reliability of the Malay CDLQI and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the Malay CDLQI as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table S23: Discriminative validity of the Malay CDLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S6) 
Comparison of differences in CDLQI 
scores between patients with mild, 
moderate and severe AD using 
ANOVA 
Difference between moderate/severe 
AD not significant (p=0.08); unclear 
whether differences between mild and 
moderate or severe were significant 
? 
33 children 
with AD 
poor 
Conclusion: One study assessed discriminative validity of the Malay CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the Malay CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
9
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7. Children’s Dermatology Life Quality Index (CDLQI) – Serbian version 
 
Table S24: Internal consistency of the Serbian CDLQI 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S7) Calculation of Cronbach's alpha α=Ϭ.ϵϮ ;stated iŶ discussioŶ sectioŶͿ + 64 children 
with AD 
poor 
Conclusion: One study assessed internal consistency of the Serbian CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Serbian CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S25: Convergent/divergent validity of the Serbian CDLQI 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S7) 
Calculation of Spearman's correlation 
coefficient to determine the association 
between EASI and CDLQI subscales 
Correlations ranged from 0.60 to 
0.74 
? 
46 children 
above the age 
of 8 years 
poor 
Conclusion: One study assessed convergent/divergent validity of the Serbian CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Convergent validity of the Serbian CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S26: Discriminative validity of the Serbian CDLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S7) 
Comparison of CDLQI scores by disease 
severity levels (mild, moderate, severe) 
using ANOVA 
All differences were statistically 
significant 
+ 
64 children 
with AD 
poor 
Conclusion: One study assessed discriminative validity of the Serbian CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the Serbian CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
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8. Children’s Dermatology Life Quality Index (CDLQI) – Spanish version (Mexico) 
 
Table S27: Internal consistency of the Mexican Spanish CDLQI 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S8) Cronbach's alpha α=Ϭ.ϴϯ + 64 children 
with AD 
poor 
Conclusion: One study assessed internal consistency of the Mexican Spanish CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Mexican Spanish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S28: Reliability of the Mexican Spanish CDLQI 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S8) 
Test-retest reliability by determining 
Spearman's correlation coefficient 
(second administration 1 week later) 
Spearman's coefficient = 0.97, p<0.001 ? 
64 children 
with AD 
fair 
Conclusion: One study assessed reliability of the Mexican Spanish CDLQI and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the Mexican Spanish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table S29: Convergent/divergent validity of the Mexican Spanish CDLQI 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S8) 
Assessment of the correlation between CDLQI 
and SCORAD and of the correlation between 
CDLQI and COOP-Dartmouth by calculating 
Spearman's correlation coefficient 
COOP-Dartmouth/CDLQI: 
0.97, p<0.001 
SCORAD/CDLQI: 0.53, p<0.001 
+ 
64 children 
with AD 
poor 
Conclusion: One study assessed convergent/divergent validity of the Mexican Spanish CDLQI, but due to poor methodological study quality no conclusion can 
be drawn 
 Convergent/divergent validity of the Mexican Spanish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
1
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9. Children’s Dermatology Life Quality Index (CDLQI) – Swedish version 
 
Table S30: Convergent/divergent validity of the Swedish CDLQI 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S9) 
Calculation of Spearman's 
correlation coefficient to 
determine the association 
between CDLQI and DFI, 
CDLQI and R&L score and 
CDLQI and objective SCORAD 
CDLQI/DFI: 0.44 (p<0.01); CDLQI/R&L: 0.31 
(p<0.05); CDLQI/oSCORAD: 0.18 (p>0.05) 
? 
50 children 
with eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the Swedish CDLQI, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the Swedish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S31: Discriminative validity of the Swedish CDLQI 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S9) 
Comparison of scores of children with 
eczema and children with eczema and 
asthma, allergic rhinoconjunctivitis, 
food allergy/intolerance or urticaria 
(AAFU) using ANOVA; Comparison of 
scores of younger and older children 
No significant difference between 
children with eczema and children 
with eczema and AAFU 
Mean CDLQI score was significantly 
higher for younger children than for 
older ones (p<0.05) 
? 
50 children 
with eczema 
fair 
Conclusion: One study assessed discriminative validity of the Swedish CDLQI and indicated unclear discriminative validity as a QoL instrument for eczema 
 Discriminative validity of the Swedish CDLQI as a measurement of QoL: unclear 
 Quality of evidence: fair 
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10. Childhood Impact of Atopic Dermatitis (CIAD) – Dutch version 
 
Table S32: Internal consistency of the Dutch CIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of Cronbach's 
alpha 
Cronbach's alpha ranged from 0.72 to 0.85 in 
all countries 
+ 
48 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed internal consistency of the Dutch CIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the Dutch CIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S33: Reliability of the Dutch CIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of test-retest correlations (type 
of correlation coefficient not described) 
0.78 (Netherlands) ? 
22 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed reliability of the Dutch CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the Dutch CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
 
1
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Table S34: Content validity of the Dutch CAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Interviews (15 NL, 65 total) with 
parents to explore the effect AD has 
on their children to generate 
wording for items. Tested for 
cultural applicability across 
countries. Parents completed the 
draft questionnaire and were asked 
in field-test interviews to comment 
on its understandability, 
comprehensiveness, and relevance. 
More than 150 items after item 
generation phase. Reduction to 55 
items by researchers. Initial version 
relevant to parents. Removal of ten 
items and modification of three items 
based on field-test interviews. 12 of the 
final 45 items formed the basis for 
creation of the CIAD. No specific 
content validity tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
15 parents of 
children with 
AD (item 
generation) 
 
20 parents of 
children with 
AD (field test) 
poor 
Conclusion: One study assessed content validity of the Dutch CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the Dutch CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S35: Convergent/divergent validity of the Dutch CIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S10) 
Correlation of CIAD scores with scores on 
the Psychological General Well-Being Index 
(PGWB) 
Correlations between 0.38 and 
0.65 
? 
48 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the Dutch CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the Dutch CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
1
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Table S36: Cross-cultural validity of the Dutch CIAD 
Author 
Cross-cultural validity 
Method Result Interpretation Study base COSMIN score 
(S10) 
Assessment of country-specific DIF and 
splitting/removal of items exhibiting DIF 
Europe: Four items exhibited 
significant DIF --> items were split 
by country; three misfitting items 
removed 
+ 
48 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed cross-cultural validity of the Dutch CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Cross-cultural validity of the Dutch CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
1
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11. Childhood Impact of Atopic Dermatitis (CIAD) – English version (UK) 
 
Table S37: Internal consistency of the English CIAD (UK) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of Cronbach's 
alpha 
Cronbach's alpha ranged from 0.72 to 0.85 in 
all countries 
+ 
21 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed internal consistency of the UK version of the CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the English CIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S38: Reliability of the English CIAD (UK) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of test-retest correlations (type 
of correlation coefficient not described) 
Correlations ranged from 0.78 in 
the Netherlands to 0.86 in the US 
? 
21 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed reliability of the UK version of the CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the English CIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
 
1
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Table S39: Content validity of the English CIAD (UK) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Interviews (35 UK, 65 total) with 
parents to explore the effect AD has 
on their children to generate 
wording for items. Tested for 
cultural applicability across 
countries. Parents completed the 
draft questionnaire and were asked 
in field-test interviews to comment 
on its understandability, 
comprehensiveness, and relevance. 
More than 150 items after item 
generation phase. Reduction to 55 
items by researchers. Initial version 
relevant to parents. Removal of ten 
items and modification of three items 
based on field-test interviews. 12 of the 
final 45 items formed the basis for 
creation of the CIAD. No specific 
content validity tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
35 parents of 
children with 
AD (item 
generation) 
 
20 parents of 
children with 
AD (field test) 
poor 
Conclusion: One study assessed content validity of the UK version of the CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the English CIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S40: Convergent/divergent validity of the English CIAD (UK) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S10) 
Correlation of CIAD scores with scores on 
the Psychological General Well-Being Index 
(PGWB) 
Correlations between 0.38 and 
0.65 
? 
21 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the UK version of the CIAD, but due to poor methodological study quality no conclusion can be 
drawn 
 Convergent/divergent validity of the English CIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S41: Cross-cultural validity of the English CIAD (UK) 
Author 
Cross-cultural validity 
Method Result Interpretation Study base COSMIN score 
(S10) 
Assessment of country-specific DIF and 
splitting/removal of items exhibiting DIF 
Europe: Four items exhibited 
significant DIF --> items were split 
by country; three misfitting items 
removed 
+ 
21 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed cross-cultural validity of the UK version of the CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Cross-cultural validity of the English CIAD (UK) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
0
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12. Childhood Impact of Atopic Dermatitis (CIAD) – English version (US) 
 
Table S42: Internal consistency of the English CIAD (US) 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of Cronbach's 
alpha 
Cronbach's alpha ranged from 0.72 to 0.85 in 
all countries 
+ 
243 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed internal consistency of the US version of the CIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the English CIAD (US) as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S43: Reliability of the English CIAD (US) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of test-retest correlations (type 
of correlation coefficient not described) 
0.86 (US) ? 
243 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed reliability of the US version of the CIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the English CIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
 
 
2
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Table S44: Content validity of the English CIAD (US) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Tested items for cultural 
applicability across countries. 
Parents completed the draft 
questionnaire and were asked in 
field-test interviews to comment on 
its understandability, 
comprehensiveness, and relevance. 
Reduction of initial item pool to 55 
items by researchers. Initial version 
relevant to parents. Removal of ten 
items and modification of three items 
based on field-test interviews. 12 of the 
final 45 items formed the basis for 
creation of the CIAD. No specific 
content validity tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
20 parents of 
children with 
AD 
poor 
Conclusion: One study assessed content validity of the US version of the CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the English CIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S45: Structural validity of the English CIAD (US) 
Author 
Structural validity 
Method Result Interpretation Study base COSMIN score 
(S10) 
Assessment of overall fit to 
the Rasch model using Chi-
square-statistics 
Chi² statistics significant at 5% level both for 
Europe and the USA (p<0.002 and p<0.004, 
respectively); however, they used Bonferroni 
correction, so these p values may in fact be not 
significant (corrected alpha level not reported) 
? 
243 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed structural validity of the US version of the CIAD and indicated unclear structural validity as a QoL instrument for eczema 
 Structural validity of the English CIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: fair 
 
2
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Table S46: Convergent/divergent validity of the English CIAD (US) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S10) 
Correlation of CIAD scores with scores on 
the Psychological General Well-Being Index 
(PGWB) 
Correlations between 0.38 and 
0.65 
? 
243 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the US version of the CIAD, but due to poor methodological study quality no conclusion can be 
drawn 
 Convergent/divergent validity of the English CIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S47: Responsiveness of the English CIAD (US) 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(S10) 
ANCOVA to test for differences in change 
scores between elidel and placebo group 
USA: no significant differences - 
243 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed responsiveness of the US version of the CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the English CIAD (US) as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
0
4
 
33 
 
13. Childhood Impact of Atopic Dermatitis (CIAD) – French version 
 
Table S48: Internal consistency of the French CIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of Cronbach's 
alpha 
Cronbach's alpha ranged from 0.72 to 0.85 in 
all countries 
+ 
52 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed internal consistency of the French CIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the French CIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S49: Reliability of the French CIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of test-retest correlations (type 
of correlation coefficient not described) 
Correlations ranged from 0.78 in 
the Netherlands to 0.86 in the US 
? 
52 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed reliability of the French CIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the French CIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table S50: Content validity of the French CIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Tested items for cultural 
applicability across countries. 
Parents completed the draft 
questionnaire and were asked in 
field-test interviews to comment on 
its understandability, 
comprehensiveness, and relevance. 
Reduction of initial item pool to 55 
items by researchers. Initial version 
relevant to parents. 12 of the final 45 
items formed the basis for creation of 
the CIAD. No specific content validity 
tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
19 parents of 
children with 
AD 
poor 
Conclusion: One study assessed content validity of the French CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the French CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S51: Convergent/divergent validity of the French CIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S10) 
Correlation of CIAD scores with scores on 
the Psychological General Well-Being Index 
(PGWB) 
Correlations between 0.38 and 
0.65 
? 
52 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the French CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the French CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S52: Cross-cultural validity of the French CIAD 
Author 
Cross-cultural validity 
Method Result Interpretation Study base COSMIN score 
(S10) 
Assessment of country-specific DIF and 
splitting/removal of items exhibiting DIF 
Europe: Four items exhibited 
significant DIF --> items were split 
by country; three misfitting items 
removed 
+ 
52 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed cross-cultural validity of the French CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Cross-cultural validity of the French CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
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14. Childhood Impact of Atopic Dermatitis (CIAD) – German version 
 
Table S53: Internal consistency of the German CIAD 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of Cronbach's 
alpha 
Cronbach's alpha ranged from 0.72 to 0.85 in 
all countries 
+ 
87 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed internal consistency of the German CIAD and indicated adequate internal consistency as a QoL instrument for eczema 
 Internal consistency of the German CIAD as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S54: Reliability of the German CIAD 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S10) 
Calculation of test-retest correlations (type 
of correlation coefficient not described) 
Correlations ranged from 0.78 in 
the Netherlands to 0.86 in the US 
? 
87 parents of 
children with 
eczema 
fair 
Conclusion: One study assessed reliability of the German CIAD and indicated unclear reliability as a QoL instrument for eczema 
 Reliability of the German CIAD as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table S55: Content validity of the German CIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Tested items for cultural 
applicability across countries. 
Parents completed the draft 
questionnaire and were asked in 
field-test interviews to comment on 
its understandability, 
comprehensiveness, and relevance. 
Reduction of initial item pool to 55 
items by researchers. Initial version 
relevant to parents. Removal of ten 
items and modification of three items 
based on field-test interviews. 12 of the 
final 45 items formed the basis for 
creation of the CIAD. No specific 
content validity tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
19 parents of 
children with 
AD 
poor 
Conclusion: One study assessed content validity of the German CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the German CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S56: Convergent/divergent validity of the German CIAD 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S10) 
Correlation of CIAD scores with scores on 
the Psychological General Well-Being Index 
(PGWB) 
Correlations between 0.38 and 
0.65 
? 
87 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the German CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the German CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S57: Cross-cultural validity of the German CIAD 
Author 
Cross-cultural validity 
Method Result Interpretation Study base COSMIN score 
(S10) 
Assessment of country-specific DIF and 
splitting/removal of items exhibiting DIF 
Europe: Four items exhibited 
significant DIF --> items were split 
by country; three misfitting items 
removed 
+ 
87 parents of 
children with 
eczema 
poor 
Conclusion: One study assessed cross-cultural validity of the German CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Cross-cultural validity of the German CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
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15. Childhood Impact of Atopic Dermatitis (CIAD) – Italian version 
 
Table S58: Content validity of the Italian CIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Interviews (15 Italy, 65 total) with 
parents to explore the effect AD has 
on their children to generate 
wording for items. Tested for 
cultural applicability across 
countries. Parents completed the 
draft questionnaire and were asked 
in field-test interviews to comment 
on its understandability, 
comprehensiveness, and relevance. 
More than 150 items after item 
generation phase. Reduction to 55 
items by researchers. Initial version 
relevant to parents. Removal of ten 
items and modification of three items 
based on field-test interviews. 12 of the 
final 45 items formed the basis for 
creation of the CIAD. No specific 
content validity tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
15 parents of 
children with 
AD (item 
generation) 
 
8 parents of 
children with 
AD (field test) 
poor 
Conclusion: One study assessed content validity of the Italian CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the Italian CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
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16. Childhood Impact of Atopic Dermatitis (CIAD) – Spanish version 
 
Table S59: Content validity of the Spanish CIAD 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S11) 
Tested items for cultural 
applicability across countries. 
Parents completed the draft 
questionnaire and were asked in 
field-test interviews to comment on 
its understandability, 
comprehensiveness, and relevance. 
Reduction of initial item pool to 55 
items by researchers. Initial version 
relevant to parents. 12 of the final 45 
items formed the basis for creation of 
the CIAD. No specific content validity 
tests, e.g. examining 
comprehensiveness and relevance, 
were conducted for these 12 items. 
? 
20 parents of 
children with 
AD 
poor 
Conclusion: One study assessed content validity of the Spanish CIAD, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the Spanish CIAD as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
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17. DISABKIDS Atopic Dermatitis Module (DISABKIDS-ADM) – proxy-reported Portuguese version (Brazil) 
 
Table S60: Internal consistency of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S12) 
Calculation of Cronbach's 
alpha (proxy-reported 
version) 
Cronbach's alpha was 0.7239 for impact 
dimension and 0.8604 for stigma dimension 
+ 
52 parents of 
children and 
adolescents 
with eczema 
poor 
Conclusion: One study assessed internal consistency of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM, but due to poor methodological 
study quality no conclusion can be drawn 
 Internal consistency of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S61: Convergent/divergent validity of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S12) 
Correlation of scores with parent-
evaluated disease severity by 
calculation of Pearson's correlation 
coefficient (proxy-reported version) 
Impact dimension: r=-0.401 to -0,695 
;p≤Ϭ.ϬϬϯͿ; stigŵa diŵeŶsioŶ: r=-0.346 
to -Ϭ.ϲϰϮ ;p≤Ϭ.ϬϭϮͿ 
? 
52 parents of 
children and 
adolescents 
with eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM, but due to poor 
methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S62: Discriminative validity of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S12) 
Comparison of scores of 
different severity groups using 
ANOVA (proxy-reported 
version) 
Statistically significant differences in both 
dimensions between mild, moderate and 
severe disease (P<0.001), but no statistically 
significant differences between moderate and 
severe disease in both dimensions 
? 
52 parents of 
children and 
adolescents 
with eczema 
poor 
Conclusion: One study assessed discriminative validity of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM, but due to poor methodological 
study quality no conclusion can be drawn 
 Discriminative validity of the proxy-reported Brazilian Portuguese version of DISABKIDS-ADM as a measurement of QoL: unclear 
 Quality of evidence: poor 
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18. DISABKIDS Atopic Dermatitis Module (DISABKIDS-ADM) – self-reported Portuguese version (Brazil) 
 
Table S63: Internal consistency of the self-reported Brazilian Portuguese version of DISABKIDS-ADM 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S12) 
Calculation of Cronbach's 
alpha (self-reported version) 
Cronbach's alpha was 0.7024 for impact 
dimension and 0.8124 for stigma 
dimension 
+ 
52 children and 
adolescents with 
eczema 
poor 
Conclusion: One study assessed internal consistency of the self-reported Brazilian Portuguese version of DISABKIDS-ADM, but due to poor methodological 
study quality no conclusion can be drawn  
 Internal consistency of the self-reported Brazilian Portuguese version of DISABKIDS-ADM as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S64: Convergent/divergent validity of the self-reported Brazilian Portuguese version of DISABKIDS-ADM 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S12) 
Correlation of scores with patient-
evaluated disease severity by 
calculation of Pearson's correlation 
coefficient (self-reported version) 
Impact dimension: r=-0.465 to -0.609 
;p≤Ϭ.ϬϬϭͿ; stigŵa diŵeŶsioŶ: 
r=0.417 to -Ϭ.ϱϱϱ ;p≤Ϭ.ϬϬϮͿ 
? 
52 children and 
adolescents with 
eczema and their 
parents 
poor 
Conclusion: One study assessed convergent/divergent validity of the self-reported Brazilian Portuguese version of DISABKIDS-ADM, but due to poor 
methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the self-reported Brazilian Portuguese version of DISABKIDS-ADM as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S65: Discriminative validity of the self-reported Brazilian Portuguese version of DISABKIDS-ADM 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S12) 
Comparison of scores of 
different severity groups using 
ANOVA (self-reported version) 
Statistically significant differences in both 
dimensions across all disease severity 
categories (P<0.001) 
+ 
52 children and 
adolescents with 
eczema and their 
parents 
poor 
Conclusion: One study assessed discriminative validity of the self-reported Brazilian Portuguese version of DISABKIDS-ADM, but due to poor methodological 
study quality no conclusion can be drawn 
 Discriminative validity of the self-reported Brazilian Portuguese version of DISABKIDS-ADM as a measurement of QoL: unclear 
 Quality of evidence: poor 
2
1
6
 
45 
 
19. DISABKIDS Atopic Dermatitis Module (DISABKIDS-ADM) – unknown language version 
 
Table S66: Content validity of DISABKIDS-ADM (unknown language version) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S13) 
Item selection from focus groups and semi-structured 
interviews; pilot study: item reduction by calculation of 
percentages of 'never' or 'not applicable' responses, 
cognitive interviews with affected children and adolescents, 
and clinical judgment of clinicians and investigators 
? ? 
Item selection: 
unknown 
Pilot study: 29 
AD patients 
poor 
Conclusion: One study assessed content validity of DISABKIDS-ADM (unknown language version), but due to poor methodological study quality no conclusion 
can be drawn 
 Content validity of DISABKIDS-ADM (unknown language version) as a measurement of QoL: unclear 
 Quality of evidence: poor 
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20. Infants’ Dermatitis Quality of Life Index ȋIDQoLȌ – Arabic version 
 
Table S67: Internal consistency of the Arabic IDQoL 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S14) Cronbach's alpha α=Ϭ.ϴϳ + 370 AD patients + 120 controls poor 
Conclusion: One study assessed internal consistency of the Arabic IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Arabic IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S48: Convergent/divergent validity of the Arabic IDQoL 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S14) 
Correlation of items and severity (not described 
which correlation coefficient was calculated) 
Correlations range from 
0.51-0.72 
? 
370 AD 
patients 
poor 
Conclusion: One study assessed convergent/divergent validity of the Arabic IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the Arabic IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S69: Discriminative validity of the Arabic IDQoL 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S14) 
Calculation of p value for item 
and total IDQoL scores for 
patients with mild, moderate and 
severe AD according to SCORAD 
Statistically significant for mild vs. 
moderate, mild vs. severe, moderate vs. 
severe (p<0.000 for all items and for the 
total score) 
+ 
370 cases with 
AD 
poor 
Conclusion: One study assessed discriminative validity of the Arabic IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the Arabic IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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21. Infants’ Dermatitis Quality of Life Index ȋIDQoLȌ – Dutch version 
 
Table S70: Reliability of the Dutch IDQoL 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S15) 
Calculation of the Intraclass 
Correlation Coefficient between 
adŵiŶistratioŶ ϭ aŶd Ϯ ;Δt=ϮϰhͿ 
ICC for overall scale = 0.89; ICC for 
individual questions ranged from 0.485 to 
0.941 
+ 
58 parents of 
children with 
AD 
fair 
Conclusion: One study assessed reliability of the Dutch IDQoL and indicated adequate reliability as a QoL instrument for eczema 
 Reliability of the Dutch IDQoL as a measurement of QoL: adequate 
 Quality of evidence: fair 
 
Table S71: Convergent/divergent validity of the Dutch IDQoL 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S15) 
Calculation of Spearman's 
correlation coefficient to 
determine relationship 
between IDQoL and parent-
assessed severity, Three Item 
Severity Score (TIS) and 
oSCORAD 
IDQoL/parent-assessed severity: 0.728 
(first visit), 0.662 (second visit) 
IDQoL/TIS: 0.134 (first visit), 0.356 (second 
visit) 
IDQoL/oSCORAD: 0.080 (first visit), 0.248 
(second visit) 
? 
66 parents of 
children with AD 
(first visit) 
65 parents of 
children with AD 
(second visit) 
poor 
Conclusion: One study assessed convergent/divergent validity of the Dutch IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Convergent/divergent validity of the Dutch IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
2
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22. Infants’ Dermatitis Quality of Life Index ȋIDQoLȌ – English version (UK) 
 
Table S72: Reliability of the English IDQoL (UK) 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S16) 
Calculation of Spearman's 
correlation coefficients 
between the two assessments 
r=0.91 ? 
72/102 24 
hour delayed 
questionaires 
received 
poor 
Conclusion: One study assessed reliability of the UK version of the IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the UK version of the IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S73: Content validity of the English IDQoL (UK) 
Author 
Content validity 
Method Result Interpretation Study base COSMIN score 
(S16) 
92 parents of infants aged under 4 
years with AD attending a Paediatric 
Dermatology outpatient department 
were asked to write down all the 
ways that the AD affected their child 
70 responses collected; construction of 
an initial nine item questionnaire 
(IELQI); a tenth question was added 
after a pilot study 
? 
92 parents of 
infants with 
AD 
poor 
Conclusion: One study assessed content validity of the UK version of the IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Content validity of the UK version of the IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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Table S74: Convergent/divergent validity of the English IDQoL (UK) 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S16) 
Calculation of the correlation between 
IDQoL and FDI and between IDQoL and 
parent-rated severity using Spearman's 
correlation coefficient 
IDQoL/FDI: r=0.87 
IDQoL/severity: r=0.58 
? 
89 parents of 
infants with 
AD 
fair 
(S17) 
Calculation of Spearman's correlation 
coefficient to compare scores of 
IDQOL/DFI and IDQOL/parental severity 
assessment (PAGS) 
IDQOL/DFI: 0.776 (P<0.0001); 
IDQOL/PAGS 0.636 (P<0.0001) 
Correlations of individual IDQOL 
items with PAGS range from 0.26-
0.59 
? 
203 parents of 
children with 
AD 
poor 
Conclusion: Two studies assessed convergent/divergent validity of the UK version of the IDQoL and indicated unclear convergent validity as a QoL instrument 
for eczema  
 Convergent validity of the UK version of the IDQoL as a measurement of QoL: unclear 
 Quality of evidence: fair 
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Table S75: Responsiveness of the English IDQoL (UK) 
Author 
Responsiveness 
Method Result Interpretation Study base COSMIN score 
(S16) 
Comparison of IDQoL scores before and after 
treatment using Wilcoxon's signed rank test. 
They also plot Change in IDQOL vs. change in 
clinical severity, but don't say whether their 
correlation is significant. Also, they don't say 
what treatment was and the time between 
assessments. 
Difference in scores was 
statistically significant 
(p=0.0473) 
? 
25 parents of 
infants with 
AD 
poor 
(S17) 
Comparison of scores before and after 
intervention using ANOVA 
Median IDQOL score fell from 
8 before treatment to 5.5 
after treatment (P<0.0001); p 
values for analysis of different 
severity subgroups not given. 
Didn't assess correlation 
between change in severity or 
DFI with IDQOL. 
? 
50 parents of 
children with 
AD 
poor 
Conclusion: Two studies assessed responsiveness of the UK version of the IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Responsiveness of the UK version of the IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
2
2
3
 
52 
 
23. Infants’ Dermatitis Quality of Life Index ȋIDQoLȌ – Italian version 
 
Table S76: Internal consistency of the Italian IDQoL 
Author 
Internal consistency 
Method Result Interpretation Study base COSMIN score 
(S18) Cronbach's alpha α=Ϭ.ϳϰϯ ;first testͿ; α=Ϭ.ϳϰϬ ;secoŶd testͿ + 21 children 
with AD 
poor 
Conclusion: One study assessed internal consistency of the Italian IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Internal consistency of the Italian IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S77: Reliability of the Italian IDQoL 
Author 
Reliability 
Method Result Interpretation Study base COSMIN score 
(S18) 
Intraclass Correlation Coefficient 
(ICC) for the total score 
ICC=0.950 (P<0.0001) + 
21 children 
with AD 
poor 
(S18) 
Weighted Kappa for scores of 
individual questions 
Weighted Kappa ranged from 0.632-
1.000 
? 
21 children 
with AD 
poor 
(S18) 
Comparison of scores of tests 1 
and 2 using Wilcoxon rank scores 
No significant differences between the 
two administrations according to 
Wilcoxon test 
+ 
21 children 
with AD 
poor 
Conclusion: One study assessed reliability of the Italian IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Reliability of the Italian IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
 
2
2
4
 
53 
 
Table S78: Convergent/divergent validity of the Italian IDQoL 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S18) 
Calculation of Spearman's 
correlation coefficient to 
determine the relationship 
between IDQoL and FDI, IDQoL and 
parent-reported severity, and 
IDQoL and SCORAD 
First administration: 
IDQoL/FDI 0.763, IDQoL/parent-reported 
severity 0.486, IDQoL/SCORAD 0.764 
Second administration: 
IDQoL/FDI 0.828, IDQoL/parent-reported 
severity 0.591 
? 
21 children 
with AD 
poor 
Conclusion: One study assessed convergent/divergent validity of the Italian IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Convergent validity of the Italian IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
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24. Infants’ Dermatitis Quality of Life Index ȋIDQoLȌ – Swedish version 
 
Table S79: Convergent/divergent validity of the Swedish IDQoL 
Author 
Hypothesis testing (convergent/divergent validity) 
Method Result Interpretation Study base COSMIN score 
(S9) 
Calculation of Spearman's correlation 
coefficient to determine the association 
between IDQoL and DFI, IDQoL and R&L 
score and IDQoL and objective SCORAD 
IDQoL/DFI: 0.78 (p<0.01); 
IDQoL/R&L: 0.48 (p<0.05); 
IDQoL/oSCORAD 0.30 (p>0.05) 
? 
28 infants with 
eczema 
poor 
Conclusion: One study assessed convergent/divergent validity of the Swedish IDQoL, but due to poor methodological study quality no conclusion can be drawn  
 Convergent/divergent validity of the Swedish IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
 
Table S80: Discriminative validity of the Swedish IDQoL 
Author 
Hypothesis testing (discriminative validity) 
Method Result Interpretation Study base COSMIN score 
(S9) 
Comparison of scores of infants with eczema 
and infants with eczema and asthma, allergic 
rhinoconjunctivitis, food allergy/intolerance or 
urticaria (AAFU) using ANOVA 
No significant difference 
between infants with 
eczema and infants with 
eczema and AAFU 
- 
28 infants with 
eczema 
poor 
Conclusion: One study assessed discriminative validity of the Swedish IDQoL, but due to poor methodological study quality no conclusion can be drawn 
 Discriminative validity of the Swedish IDQoL as a measurement of QoL: unclear 
 Quality of evidence: poor 
2
2
6
 
55 
 
References 
S1. Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai JS, et al. Development of the 
Childhood Atopic Dermatitis Impact Scale: initial validation of a quality-of-life measure for young 
children with atopic dermatitis and their families. J Invest Dermatol 2005;125(6):1106-1111. 
S2. Chamlin SL, Lai JS, Cella D, Frieden IJ, Williams ML, Mancini AJ, et al. Childhood Atopic 
Dermatitis Impact Scale: reliability, discriminative and concurrent validity, and responsiveness. Arch 
Dermatol 2007;143(6):768-772. 
S3. Neri E, Agostini F, Gremigni P, Gobbi F, Casu G, Chamlin SL, et al. Italian validation of the 
Childhood Atopic Dermatitis Impact Scale: a contribution to its clinical application. J Invest Dermatol 
2012;132(11):2534-2543. 
S4. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with 
atopic eczema. Br J Dermatol 2006;154(4):719-725. 
S5. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial 
validation and practical use. Br J Dermatol 1995;132(6):942-949. 
S6. Aziah MS, Rosnah T, Mardziah A, Norzila MZ. Childhood atopic dermatitis: a measurement of 
quality of life and family impact. Med J Malaysia 2002;57(3):329-339. 
S7. Maksimovic N, Jankovic S, Marinkovic J, Sekulovic LK, Zivkovic Z, Spiric VT. Health-related 
quality of life in patients with atopic dermatitis. J Dermatol 2012;39(1):42-47. 
S8. Ramirez-Anaya M, Macias ME, Velazquez-Gonzalez E. Validation of a Mexican Spanish version 
of the Children's Dermatology Life Quality Index. Pediatr Dermatol 2010;27(2):143-147. 
S9. Ganemo A, Svensson A, Lindberg M, Wahlgren CF. Quality of life in Swedish children with 
eczema. Acta Derm Venereol 2007;87(4):345-349. 
S10. McKenna SP, Doward LC, Meads DM, Tennant A, Lawton G, Grueger J. Quality of life in 
infants and children with atopic dermatitis: addressing issues of differential item functioning across 
countries in multinational clinical trials. Health Qual Life Outcomes 2007;5:45. 
S11. McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohlmann T, Niero M, et al. International 
development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res 
2005;14(1):231-241. 
S12. Deon KC, Santos DM, Bullinger M, Santos CB. Preliminary psycometric assessment of the 
Brazilian version of the DISABKIDS Atopic Dermatitis Module. Rev Saude Publica 2011;45(6):1072-
1078. 
S13. Baars RM, Atherton CI, Koopman HM, Bullinger M, Power M, group D. The European 
DISABKIDS project: development of seven condition-specific modules to measure health related 
quality of life in children and adolescents. Health Qual Life Outcomes 2005;3:70. 
S14. Alzolibani AA. Cultural adaptation of the Arabic version of the Infants` Dermatitis Quality of 
Life Index. Saudi Med J 2013;34(5):518-524. 
S15. van Valburg RW, Willemsen MG, Dirven-Meijer PC, Oranje AP, van der Wouden JC, Moed H. 
Quality of life measurement and its relationship to disease severity in children with atopic dermatitis 
in general practice. Acta Derm Venereol 2011;91(2):147-151. 
S16. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants' Dermatitis Quality of Life Index. Br J 
Dermatol 2001;144(1):104-110. 
S17. Beattie PE, Lewis-Jones MS. An audit of the impact of a consultation with a paediatric 
dermatology team on quality of life in infants with atopic eczema and their families: further 
validation of the Infants' Dermatitis Quality of Life Index and Dermatitis Family Impact score. Br J 
Dermatol 2006;155(6):1249-1255. 
S18. Baranzoni N, Scalone L, Mantovani L, Portu SD, Monzini M, Giannetti A. Validation of the 
Italian version of the Infants' Dermatitis Quality of Life and Family Dermatitis indexes. G Ital Dermatol 
Venereol 2007;142(5):423-432. 
 
227 
